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Paranimfen:    Bas W. T. Gruijters 
     Christien A. Schortinghuis 
 
  
1  PROTEINS AND CONFORMATIONAL 
RESTRICTION 
 
1.1 Introduction 
 
Nature’s complexity culminated in the evolution of ‘living’ organisms. The basis 
of these organisms is formed by complex catalysts which are necessary to drive 
metabolics along complicated pathways. Despite the variety of function of these 
catalysts they consist of repetitive chains of a limited set of 20 amino acid 
building blocks. A larger set is provided by Nature through post-translation 
modifications. 
Chains of amino acids fold into specific three-dimensional shapes. This folding 
eventually determines to a large extent the biological activity of the sequence. 
Two of the basic secondary structural elements that occur locally in protein 
structures are α-helices and β-sheets. While α-helical peptides have been studied 
in great detail and considerable advances have been made in understanding the 
energetics of helix formation,1 β-sheets have until recently received less 
attention. The β-sheet classifications can be further characterized as shown in 
Table 1 for turns that occur in β-sheet structures (parallel linear sequences do 
not necessarily end in a turn). 
 
 
Figure 1. α-Helix and β-turn 
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Tabel 1     
Turn type φ2 ψ2 φ3 ψ3 
I −60°  −30° −90°    0° 
I`  60°  −30°  90°    0° 
II −60° 120°  80°    0° 
II`  60° 120° −80°    0° 
III −60°  −30° −60° −30° 
III`  60°  −30°  60° −30° 
IV Other 
 
 
The α-helices and β-sheets/turns are interesting because of the relation between 
their structure and biological activity. These secondary structures are 
encountered in proteins, where they are involved in recognition and binding. 
Mimics of these secondary motifs can be useful in determining structure/activity 
relations, but naturally it is important for a peptide to retain its conformational 
features. Conformational restriction is a way to provide insight in structural-
activity relationships.  
Conformational restrictions includes stabilizing peptide motifs. For example, 
incorporation of covalent or non-covalent linkages between amino acid side 
chains could give enhanced stability. Examples include salt bridges,2 lactams,3 
disulfide bridges,4 hydrophobic interactions,5 metal ligation between natural6 and 
unnatural7 amino acids and lipid attachments.8 
In recent years, there has been an exploding interest in the use of metathesis, 
culminating in the Nobel Prize of Chemistry 2005 for Chauvin, Grubbs and 
Schrock.  
 
Figure 2. Schematic representation of metathesis: exchanging dance partners (The Chauvin9 
mechanism.) 
 
One of the features of metathesis is that it is capable of forming artificial 
macrocylic rings and carbon bridges (ring-closing metathesis or RCM), which can 
be applied to introduce conformational restriction. An important additional 
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advantage of such carbon bridges over the previously summarized restriction are 
its improved metabolic stability. Especially for small peptides where proteolytic 
degradation is a major issue, this could improve the bioavailability. Since helical 
conformations are generally favoured in apolar media, macrocyclization of small, 
hydrophobic peptide helices has been shown to be well suited to RCM.10 
 
In the following chapter an overview of ring-closing metathesis as applied in 
peptide stabilization and peptidomimetic synthesis is provided. In addition, the 
biological activity of ring-closed compounds is described. 
 
1.2 Beta-turn mimics based on RCM 
 
Already in the early stages of the development of olefin metathesis, the Grubbs 
group used this methodology in peptide synthesis.  
Initial studies started with the closure of N-allylated allylglycine derivative 2, 
giving rise to a six-membered ring. More vigorous conditions were required  to 
close precursors 4 and 6, which were lower yielding due to the less favorable ring-
size of the resulting products. 
NBocMeO2C
Boc
NMeO2C
91%
N NBoc
O
MeO2C
N NBoc
O
MeO2C 51%
NMeO2C
O
NHBoc
NMeO2C
O
NHBoc
52%
Ru
Ph
PCy3
PCy3
Cl
Cl
1
2 3
4 5
6 7
a
b
b
 
Scheme 1. Reagents and conditions: a) 1 (5%), PhMe, RT, 2h; b) 1 (16%), PhMe, RT, 24h. 
 
Grubbs and coworkers also focused on the synthesis of compounds that mimicked 
natural disulfide-stabilized peptides. As an example, the motif present in 8 is 
found in redox-active peptides where the sulfur-bridge locks the peptide into a β-
Chapter 1 
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turn.11 It was thought that replacement of the sulfur-bridge in biologically active 
compounds by other linkages increases metabolic stability. It was anticipated 
that the internal hydrogen bond might dispose the diene in a conformation that is 
well suited for ring closure. 
 
N
O N
N
H
O
BocHN CONHMe
O Me
S
S
Me
H
N
O N
N
H
O
BocHN CONH-Gly-OR2
O R1
H
N
O N
N
H
O
BocHN CONHBn
O Me
H
Me
11, R1= CH2-pPh-OH, CH2-pPh-O(CBz(Br))
12, R2 = Me, solid support
8
10
N
O HN
N
H
O
BocHN CONHBn
O MeMe
9
 
Scheme 2. Balaram’s tetramer and Grubbs’ carbon mimics. 
 
Precursor 9 was made using racemic allylglycine residues, but interestingly, 
instead of forming a statistical mixture of four stereoisomers, only the (S,S,S)-
tetramer 10 was formed in 60%. Replacement of 2-aminoisobutyric acid (Aib) by 
tyrosine (viz. 11),12 or of the Pro-Aib by the Leu-Leu sequence also produced 
cyclization products, showing that there is no need for imposing constrained 
rotation by the gem-dimethyl groups (i.e. the Thorpe-Ingolg effect) to ensure 
cyclization. Finally, on solid support (12) the reaction also proceeded well. 
The group of Katzenellenbogen used a different approach to prepare a type I β-
turn.13 It was hypothesized that an externally constrained 10-membered ring 
(Scheme 3) could replace Gly-Leu in Substance P and thus result in increased 
biological activity.14 They prepared dipeptide 13, which was successfully cyclized 
to β-turn mimic 14 in 65%. The closure of 13 was the first example of a 10-
membered lactam-ring. 
 Proteins and conformational restriction 
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N
H
MeO2C
NHBoc
O
N
H
MeO2C
NHBoc
O
N
H
NH
O
HN O
MeO2C
Ph
O
NHBoc
Ph
13 14 15  
Scheme 3. Reagents and conditions: 1 (10%), CH2Cl2, RT, 18h (65%) 
 
With core ring system 14 in hand, 15 was prepared in several steps for 
conformational analysis and biological evaluation. This analysis showed that the 
tetrapeptide derivative 15 restricted the central φ and ψ torsion angles to within 
30° of the ideal angles for a type I β-turn.  
 
Further research on small cyclic dipeptides was carried out by Liskamp et al. who 
successfully cyclized N-allyl functionalized bulky amino acids.15 Optimal 
conditions were found with 1,1,2-trichloroethane as solvent at reflux 
temperature, using the first generation Grubbs catalyst. 
 
N N
R2 O
CO2Et
R1
Boc
or Me
N N
R2 O
CO2Et
R1
Boc
or Me
16a-g 17a-g  
Scheme 4. Reagents and conditions: 1, 1,1,2-trichloroethane, 85-115 °C. 
R1 H H Bn iBu H Bn iBu 
R2 H Bn H H iBu Bn iBu 
Yield (%) 73 59 51 50 35 27 53 
 
In order to investigate the properties of the β-turn mimics, the trans-adaptation 
of secondary amides prevents efficient conversion. N-Allyl-substitution masks the 
properties of the turn but the tertiary structure can adopt a cis-conformation, 
thus facilitating the ring closure. 
Using dimethoxybenzyl (DMB) as a reversible protecting group, Reitz et al. 
successfully cyclized dipeptide 18 to give 19 which was further elaborated into 
derivatives 20-23 of which the β-turn properties were investigated with X-ray 
and NMR spectroscopy (Scheme 5).16 They were found to have a close 
resemblance to the VIa β-turn, thus making these unique turns potentially useful 
tools for novel constrained peptidomimetics. 
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N
O
BocHN CO2Me
DMB
N
O
BocHN CO2Me
DMB
N
HO
AcHN CONHMe
N
HO
AcHN CONHMe N
HO
AcHN CONHMe N
HO
AcHN CONHMe
80%
18 19 20
21 22 23  
Scheme 5. Reagents and conditions: 1 (10%), CH2Cl2, reflux. 
 
The group of Lubell extended the macrocyclic dipeptide chemistry by making 8-, 
9-, and 10-membered rings as shown in Scheme 6.17 The importance of transient 
N-protection of the central amide is underlined, since only 24d could be cyclized 
in unprotected form. 
N
O
BocHN CO2Me
DMB
(  )n(  )m
N
O
BocHN CO2Me
DMB
(  )n(  )m a, m = 1, n = 1
b, m = 2, n = 1
c, m = 1, n = 2
d, m = 2, n = 2
24a-d 25a-d  
Scheme 6. Reagents and conditions: 1 (20%), CH2Cl2, reflux. 
 
The group of Iqbal used ring-closing metathesis in order to stabilize small cyclic 
oligopeptides by conformation constrain.18 After several investigations 
cyclopeptides 26-28 were identified using extensive NMR-studies as constrained 
310 helical structures (Scheme 7). Also, 29 was found to adopt a type VIa or VIb β-
turn  in CDCl3 and the more polar DMSO-d6 respectively.  
N
N
O
O
O NH
Me
O
N
N
O
N
O
HN
Ph
O NH
O
Me
Me
H
H
O
O
NHO
N
O N
O
NH
Me
Me
OPh H
N
HN
O N
O
Me
Me
O
N
Ph
O
H
H
N
NH
O
Ph
NO
O NH
OH
26
27 29
3028
Me
Me
 
Scheme 7. Iqbal’s cyclopeptides. 
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1.3  Peptide conformations 
 
The Grubbs group continued their efforts developing metathesis for carbon-
tethering amino acids in a series of helical peptides.19 The frequently 
encountered α-helix, as shown schematically as 31 (Scheme 8), fully 
characterized by Balaram proved to be a good example.20  
 
i
i + 4
NHBoc
CO2Me
i
i + 4
NHBoc
CO2Me
O
O
31 32, X = Ser*  (n=1)
33, X = Hse* (n=2)
NHBoc
CO2Me
O
O
34 = 83%
35 = 88%  
Scheme 8. Reagents and conditions: 1 (20%), CHCl3, RT then H2, Pd/C. (31 = Boc-Val-Ala-Leu-
Aib-Val-Ala-Leu-OMe, 32, 33 = Boc-Val-X-Leu-Aib-Val-X-Leu-OMe) (Hse = homoserine; * = 
allylated). 
 
Helical structures 32  and 33 were equipped with allylgroups at the serine 
positions. After ring-closing metathesis and hydrogenation the peptides 34 and 
35 were isolated in excellent yield, which suggests preorganization of the helix. 
Further research revealed indeed this preorganization of 32 and 33 in apolar 
solvents.21 Interestingly, a subtle conformational shift from 310 to an α-helix of 34 
was observed in CHCl3 as a solvent whereas 35 maintained a 310-helical 
conformation in both solution and the solid state.  
 
Liskamp et al. used another approach, coined a ‘Rolling Loop Scan’.22 This phrase 
involves the functionalization of two variable amides in a peptide with olefinic 
chains. By having the functionalization at various amide positions the resulting 
lactam ring size will differ and contain various residues. This should allow a 
rapid screening of stabilization effects or local conformations of the peptide 
(Scheme 9). It appeared that some ‘rules’ apply with respect to orientation of the 
chain size and successful cyclization. If two amide bonds are involved in the loop, 
N-allylamides have to be used in the starting bis-alkylated peptide (n = 1); if 
three amides are involved in the loop, N-pentenylamides have to be used (n = 3); 
Chapter 1 
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if four or more amide bonds are involved in the loop, N-butenylamides will work 
(n = 2). 
O
N
O
N
CO2MeBocHN
amino acid
residues
amino acid
residues
amino acid
residues
(  )n(  )n
O
N
O
N
CO2MeBocHN
amino acid
residues
amino acid
residues
amino acid
residues
(  )n(  )n
n = 1, 2, 3
Boc-Tyr-Gly-Gly-Phe-Leu-OMe
36
37
 
Scheme 9. Rolling loop scan on  Leu-enkephalin (Boc-Tyr-Gly-Gly-Phe-Leu-OMe). 
 
An important publication of the group of Verdine took an alternative approach by 
screening multiple configurations of cross-linking where the olefinic chains 
differed in positions, stereochemistry and length.23 Incorporating amino acids 38 
or 39 in the sequence of RNase A allowed to observe the changes of helical 
content owing to specific modifications (Figure 3).24 The peptides were made 
using solid phase techniques and also ring-closing metathesis was performed on 
the resin. None of the peptides in the Ri,i+4S(x) (Figure 3) series underwent 
metathesis as the HPLC analysis revealed. Also in the Ri,i+4R(x) series only x = 8 
went to complete conversion as in the Si,i+4S(x) series x = 7 and x = 8 underwent 
68% and >98% conversion. The Ri,i+7S(x) series also were more successful with 
longer chain lengths.  
FmocHN CO2H
Me
S-38n
(  )n
FmocHN CO2H
Me
R-39n
(  )n
(n = 1-4,6)
(n = 1,3,4)  
Figure 3. Linked peptides. The nomenclature Ri,i+7S(11) refers to a peptide with an R and an S 
configurated amino acid at positions “i”, and “i + 7” respectively, and 11 carbons in the 
metathesized cross-link. 
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Another general trend that was observed is the dramatic effect of ringsize in 
efficiency of ring-closing metathesis. For example Ri,i+7S(8) underwent no 
cyclization at all, whereas Ri,i+7S(9) formed its corresponding 31-membered 
macrocyle to an extent of 51%. This difference might be explained by on-resin 
preorganization of the α-helix, where the tethers are too short to span the gap. 
In order to determine the cross-linking stabilization effect, the helical content of 
all cyclized peptides were measured quantitatively alongside the natural 
sequence (Ac-EWAETAAAKFLAAHA-NH2) and the unmetathesized peptide 
chain.  
 
That conformational restriction does not always lead to the desired results was 
also found by McNamara et al.25 By incorporation of a carbon-based cystine 
mimic during pepide synthesis, Ac-Lys-(Ala)4-Lys-(Ala)2-cyclo[Alg-Ala-Lys-Ala-
Alg]-(Ala)2-Lys-NH2 was compared to its native 16-mer. Unexpectedly, this 
artificial bridge did not lead to an α-helical conformation. Instead, depending on 
the solvent the peptide was found to adopt a β-turn in either a left-handed or 
right-handed conformation. It was reasoned that the improper chirality of one of 
the two stereo centers of the isostere prevents helical formation, just as Verdine 
found. 
 
With the discovery of more efficient metathesis catalysts such as 40 and 41 
(Figure 4), more research was conducted on peptide systems. 
RuCl
Cl
OMe
Me
NN MesMes
Ru
Ph
Cl
Cl
NN MesMes
PCy3
40 41  
Figure 4. Second generation Grubbs 40 and Hoveyda-Grubbs 41 catalysts. 
 
The group of Arora investigated the possibility of hydrogen-bond surrogate (HBS) 
in order to allow full access of natural solvent-exposed surfaces.26 HBS replaces 
the hydrogen bond with a carbon-based connection which could artificially 
constrain an α-helix while maintaining its specific side-chain functionalizations. 
A small library of peptides sequentially similar to Scheme 10 was successfully 
cyclized.27 
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N
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HN
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N
H
Me
HN O
Me
O
HN
O
N
H
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R
42 43
CO2H
CO2H
CO2H
HO2C
 
Scheme 10. Reagents and conditions: 41 (10%), 1,2-dichloroethane, 50 °C, 25h (55%). 
 
Following up on results from our group (see chapter 5),28 an alkyne-metathesis 
approach for rigidification was undertaken by Liskamp et al.29 in order to 
artificially constrain the antimicrobial peptide nisin Z (Scheme 11).30 This 
peptide consists of 5 consecutive thioether bridges and the knotted DE-ring at the 
C-terminus are responsible for its specific biological activity. Besides olefin 
metathesis they successfully used ring-closing alkyne metathesis (RCAM) to form 
some cyclic fragments. The advantage is that the triple bond allows selective 
reduction afterward (see chapter 5). 
 
HN
O HN
N
H
O
N
H
CO2Me
O
OMe
TrtHNOC
HN
O
BocHN
HN
O HN
N
H
O
N
H
CO2Me
O
OMe
TrtHNOC
HN
O
BocHN
Me Me (tBuO)3W
Me
Me
Me
45 46
47
Lys Asn Met Lys
Ser Ile His
Val
Dha
Lys
OH
A B C D ENisin Z (44)
GlyPro
Abu
S
Ala
AbuAla
Abu
S
Ala Asn
Ala
S
Ile
Ala
S
Ala
Leu
Dha
DhbIleH
Gly
Abu
S
Ala
Gly
Met
Leu
Ala
 
Scheme 11. Reagents and conditions: 47 (27%), toluene, reflux (18%). 
 
An initial approach involving a suitably configured peptide with four olefin 
metathesis handles (resembling peptide 45) failed. In contrast, peptide 45 
containing two alkyne functionalities was made and RCAM was successfully 
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applied. The second ring-closure of 46 was unfortunately due to solubility issues 
impossible. However, this represents a nice example where RCM and RCAM can 
be successfully used alongside each other without interference for the specific 
construction of different carbon bridges. 
 
1.4  Facilitating cyclizations 
 
Noting the problems associated with difficult on-resin preorganization Kessler 
and coworkers31 attempted to rigidify peptides by introduction of Mutters 
pseudoproline Ser(ψMe,Mepro) moiety.32 Comparing the conversion rates of RCM of 
the rigidified 10-mer with those of the unmodified molecule (serine instead of 
pseudoproline), the cyclization proceeded smoothly with excellent conversion 
rates (Figure 5).  
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Me
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N
H
NH N
H
N
H O
O
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O
N
H
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N
N
H
H
N
O
O
HO2C
O
H2N
OH
Ph
Me
Ph
HO
O
CONH2
OH
O O
H2NOC
NH
O O
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(  )n (  )n
54, n = 3; 5%
55, n = 5; 13%
52, n = 3; 3%
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OH
O
 
Figure 5. Peptides constructed using the Ser(ψMe,Mepro)-motif. Each set consists of approximately 
equimolar mixtures of the four stereoisomers with varying ring sizes. Yields are for reduction, 
deprotection and purification using RP-HPLC. 
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The introduction of pseudoproline might facilitate the metathesis reaction of 10-
mer peptides, but an obvious drawback is the presence of serine at a specific 
position. 
 
The observed difficulty of several cyclizations and the preferential 
preorganization was also observed by Toniolo and coworkers.33 They applied Cα-
methylated allylglycine (58) and its turn/helix forming properties in ring-closing 
metathesis of peptide 56 and compared the properties of the resulting cyclic 
peptide 57 with Grubbs’ cyclopeptide 10 and Balaram’s cyclic derivative 8. NMR-
studies indicated a markedly increase in intramolecular H-bonding. 
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Scheme 12. Reagents and conditions: 40, PhMe, 16 h, 80 °C then H2, PtO2 (85%). 
 
1.5  Peptidomimetics 
 
Particular applications of contrained peptides are found in the field of 
peptidomimetics. Signal transduction proteins play a major role in the complex 
dynamic networks that regulate cell function and are intensively studied for their 
potential as drug targets.  Much attention is being paid to the (mammalian) Grb2 
SH2 domain which consists of an SH2 domain flanked by two SH3 domains. This 
key component of the Ras signaling34 pathway is an important regulator of cell 
growth and differentiation and therefore a potential drugs target for cancer 
therapy.35 
Binding of natural phosphorylated tyrosine-containing ligands of Grb2 SH2 
domains take place in type-1 β-bend fashion.36 The sequence -pTyr-Val-Asn-Val- 
is recognized by the Grb2 SH2 domain and specifically the asparagine is found to 
be very important.37 Based on this motif, inhibiters were designed to mimic this 
particular sequence. 
Caravatti38 and Ettmayer39 explored the usage of cyclic peptides to serve this 
purpose. A cystine containing pentamer of Caravatti (Ac-Cys-pTyr-Ile-Asn-Cys-
NH2 (59)) was found to be the most active one (IC50 = 0.37 μM) of a small 
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library.40 Ettmayer confirmed the β-hairpin recognition by the SH2 domain and 
demonstrated that the stabilization increased the potency.  
Based on these findings, the groups of Burke41 and Liskamp42 intended to apply 
ring-closing metathesis to prepare mimics by constructing a constrained carbon 
backbone for SH2 inhibition. Burke used 60 as model platform and successfully 
prepared the cyclic mimic 61. 
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Figure 6. Burke’s Grb2 SH2 inhibitors. 
 
The increase of stability led to a 100-fold improved activity (IC50 from 2 μM to 
0.02 μM) over its unconstrained form but the initial compound 60 had, due to the 
presence of the acetate group also a similar activity (IC50 = 0.02 μM). Burke then 
redesigned the mimic in order to include the functional group at position 22 and 
found for (R)-63 (Kd = 54.9 nM and (S)-63 (Kd = 22.7 nM) an enhancement of two 
orders of magnitude compared to unstabilized 62 (Kd = 5610 nM).43  
Liskamp et al. also prepared a cyclic phosphopeptide for modulation of the signal 
transduction via the Grb2 SH2 domain. The use of RCM on an alternative 
sequence (Figure 7) was anticipated to provide the proper conformation for 
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optimal interaction with the SH2 domain. However, after cyclization the 
additional constraint of 65 did not lead to improved biological activity (Kd = 440 
nM to Kd = 600 nM). This result shows that covalent control of the peptide 
conformation is a subtle process in which other factors may play a dominant role 
as well. 
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Figure 7. Liskamp’s Grb2 SH2 inhibitors. 
 
The group of Liskamp also demonstrated the difficulties of peptide RCM in the 
synthesis of an MC4-receptor based on cyclopeptide 66.44,45 On resin cyclization 
was unsuccessful and selective cleavage resulted in mostly insoluble peptide. 
After using co-solvents, compound 67 was obtained but biological activity 
remained in the same order of magnitude as its linear starting material (EC50 = 
0.21 nm and 0.34 nM, respectively (66 = 0.01 nM)).  
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Figure 8. MC4 receptor 66 and Liskamp’s MC4 receptor 67. 
The Coates group46 investigated the biological activity of carbon mimics of the 
disulfide-constrained Bowman-Birk inhibitor.47 Using microwave assistance, 
several (R)-allylglycine-containing peptides were successfully cyclized, but their 
biological activity was at least a 10-fold less than their (S) counterparts. In 
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summary, the 31-membered macrocycle 71 showed competitive inhibition-values 
compared to disulfide 68 (Figure 9). 
peptide N
H O
Tyr OH
O
HNSerH2N
S S Ki / nM
peptide N
H O
Tyr OH
O
HNSerH2N
peptide N
H O
Tyr OH
O
HNSerH2N
peptide N
H O
Tyr OH
O
HNSerH2N
peptide N
H O
Tyr OH
O
HNSerH2N
16
11.000
490
120
1000
68
69
70
71
72  
Figure 9. Coates series of Bowman-Birke inhibitors 
Carbon analogues of oxytocin48 (73) have been reported by Vederas et al.49 In this 
example the biological activity of native oxytocin (EC50 = 2.7 ng/mL) was 
diminished by the introduction of the carbon bridge to 38 and 242 ng/mL for the 
cis- and trans-analogues of 74 respectively. Hydrogenation of the mixture to the 
corresponding saturated system reduced the activity to 338 ng/mL. 
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Figure 10. Oxytocin (73) and carbon analogues (74). 
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1.6  Conclusions 
 
Ring-closing metathesis stands out as a powerful method to introduce 
conformational restriction. On the one hand, the tolerance of the catalyst with 
respect to the peptide functional groups and on the other hand the enhanced 
metabolic stability of the carbon analogues, provides interesting opportunities. 
However, simple replacement of cystine by carbon analogues does not 
automatically lead to enhanced biological activity. The locking of peptide motifs 
requires the peptide to preorganize in order to undergo successful ring-closing 
metathesis, which may be reached by temporary N-functionalization of the 
backbone to enhance its reactivity. 
Despite the unpredictability of ease of cyclization and of the enhanced biological 
activity, ring-closing metathesis is certainly an useful tool for conformational 
restriction.  
 
1.7  Purpose and outline of this investigation 
 
In this thesis, the application of new methods to introduce conformational 
restriction in peptides is investigated. 
In chapter 1, an overview is given of recent applications of ring-closing 
metathesis being the commonly applied method to introduce conformational 
restriction in peptides. This demonstrates the potential of methylene linked 
restrictions in understanding peptide conformation and enhancing biologically 
active of peptidomimetics. 
In chapter 2 details are given concerning optimized chemo-enzymatic strategies 
for the required non-proteinogenic unsaturated amino acids.  
Chapter 3 details synthetic investigations into the application of zinc/copper-
mediated couplings to functionalize acetylenic amino acids with alkyl-groups. 
In chapter 4 preliminary results are given detailing attempts to use Cu(I) 
catalyzed cycloadditions for restriction of peptides. 
Chapter 5 ring-closing alkyne metathesis is introduced as a new tool to generate 
conformational restriction in peptides.  
In chapter 6 a natural product synthesis is pursued in order to compare the 
synthesis and activity of FE399 and its carbon-derivative. 
This research was conducted as part of a STW-collaboration. The other members 
of this project were Prof. Hans Schoemaker (University of Amsterdam/DSM 
research), Prof. Jan van Hest and Dr. Lee Ayres (Radboud University Nijmegen) 
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and Prof. Herman Overkleeft, Dr. Mark Overhand and Dr. Gijs Grotenbreg 
(University of Leiden). 
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2 SYNTHESIS OF ENANTIOPURE 
ACETYLENE-CONTAINING AMINO ACIDS 
 
2.1  Introduction 
 
Acetylene-containing amino acids play an increasingly important role as 
witnessed by the numerous applications in synthesis and chemical biology.1 
Throughout this thesis several facets of the versatility of these amino acids are 
shown. Since the availability of these compounds in enantiopure form is crucial, 
this chapter will focus on enantioselective syntheses of these building blocks. 
Many synthetic strategies have been developed over the years and a brief 
overview of representative methods, each with its own distinct advantages and 
disadvantages, will be provided.2 
Most of the initial examples rely on diastereoselective alkylations employing 
suitable chiral auxiliaries. An early example starts from imine 1, derived from 
(R)-camphor and glycine tert-butyl ester, which was alkylated by Chadha and 
coworkers in a moderately diastereoselective manner (Scheme 1).3 
 
CO2tBuN
Me
CO2tBuN
Me
a
1 2  
Scheme 1. Reagents and conditions: a) LDA, propargyl bromide, THF, 78%, 67% de. 
 
Inversely, introduction of a chiral ester auxiliary may lead to optically active 
amino acids via a similar alkylation procedure.4 The example shown in Scheme 2 
shows an excellent diastereoselective alkylation (98% de), albeit that in this case 
the method is less attractive due to a troublesome removal of the chiral auxiliary 
thereby reducing the overall  yield to 51%. 
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N
O
N SMe
SMe
OMOMMOMO CO2HH2N
a
3 (S)-4  
Scheme 2. Reagents and conditions: a) LDA, propargyl bromide, THF then HCl, THF/H2O, 51%, 
98% ee. 
 
Since then, several examples of N-tethered chiral auxiliaries have emerged 
derived from sulfonamides,5 amino acids or peptide-based nickel complexes.6,7  
In contrast to alkylation reactions where a stoichiometric amount of the chiral 
auxiliary is required, more recently attention has been paid to enantiomerically 
pure phase-transfer catalysts (Scheme 3) that provide the desired amino acid 
using a catalytic amount of the chiral reagent in a two phase system. After the 
two phase protocol for the production of racemic amino acids had already been 
developed some time ago by O’Donnell,8 the Corey group and Lygo’s group 
showed almost simultaneously that use of cinchonidine- or cinchonine-derived 
chiral phase-transfer catalysts gave the corresponding amino acids in good to 
excellent ee’s. Both methods differ only in the functionalization of the hydroxyl 
group of the chiral ligand.9,10 A completely different class of BINAP-based 
catalysts was recently introduced by Maruoka,11 who showed that they can be 
used to give the alkylation products in high optical purities (up to 98%) with 
rather low catalyst loadings of 1 mol%. The efficiency of this elegant method can 
be enhanced by the addition of crown ethers.12 
 
N
Ar
Ar
Ar
Ar
CO2tBuNPh
Ph
CO2tBuNPh
Ph
a
5 6
N
RO N
R = Allyl; Corey
R = H; Lygo Maruoka
Br
 
Scheme 3. Reagents and conditions: a) PhMe, 50% aqueous KOH, 0 °C, 92%, 86% ee (Ar = 3,5-
diphenylphenyl). 
 
Apart from chemical methods, biocatalysts have since long also been applied for 
the preparation of acetylene-containing amino acids. As early as in 1969, 
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Havinga demonstrated that propargylglycine could be obtained in enantiopure 
form using a lipase.13 In the late 1980s, Whitesides showed that acylases could be 
used for the synthesis of enantiopure propargylglycine.14 More recently other 
enzymatic methods followed, for example involving lipases.15 One of the more 
recent examples was published by the group of Nosal, who employed the enzyme 
α-chymotrypsin to resolve propargylglycine derivative 7.16 As in this case, most of 
these enzymatic reactions lead to the availability of both enantiomers, which may 
be an advantage. Other specific biocatalysts can be deployed for direct selective 
amination or alkylation,17 giving rise to only one enantiomer altogether as 
exemplified for 11 and 12. However, no specific enzymatic system has been 
published to prepare propargylglycine in this way. 
 
BocHN CO2Me BocHN CO2H
α-chymotrypsin
7 8
CO2H CO2H
NH2
NH3
R R
R = CO2H; aspartate ammonia lyase
R = Ph; phenylalanine ammonia lyase
9, 10 11, 12
 
Scheme 4. α-Chymotrypsin, 0.1 M phosphate buffer pH = 8, 20 h, ee >99%. 
 
The high selectivity that is often displayed by enzymes, combined with the fact 
that the production of enzymes is easy to scale up, makes that enzymatic 
resolution can be readily employed for industrial purposes. Nowadays, various of 
such industrial scale syntheses exist, each of them responsible for the production 
of several thousands of tons of enantiopure amino acids.18 
In conjunction with a chemoenzymatic pathway that was developed in our group 
in collaboration with DSM (Geleen, The Netherlands) for the synthesis of 
acetylene-containing amino acids,21 this chapter will detail the optimization of 
some of our previous routes and thus show how the amino acids employed in this 
thesis were obtained. These amino acids will be used for several applications as 
described in the additional chapters of this thesis. 
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2.2  Retrosynthetic approach 
 
The focus of this chapter will be on the synthesis of the non-proteinogenic amino 
acids 4 and 13-15 (Scheme 5) in both enantiomeric forms. 1,19,20,21 
CO2HH2N CO2HH2N
Me
4
CO2HH2N CO2HH2N
Me
Me
13 14 15  
Scheme 5. Acetylene-containing amino acids, used in both enantiomeric forms in this thesis. 
 
The retrosynthetic approach is shown in Scheme 6. Key in this process is an 
enzymatic resolution of the racemic amino acid amides 17-20, which are 
enantioselectively hydrolyzed by an aminopeptidase to the give the (S)-acids 4, 
13-15, while the (R)-amides 17-20 remain intact.  
 
H2N CONH2
N CO2MePh
Ph
O
16 17 (n = 1, R = H)
18 (n = 1, R = Me)
R
(  )n(  )n
21 (n = 2)
22 (n = 3)
Me
H
H2N CO2H H2N CONH2
(S)-4, 13-15 (R)-17-20
A
n = 1
B
n = 2,3
enzymatic     resolution
R R
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19 (n = 2, R = Me)
20 (n = 3, R = Me)
 
Scheme 6. Retrosynthetic approach for the synthesis of the acetylene-containing amino acids.  
 
The required amino acid amides 17-20, in turn, can be obtained in several ways. 
In our group, we mainly relied on two approaches being (i) alkylation of the so-
called O’Donnell synthon 16 (Scheme 6, path A),22 and (ii) a modified version of 
the Strecker reaction23 (path B).24 The latter pathway, requiring the 
corresponding aldehydes 21 and 22 as starting materials, generally has a higher 
atom efficiency. However, a drawback of the latter method is that allylic and 
propargylic amino acid amides (n = 1) cannot be made in this way. This is due to 
the required β,γ-unsaturated aldehyde which is rather unstable due to facile 
isomerization and/or enolization followed by subsequent aldol processes. 
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Therefore, the O’Donnell alkylation pathway was chosen for the propargylic 
amino acid amide derivatives. 
 
2.3  The O’Donnell approach (path A) 
 
The O’Donnell synthon 16 can be conveniently prepared on mol scale following a 
literature procedure involving a reaction of benzonitrile with phenylmagnesium 
bromide,25  followed by transimination with the HCl-salt of glycine methyl ester.  
 
CN NH
N CO2MePh
Ph
1624
a b
23  
Scheme 6, Reagents and conditions: a) PhMgBr, Et2O, 40 °C (73%); b) HCl·H2N-Gly-OMe, CH2Cl2 
(93%). 
 
A particular advantage of ketimine 16 is the fact that the bulky benzophenone 
substituent prevents the formation of dialkylated products. Furthermore, the 
ketimine can be efficiently hydrolyzed in a later stage under mildly acidic 
conditions, which do not affect the acetylene functions.  
 
Synthesis of the propargylic amino acids 4 and 13 requires alkylation of the 
O’Donnell synthon 16 with propargyl bromide (32) and 1-bromo-2-butyne (27), 
respectively. While propargyl bromide is relatively cheap, its methylated 
counterpart 27 is rather expensive. Therefore, preparation of the latter 
compound from inexpensive propargyl alcohol (25) is more cost effective, 
especially for large scale synthesis as in our case. Thus, propargyl alcohol was 
deprotonated twice using lithium amide in liquid ammonia (the dilithium-salt 
precipitates completely in ammonia), followed by addition of 1 equiv of methyl 
iodide to give the monomethylated product 2-butynol (26). This was then 
transformed into the corresponding bromide 27 using 0.35 equiv of phosphorous 
tribromide (Scheme 7). Careful addition of alcohol 26 to the tribromide at –78 °C 
resulted after several hours in the corresponding phosphite, which upon refluxing 
was converted into the desired bromide 27. 
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2726
OH
25
OH
Me b
Br
Me
 
Scheme 7. Reagents and conditions: a) LiNH2,, NH3, –33 °C, then MeI; b) PBr3, Et2O, –78 °C to 
reflux (47%, yield over 2 steps). 
 
Alkylation of the O’Donnell synthon 16 was performed using sodium hydride (1.1 
equiv), the halides 27 and 32 (1.3 equiv) and a catalytic amount of lithium iodide 
in refluxing THF. The reactions were monitored by TLC and stopped directly 
upon completion in order to suppress degradation of the product. Besides the use 
of bromide 27, the alkylation was also carried out with the corresponding 
mesylate 33, prepared from 26 upon reaction with mesyl chloride. However, this 
resulted in a rather poor yield of 45%. 
N CO2MePh
Ph
N CO2MePh
Ph
R
N CONH2
R
Ph
28: R = H (99%) 
29: R = Me (98%)
H2N CONH2
R
17: R = H (67%)
18: R = Me (70%)
(yield over four steps)
R
X
H3N CONH2
R
a b
c
d
16 17: R = H
18: R = Me
30: R = H
31: R = Me
Cl
32: R = H, X = Br
33: R = Me, X = OMs
27: R = Me, X = Br
  
Scheme 8. Reagents and conditions: a) 27 or 32, NaH, LiI, THF, 60 °C; b) i: 1 M HCl, Et2O, ii: 
NH4OH; c) benzaldehyde, NaOH; d) concentrated HCl, acetone. 
 
Using bromides 27 and 32 on the other hand, the alkylated imines 28 and 29 
were obtained in excellent yield. Treatment of the crude reaction mixture with 1 
M HCl in a two phase system with ether released the free amine, after which the 
ester was reacted with concentrated ammonia (25% in water) to yield the 
required amides 17 and 18. During this conversion, partial hydrolysis26 of the 
ester was observed so that separation of the acid from the amide was necessary. 
This could be efficiently accomplished via treatment of the mixture with 
benzaldehyde under basic conditions. The amide selectively reacted with 
benzaldehyde to form the corresponding Schiff base (30, 31), so that the resulting 
mixture could be partitioned between the water soluble amino acid and the water 
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insoluble Schiff base. Redissolving the Schiff base in acetone and treatment with 
equimolar concentrated hydrochloric acid led to hydrolysis of the imine function 
and precipitation of the amino acid amide as its HCl-salt. Simple filtration then 
yielded the desired amides 17 and 18 in good overall yields of 67 and 70%, 
respectively. Due to the fact that the products can be readily purified in the final 
step, the whole sequence can be carried out without intermediate 
chromatography and therefore easily scaled up. 
 
2.4  Strecker synthesis (path B) 
 
In the Strecker reaction, an aldehyde is transformed into the corresponding 
aminonitrile, which in turn can be hydrolyzed into racemic amino acids in high 
yields. In Scheme 10, a modified pathway is shown which leads to the required 
amino acid amides. This involves the availability of aldehydes 21 and 22, which 
were prepared on large scale as shown in Scheme 9. Commercially available 2-
chloromethyltetrahydrofuran (34) and 2-chloromethyltetrahydropyran (35) were 
both treated with sodium amide in liquid ammonia to undergo a double 
elimination, thus affording the acetylenes 36 and 37. Subjection of the crude 
acetylenes to lithium amide in liquid ammonia, followed by the addition of one 
equiv of methyl iodide provided the alcohols 38 and 39, which were obtained in 
good overall yields after distillation.27 Subsequently, the alcohols were oxidized to 
the corresponding aldehydes 21 and 22 using a typical Swern oxidation.  
 
OH
O
NH2
a b
34: n = 1
35: n = 2
(  )n
Cl
36: n = 1 (84%)
37: n = 2 (81%)
(  )n
OH
Me
(  )n
O
Me
(  )n
21: n = 1
22: n = 2
H
38: n = 1 (84%)
39: n = 2 (81%)
c
O
Cl
HH
NH2
LiO
Cl
H
34 40
 
Scheme 9. Reagents and conditions: a) NaNH2, NH3; b) LiNH2, NH3, then MeI; c) (COCl)2, 
DMSO, Et3N, CH2Cl2, –78 °C.  
 
The aldehydes 21 and 22 were in crude form directly subjected to the modified 
Strecker reaction. This reaction commenced with the condensation of ammonia 
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with aldehydes 21 and 22, followed by addition of in situ generated hydrogen 
cyanide (from equimolar amounts of NH4Cl and KCN). This led to the 
aminonitriles 41 and 42, which after evaporation were immediately treated with 
benzaldehyde and NaOH at pH = 10. This led to conversion of the amino function 
into the Schiff base with concomitant partial hydrolysis of the cyanide group. 
This process presumably proceeds in an intramolecular fashion through the 
intermediate five-membered ring N,O-acetal 43 as shown in Scheme 10. 28 
 
H3N
NH2
O
N
O
Ph
NH
O
Me
(  )n
N NH2
O
Ph
a b
c
Me
21: n = 1
22: n = 2
(  )n
H
CN
Me
(  )n
NH2
B
Me
H
H+
43
(  )n
Me
Cl
19: n = 1 (34%, from 38)
20: n = 2 (75%, from 39)
41: n = 1
42: n = 2
44: n = 1
45: n = 2  
Scheme 10. Reagents and conditions: a) NaCN, NH4Cl, NH4OH, H2O; b) PhCHO, NaOH, 
NH4OH, H2O; c) concentrated HCl, acetone. 
 
After the Schiff base formation, imine hydrolysis and subsequent precipitation 
using concentrated hydrochloric acid in acetone, the desired amino acid amide 19 
and 20 were obtained as the corresponding HCl-salts. As with the previous 
sequence, the final precipitation step allows scaling up of the whole sequence 
without the necessity of performing any column chromatography. 
 
2.5  Enzymatic resolution 
 
The enzymatic resolutions of the obtained amino acid amides were carried out 
following procedures that were previously developed by our group in 
collaboration with DSM.29 This involved the use of whole cells of Pseudomonas 
putida ATCC 12633 or whole cells of a genetically modified Escherichia coli 
strain (GMO), both of which contain an aminopeptidase that displays an 
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excellent enantioselectivity in combination with a high tolerance towards the size 
and functional groups of the side chain.  
 
H2N CONH2
(S)-amino acid
b
a
(R)-amino acid amide
R
(  )n
H2N CO2H
R
(  )n
H2N CONH2
R
(  )n
rac-amino acid amide
(R)-amino acid
H2N CO2H
R
(  )nH2N
O
X
H2N
O
X
Me
H2N
O
X
Me
H2N
O
X
Me
(  )2 (  )3
17: X = NH2
  4: X = OH
18: X = NH2
13: X = OH
19: X = NH2
14: X = OH
20: X = NH2
15: X = OH
 
 
 yield ((S)  ee) (%) yield ((R)  ee) (%) 
2-amino-pent-4-ynoic acid 39 (>96) (S)-4 38 (>96) (R)-4 
2-amino-hex-4-ynoic acid 40 (>96) (S)-13 42 (>99) (R)-13 
2-amino-hept-5-ynoic acid 40 (>96) (S)-14 41 (>96) (R)-14 
2-amino-oct-6-ynoic acid 44 (>96) (S)-15 43 (>99) (R)-15 
 
Scheme 11. Reagents and conditions: a) Whole cells from Pseudomonas putida ATCC 12633 or 
from an Escherischia coli GMO, 80 mM aqueous solution of MnSO4, pH = 9.2, 37 °C; b) Whole cells 
from Rhodococcus erythropolis NCIMB 11540, aqueous buffered (KH2PO4) solution of pH = 8.0. 
 
The enzymatic resolutions were conducted at 40 °C and pH = 9.2 in the absence 
of sodium and chloride ions. These ions are known to significantly lower the 
aminopeptidase activity. Therefore prior to the resolution these salts were 
removed using ion exchange chromatography. A 10% solution (by weight) of the 
amide in water was treated with whole cells from the E. coli GMO in a substrate 
to cell mass ratio of 500 : 1. During the reaction, small reaction samples were 
taken and analyzed via chiral HPLC analysis in order to monitor the conversion 
and the enantiomeric excess. 
After the reaction was completed, the mixture of (R)-amide and (S)-acid was 
separated by the earlier described procedure of Schiff base formation and 
subsequent extraction. The optically pure (S)-amino acid was obtained from the 
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aqueous layer and was further purified using ion exchange chromatography. The 
Schiff base of the (R)-amide was obtained via evaporation of the organic layer and 
subsequent hydrolysis and precipitation using equimolar concentrated HCl in 
acetone. Transformation of the (R)-amide into the corresponding (R)-acid was 
achieved using Rhodoccocus erythropolis NCIMB 11540 whole cells, containing a 
non-specific amidase. Thus, subjection of the (R)-amino acid amides (pH = 8.0, T 
= 37 °C) to these whole cells led to full conversion into the corresponding amino 
acids as monitored by TLC (eluent: CHCl3 : MeOH : NH4OH 6 : 3 : 1). Filtration 
over Celite to remove the cell remainders, followed by further purification using 
ion exchange chromatography delivered the optically pure (R)-amino acids 4, 13-
15. The yield and enantiomeric purity of the different products are summarized 
in Scheme 11. Generally, excellent selectivities were observed in combination 
with good overall yields for these processes.  
 
The ee’s of the amino acids obtained from the enzymatic resolution were 
determined using an in situ reaction with the tartaric acid-derived enantiopure 
anhydride (S,S) dibenzoyltartaric acid anhydride (DBTAAN (46)) and 
concomitant 1H−NMR analysis of the resulting diastereoisomers.30 
O
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Scheme 12. Reagents and conditions: a) Na2B4O7, CD3CN : D2O (1 : 1). 
 
A racemic amino acid (viz. rac-13) gives rise to two diastereoisomers, whereas an 
optically pure amino acid will solely give one diastereoisomer. Upon integration 
of the α-protons, the enantiomeric excess can be determined. 
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Scheme 13. Example of chemical shifts: entry 1: pure (S)-13, entry 2: pure (R)-13, entry 3: (~2 : 1) 
mixture. 
  
Scheme 13 shows an example. The 1H−NMR spectra show the α-anhydride 
protons of the resulting diastereoisomers. Both the anhydride and the amino acid 
α-proton shift to 5.06 ppm, while the (S)-13 amide α-proton is found at 5.48 ppm 
whereas (R)-13 is found at 5.38 ppm. A mixture of 2 : 1 of both enantiomers as 
pseudoracemic reference shows the ratio in the NMR-values of both amino acids. 
This method can be in principle generally applied for amino acids, thus allowing 
1H−NMR as a means for measuring optical purities.  
 
2.6  Conclusions 
 
In this chapter the overall synthesis of optically pure unsaturated amino acids 
has been outlined. Either alkylation of the O’Donnell ketimine (for 13) or a 
modified Strecker reaction led to the required amino acid amides for the 
enzymatic resolution. During these syntheses several improvements were 
implemented as compared to previous work. The resulting amino acids have been 
used throughout the following chapters. 
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2.8  Experimental section31 
 
1H−NMR (300 MHz) and 13C−NMR (75 MHz) spectra were recorded on a Bruker 
DMX-300 spectrometer in CDCl3 using tetramethylsilane as internal standard 
(unless stated otherwise). 1H−NMR (400 MHz) and 2D−NMR experiments 
(NOESY, COSY) were performed on a Varian Unity Inova-400 spectrometer in 
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CDCl3. All NMR spectra were recorded at 298 K, unless stated otherwise.32 
Chemical shifts are reported in parts per million (ppm). Mass spectra were 
recorded on a VG7070E double-focusing mass spectrometer using EI and CI 
modes. IR spectra were recorded on a Anadis Thermo Mattson IR300 
spectrometer. Thin layer chromatography (TLC) was carried out on Merck 
precoated silica gel 60 F-254 plates. Spots were visualized with UV, exposure to 
iodine vapor or by either dipping the TLC plate into a 6.2% aqueous sulfuric acid 
solution containing ammonium molybdate (42 g L-1) and ceric ammonium sulfate 
(3.6 g L-1) or potassium permanganate solution (made by 1.5 g KMnO4, 10 g 
K2CO3 and 2 mL 5% NaOH in 150 mL H2O) followed by charring. Column 
chromatography was carried out with Acros silica gel (0.035-0.070mm).33 Ion 
exchange chromatography was performed using Dowex 50W×4 H+-form (20-50 
mesh, Fluka). Melting points were determined on a Buchi B-545 melting point 
apparatus and are uncorrected. When necessary, reactions were performed under 
standard Schlenk conditions under an argon atmosphere. Most commercially 
available solvents and reagents were used as received. EtOAc and heptane were 
distilled prior to use. THF and Et2O were dried by distillation from sodium and 
benzophenone. Raney® 2800 nickel was purchased from Aldrich and was 
extensively washed with methanol prior to use.  
 
4-Hexynol (38). To a solution of NaNH2 (90% dispersion in mineral 
oil, 108 g, 2.48 mol) in liquid NH3 (~1 L) was added dropwise a 
solution of 2-chloromethyltetrahydrofuran (34, 100 g, 0.829 mol) in 
Et2O (50 mL). The resulting solution was stirred at –33 °C for 6 h. The reaction 
was quenched by addition of saturated aqueous ammonium chloride (500 mL) 
and the ammonia was allowed to evaporate overnight. The reaction mixture was 
extracted using Et2O (3 × 500 mL), the organic layers were combined and washed 
(brine), dried (Na2SO4) and evaporated. The crude oil 36 (70.35 g, 0.83 mol) was 
used without further purification in the subsequent methylation step. 
To a solution of Fe(NO3)3·9H2O (200 mg, 0.63 mmol) in liquid NH3 (1 L) small 
turnings (ca. 1 g) of freshly cut lithium (14.0 g, 2.00 mol) were added whenever 
the color changed from blue to grey. Then, 4-pentynol (70.4 g, 0.83 mol) was 
added dropwise using a syringe over a period of 30 min. After stirring for 1 h, 
MeI (51.8 mL, 0.820 mol) was slowly added. The mixture was quenched using 
saturated aqueous ammonium chloride (400 mL) and the ammonia was allowed 
to evaporate overnight. The resulting mixture was extracted using Et2O (3 × 600 
mL), dried (MgSO4) and evaporated. Further purification using vacuum 
HO
Me
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distillation (300 mbar, 50 °C) yielded 38 as a colorless oil (56.7 g, 0.58 mol, 70% 
over 2 steps). 1H−NMR (400 MHz, CDCl3) δ 3.73 (t, J = 6.1 Hz, 2H, CH2OH), 
2.25–2.20 (m, 2H, C≡CCH2), 1.85 (br s, 1H, OH), 1.75 (t, J = 2.6 Hz, 3H, C≡CMe), 
1.74–1.67 (m, 2H, HOCH2CH2).  
 
5-Heptynol (39). Using the previously described method, 2-
chloromethyltetrahydropyran (35, 75.0 g, 0.557 mol) was ring 
opened and methylated to yield after vacuum distillation (17 
mbar, 105 °C) 39 as an oil (50.6 g, 0.451 mol, 81% over 2 steps). 1H−NMR (400 
MHz, CDCl3) δ 3.68–3.65 (m, 2H, CH2OH), 2.19–2.14 (m, 2H, C≡CCH2), 1.77 (t, J 
= 2.6 Hz, 3H, C≡CMe), 1.68–1.60 (m, 2H, HOCH2CH2), 1.68–1.60 (m, 2H, CH2), 
1.38 (br s, 1H, OH). 
 
2-Amino-5 heptynoic acid amide (19). To a solution of oxalyl 
chloride (90 mL, 0.965 mol) in CH2Cl2 (1.25 L) at –78 °C was 
added slowly freshly distilled DMSO (87 mL, 1.24 mol). After stirring for 10 min, 
a solution of 4-hexynol (38, 56.6 g, 0.577 mol) in CH2Cl2 (50 mL) was added 
slowly and the reaction was stirred for an additional hour at –78 °C. Then freshly 
distilled Et3N (282 mL, 2.01 mol) was added and the reaction was allowed to 
warm to room temperature while vigorously stirred. The reaction was quenched 
by adding aqueous saturated ammonium chloride (400 mL) and the mixture was 
extracted using Et2O (3 × 400 mL). The combined organic layers were washed 
(brine), dried over Na2SO4 and gently evaporated since the aldehyde was rather 
volatile. The crude 4-hexynal (21) was obtained as a yellowish oil and directly 
used in the Strecker reaction. 
To a solution of NaCN (28.3 g, 0.577 mol) in NH4OH (25 M, 500 mL) and H2O 
(200 mL) was added NH4Cl (30.28 g, 0.577 mol) and the resulting solution was 
stirred for 30 min after which the crude aldehyde in MeOH (50 mL) was added. 
The reaction mixture was stirred for 4 h at 40 °C. It was extracted with Et2O (3 × 
500 mL) and the combined organic layers were concentrated in vacuo to give the 
crude aminonitrile as a yellow oil. Caution is required since this can undergo a 
retro reaction releasing hydrogen cyanide. 
The crude oil was redissolved in NH4OH (25 M, 500 mL) diluted with H2O (200 
mL) and treated with 10 M NaOH (57.7 mL, 0.577 mol) and benzaldehyde (56.0 
mL, 0.577 mol). The resulting mixture was stirred for 4 h at ambient 
temperature. The reaction mixture was extracted using CH2Cl2 (3 × 400 mL), the 
combined organic layers were washed (brine, 200 mL) and concentrated. The 
Me
HO
H2N CONH2
Me
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crude Schiff base thus obtained was dissolved in acetone (350 mL) and treated 
with concentrated hydrochloric acid (37%, 50.8 mL, 0.577 mol). The resulting 
precipitation was collected by filtration and washed using acetone (100 mL), 
yielding the desired amino acid amide 19 (35.4 g, 0.201 mol, 34%) as a white-
powdered HCl-salt. 1H−NMR (400 MHz, D2O) δ 4.16 (t, J = 6.8 Hz, 1H, CαH), 
2.39–2.35 (m, 2H, C≡CCH2), 2.14–2.03 (m, 2H, CαCH2), 1.78 (t, J = 2.5 Hz, 3H, 
C≡CMe). 
 
2-Amino-6-octynoic acid amide (20). 5-Heptynol (28, 20.0 
g, 0.178 mol) underwent the previously described 
transformations to yield eventually the desired amino acid 
amide 20 (25.5 g, 0.134 mol, 75%) as a white-powdered-HCl 
salt. 1H−NMR (400 MHz, D2O) δ 4.07 (t, J = 6.5 Hz, 1H, CαH), 2.26–2.23 (m, 2H, 
C≡CCH2), 2.03–1.98 (m, 2H, CH2), 1.77 (t, J = 2.5 Hz, C≡CMe), 1.62–1.57 (m, 2H, 
CH2). 
 
1-Bromo-2-butyne (27). To a solution of Fe(NO3)3·9H2O (100 mg, 
0.24 mmol) in liquid NH3 (1 L) small turnings (ca. 1 g each) of 
freshly cut Li (20.0 g, 2.86 mol) were added when the color changed from blue to 
grey. Propargyl alcohol (70.0 g, 1.20 mol) was added dropwise over a period of 30 
min. After stirring for 1 h, MeI (75.0 mL, 1.20 mol) was slowly added. The 
mixture was quenched after 2 h using saturated aqueous ammonium chloride 
(400 mL) and the ammonia was allowed to evaporate overnight. The resulting 
mixture was extracted using Et2O (3 × 500 mL), dried (MgSO4) and evaporated to 
give 26 (64.5 g, 0.89 mol) as a yellow oil. 1H−NMR (400 MHz, CDCl3) δ 4.24–4.21 
(m, 2H, CH2OH), 1.86 (t, J = 2.4 Hz, 3H, Me).  
The crude oil 26 (64.5 g, 0.89 mol) was dissolved in Et2O (240 mL) and pyridine 
(12 mL) was added. After cooling to –78 °C, PBr3 (32.4 mL, 340 mmol) was added 
dropwise and the mixture was stirred vigorously for 2 h. The reaction mixture 
was slowly warmed to ambient temperature and subsequently refluxed for 30 
min. After quenching with brine (100 mL), the mixture was extracted with Et2O 
(3 × 150 mL) and concentrated in vacuo. Purification via distillation (bp: 130 °C) 
yielded 27 as a colorless oil (79.5 g, 0.60 mol, 50%). 1H−NMR (300 MHz, CDCl3) δ 
3.91 (q, J = 2.5 Hz, 2H, CH2Br), 1.89 (t, J = 2.6 Hz, 3H, Me); 13C−NMR (50 MHz, 
CDCl3) δ 83.5, 74.3, 15.6, 3.7. 
 
H2N CONH2
Me
Me
Br
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2-Amino-4-hexynoic acid amide (18). To a solution of glycine 
diphenylketimine methyl ester 16 (80.1 g, 317 mmol) and LiI (5.0 
g, 31.7 mmol) in THF (1 L) was added NaH (12.7 g of a 60% 
dispersion in mineral oil, 317 mmol). After heating to reflux, freshly distilled 1-
bromo-2-butyne (27, 30.5 ml, 360 mmol) in THF (50 mL) was added dropwise 
over a period of 45 min. The reaction was refluxed for 2 h and after cooling to 
room temperature quenched using aqueous saturated ammonium chloride (600 
mL). The reaction mixture was extracted using Et2O (3 × 700 mL) and the 
organic phase was washed (brine, 500 mL), dried (Na2SO4) and evaporated, 
yielding 29 as a dark oil (111 g, 311 mmol) in 98% yield.  
The crude oil (110 g, 360 mmol) was dissolved in Et2O (1 L) and aqueous 
hydrochloric acid was added (1 M, 340 mL) at 0 °C. The resulting mixture was 
vigorously stirred overnight at room temperature. The resulting mixture was 
extracted using water and the combined aqueous layers were evaporated, 
yielding a yellowish solid. The solid thus obtained was dissolved in ammonia 
(25%, 800 mL) and after stirring for 2 h the mixture was evaporated. The solid 
was redissolved in water (500 mL) and after the addition of benzaldehyde (33.5 g, 
317 mmol) stirring was continued overnight. The aqueous layer was extracted 
with CH2CL2 (3 × 500 mL) and the combined organic layers were washed (brine), 
dried (MgSO4) and evaporated. Then the oil was dissolved in acetone and 
aqueous hydrochloric acid (37%, 25 mL) was added dropwise, causing the desired 
amide to precipitate. After filtration the residue was washed using acetone, thus 
yielding 18 (37.0 g, 227 mmol, 70.1%) as a white solid. 1H−NMR (D2O, 300 MHz) 
δ 3.55 (t, J = 5.8 Hz, CαH), 2.55–2.53 (m, 2H, C≡CCH2), 1.79 (t, J = 2.5 Hz, 
C≡CMe). 
2-Amino-4-pentynoic acid amide (17). Using the previously 
described method, glycine diphenylketimine methyl ester (16, 20.0 
g, 79.0 mmol) was alkylated with propargyl bromide (12.8 g, 103 
mmol) yielding 17 (23.0 g, 78.0 mmol) as a yellowish oil. Further treatment as 
described previously yielded after ion exchange chromatography (Dowex 50W×4 
H+-form, 20−50 mesh, Fluka) a yellowish powder (5.18 g, 46.0 mmol, 78%). 
1H−NMR (D2O, 400 MHz) δ 4.37 (t, J = 5.8 Hz, 1H, CαH), 3.07–3.05 (m, 2H, 
C≡CCH2), 2.75 (t, J = 2.1 Hz, 1H, C≡CH). 
 
General procedure for the enzymatic 
resolution, exemplified for 2-amino-4-
pentynoic acid (4). A solution of the racemic 
Me
CONH2H2N
CO2HH2N CO2HH2N
CONH2H2N
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amide 17 (12.0 g, 105 mmol) in distilled H2O (80 mL) was brought to pH = 9.2 
with 1 N aqueous KOH, followed by addition of an 80 mM solution of MnSO4 
until a 1 mM concentration was reached. H2O was added until a volume of 120 
mL was reached. Then whole E. coli DH5a/ pTrpLAP cells (48 mg) in a HEPES 
buffer (1 mL) were added. The reaction mixture was shaken at 40 °C for 24 h. 
The reaction mixture was brought to pH = 6 by carefully adding H2SO4. The 
enzyme was filtered off the solution, and by adding NaOH the pH was brought at 
8−9; then benzaldehyde (7.5 mL, ~0.7 equiv) was added and the resulting 
mixture was stirred for 4 h. The mixture was extracted using CHCl3 and the 
aqueous layer was concentrated and purified on ion exchange chromatography 
(Dowex 50). Upon lyophilization, (S)-4 was obtained as a white powder (4.7 g, 42 
mmol, 39%).  
The organic layer was concentrated and redissolved in acetone (300 mL) after 
which aqueous concentrated HCl was added (~6 mL, 37%), causing a 
precipitation. After filtration the HCl-salt of (R)-amino acid amide 17 (6.0 g, 41.0 
mmol, 38%) was obtained. The (R)-amino acid amide was dissolved in buffer 
(concentration 5%, pH = 8 (500 mL 0.1 M NaH2PO4 + 467 mL 0.1 M NaOH). 
Enzyme extracts from Rhodoccocus erythropolis (NCIMB 11540, 0.2 equiv in 
weight) were added and the reaction mixture was stirred at 37 °C for 3h. The 
reaction mixture was filtered over a short path of Celite, acidified to pH = 5, 
concentrated and further purified by ion exchange chromatography (Dowex 50). 
Concentration using freeze-drying yielded (R)-4 as a white fluffy solid (4.6 g, 40 
mmol, 38%).1H−NMR (D2O, 400 MHz) δ 4.37 (t, J = 5.75 Hz, 1H, CαH), 3.06−3.05 
(m, 2H, C≡CCH2), 2.75 (t, J = 2.4 Hz, 1H, C≡CH); 13C−NMR (100 MHz, D2O) δ 
175.5, 77.1, 76.3, 55.7, 23.3. 
2-Aminohex-4-ynoic acid (13). Using the 
previously described method for enzymatic 
resolution, 18 (20.2 g, 0.124 mol) was converted in 
(S)-13 (6.22 g, 49 mmol, 40%) and (R)-13 (6.55 g, 52 
mmol, 42%), both as a fluffy white solid. 1H−NMR (D2O, 400 MHz) δ 3.85−3.83 
(m, 1H, CαH), 2.77−2.75 (m, 2H, C≡CCH2), 1.77 (t, J = 2.4 Hz), 3H, C≡CMe); 
13C−NMR (100 MHz, D2O) δ 175.9, 84.4, 74.7, 56.1, 23.6, 5.2. 
 
2-Aminohept-5-ynoic acid (14). Using the 
previously described method for enzymatic 
resolution, 19 (14.1 g, 80 mmol) was 
converted in (S)-14 (4.49 g, 32 mmol, 40%) and (R)-14 (4.73 g, 33 mmol, 41%), 
Me
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CO2HH2N
Me
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both as a fluffy white solid. 1H−NMR (D2O, 400 MHz) δ 3.84 (dd, J = 5.2 Hz, 7.4 
Hz, 1H, CαH), 2.40−2.21 (m, 2H, C≡CCH2), 2.19−2.07 (m, 1H, CαCH2), 2.05−1.94 
(m, 1H, CαCH2), 1.77 (t, J = 2.41 Hz, 3H, C≡CMe); 13C−NMR (100 MHz, D2O) δ 
176.0, 82.0, 79.5, 55.1, 32.6, 17.0, 5.2. 
 
2-Aminooct-6-ynoic acid (15). Using the 
previously described method for enzymatic 
resolution, 20 (22.0 g, 0.115 mol) was 
converted in (S)-15 (7.87 g, 51 mmol, 44%) 
and (R)-15 (7.69 g, 50 mmol, 43%), both as a fluffy white solid. 1H−NMR (D2O, 
400 MHz) δ 3.76 (t, J = 6.1 Hz, 1H, CαH), 2.25−2.21 (m, 2H, C≡CCH2), 2.11−1.88 
(m, 2H, CH2), 1.77 (t, J = 2.5 Hz, 3H, C≡CMe), 1.68−1.48 (m, 2H, CH2); 13C−NMR 
(100 MHz, D2O) δ 174.9, 81.7, 80.8, 55.5, 32.7, 26.3, 20.3, 5.1. 
 
General procedure for (S,S)-DBTAAN mediated ee determinations. 
In a NMR−tube, the amino acid (4 mg) was mixed with 0.4 M Na2B4O7 (0.5 mL in 
D2O) and (S,S)-DBTAAN (0.5 mL, 50 mM in CD3CN). After 3 h, 1H−NMR was 
recorded using CD3CN as lock signal. For the ee-determination, the integral 
values of the anhydride α-proton were compared to a reference racemic mixture. 
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3   CONSTRAINED CYSTINE MIMICS 
 
3.1  Introduction 
 
Introduction of covalent linkage in peptide structures in order to stabilize the 
tertiary structure is a feature occurring in Nature. This mostly proceeds through 
the formation of sulfur bridges resulting in cystine (1) cross-links, which, 
however, are susceptible to natural degradation pathways. Hence, obvious 
artificial constraints in peptides might be based on the corresponding carbon 
analogues 2, e.g. diaminosuberic acid-derived cross-links (Figure 1).  
 
HO2C
NH2
S
S
NH2
CO2H
HO2C
NH2
NH2
CO2H
1 2  
Figure 1. Cystine (1) and diaminosuberic acid (2). 
 
Nevertheless, to create a good mimic, the properties of the carbon bridge should 
not deviate too much from its sulfur counterpart. In comparing the sulfur to the 
carbon bridge, there is a difference in flexibility, but also in the electronic 
properties. The group of Tirrell investigated the in vivo substitution of 
methionine with a series of (un)saturated amino acids with side chains of various 
lengths.1 It was shown that the acetylene moiety served particularly well as a 
mimic of the methyl thioether moiety of methionine in bacterial protein 
synthesis. Calculated equipotential surfaces on methionine showed that the 
electron density associated with the triple bond is positioned similar to that of 
the thioether of methionine, despite the difference in geometry of the side chain. 
Taking this into account, we performed similar orbital modeling on cystine and 
its alkyl, olefin and alkyne counterparts (Figure 2).2 The electron density is 
concentrated at the sulfur bridge due to the sulfur d-orbitals. This electron 
density is absent in the saturated carbon isostere 2 (the observed density is due 
to proximity effects of the functional groups) and rather minute in its olefin 
counterpart 3. The alkyne isostere 4, however, shows a clear band around the 
unsaturation, caused by the sp-hybridization of the carbons. 
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Figure 2. Electron potentialsurfaces: cystine (1), the alkyl (2), alkene (3) and alkyne (4) isosteres.3 
 
Currently, several synthetic routes to diaminosuberic acid derivatives are 
available, which are briefly surveyed in this section. Most of these syntheses 
consist of two (protected) glutamates, which are connected using the 
Kolbedimerization (Scheme 1).4 This reaction proceeds via electrolysis, 
generating an unstable radical on the anode, that after loss of CO2 results in 
dimerization. A significant drawback of this approach is that orthogonal 
protection is difficult due to the formation of statistical mixtures of products. 
Apart from this, the dimerization proceeds generally in low yields. 
 
R1HN CO2R
R1HN CO2R
NHR1RO2C
electrolysis
31%
CO2H
 
Scheme 1. Kolbe electrolysis. 
 
A synthesis of the Peterson group involves use of the chiral catalyst 7 to generate 
two new stereocenters in a double asymmetric alkylation of the glycine-derived 
ketimine 5 (Scheme 2).5 An interesting drawback is the directing effect of the 
first stereocenter in the second alkylation, causing that the diastereoselectivity is 
significantly lower than the enantioselectivity of the first step. 
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N CO2tBuPh
Ph
N CO2tBuPh
Ph
N CO2tBu
Ph
PhN
OH
N
H
Br
5 6
7
H
 
Scheme 2. Reagents and conditions: Catalyst 7 (10 mol %) 50% aqueous KOH/toluene, (E)-1,4-
dibromo-2-butene (de 82%, ee >95%). 
 
These two examples give rise to diaminosuberic acid, but the drawback of 
orthogonal protection remains. There is no discrimination possible between the 
identical functional groups. To solve this problem each stereocenter has to be 
generated independently from differently protected glycine moieties or the two 
amino acid moieties must be linked via the side chains using appropriate 
orthogonal protective groups. An example by Williams et al. of the latter 
approach is shown in Scheme 3,6 where two allylglycine moieties are connected to 
a tether in an asymmetric fashion. Ring-closing metathesis, followed by 
deprotection leads to orthogonally protected diaminosuberic acid derivative 10. 
 
O
O
O
BocHN
HN
O
CO2Ph O
O
O
BocHN
HN
O
CO2Ph
BocHN CO2H
H2N CO2Ph
Ru
PCy3
Cl
Cl
Ph
PCy3
a b
11
8 9 10  
Scheme 3. Reagents and conditions: a) catalyst 11, CH2Cl2 (82%); b) i: H2, Pd/C; ii: pTSA, H2O. 
 
Apart from the fact that this is a lengthy route, the metathesis reaction gives rise 
to a mixture of (E)- and (Z)-isomers (viz. 9). To solve this, the resulting double 
bound is often reduced with concomitant removal of the benzyl protective groups. 
However, besides the fully saturated structure – which is more flexible than 
cystine and lacks its electronic properties – one would also like to have access to 
the unsaturated suberic acid derivatives in geometrically pure form.  
Acetylene-based diaminosuberic acid derivatives such as alkyne isostere 4 
(Figure 2) are even more interesting mimics of cystine, especially considering the 
electron potential surfaces. The latter class of molecules can be formed via ring-
closing alkyne metathesis, in an approach that resembles the one of Williams 
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(Scheme 4). Proof for this concept was generated in our own group in a 
collaborative effort,7 leading to well-defined cystine mimics 13 and 14 with 
comparable rigidity. Although this sequence was applied to form olefin- and 
acetylene-containing diaminosuberic acid derivatives, we have not been fully able 
to prepare orthogonally protected unsaturated cystine mimics. 
 
O
O
NH
O
CO2tBu
Me
O NHBoc
Me
O
O
NH
O
CO2tBu
O NHBoc
BocHN CO2H
FmocHN CO2tBu
(tBuO)3W
Me
Me
Me
a b
15
12 13 14  
Scheme 4. Reagents and conditions: a) 15, PhCl, 80 °C (66%); b) H2, Pd/C then FmocOSu (76%). 
 
Thus, in order to create access to the desired unsaturated orthogonally protected 
cystine mimics, a direct C-C bond forming reaction between two optically active 
amino acid fragments would be the most straightforward method. Considering 
potential pitfalls such as orthogonal protection, racemization of the stereocenters 
and vulnerability of the acetylene bond, the available synthetic tools that might 
be applied are rather limited.  
General methods to make sp-sp3 C-C bonds involve deprotonation of the 
acetylene moiety using a strong base (typically BuLi or EtMgBr), followed by  
nucleophilic attack on a suitable alkylating reagent. Obviously, this sequence 
cannot easily be applied to amino acid synthesis due to the risk of racemization of 
the amino acid stereocenters. Therefore, alternative activation of the functional 
groups involved is required. Interestingly, in searching the literature for suitable 
methodology, only a limited number of methods was identified that could be 
applied to our situation. We envisioned that the coupling of a haloacetylene with 
an iodide-derived Zn-Cu reagent would be a sufficiently mild method to reach our 
goal (Scheme 5). 
CO2R3RHN
R1O2C NHR2
CO2R3RHN
R1O2C NHR2
Br
I
16 17
18
 
Scheme 5. Retrosynthesic approach to unsaturated cystine mimics. 
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Early reports by Knochel indicate that zinc/copper reagents do not react with 
ketones,8 esters and nitriles and react under generally mild reaction conditions 
with suitable electrophiles. As shown in Scheme 6, a primary or secondary iodide 
(19) can be transformed into the stable organozinc compound 20, which after 
transmetalation to the copper complex 21, can react with a haloacetylene (22) to 
form the new acetylene 23. 
 
R I
Zn*, THF, 25-40 oC
4-12 h
R ZnI
CuCN. 2LiX
0 oC, 10 min
R Cu(CN)ZnI
19 20 21
X R1
R R1
23
22
 
Scheme 6. Formation zinc/copper reagents. 
 
Extensive research on zinc activation of iodonated amino acids has been 
performed by the group of Jackson.9 
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Scheme 7. Stabilization of the zinc intermediate in DMF. 
 
Coordination of the carbamate carbonyl (viz. 24) in THF is expected to give 
elimination to form an acrylate,10 but since a bidentate complex with the ester 
carbonyl is formed, the elimination is prevented. This was proven by comparison 
with the corresponding β- and γ-amino acid-derived organozinc/copper species, 
where the stabilizing effects were less pronounced and thus more elimination 
was observed. This was further underlined by the observation that replacement 
of the ester by an amide also gave a decrease of the stabilizing effect. Titration 
experiments with DMF showed a progressive weakening of the coordination of 
zinc with the carbamate and strengthening of the coordination to the ester group 
(viz. 25).11 Although both THF and DMF are suitable solvents for organozinc 
reagents, this result suggests that in this case DMF is the solvent of choice. 
In the course of our work,12 a successful application was published by the Trost 
group,13 in which the (S)-serine-derived iodide 27 was coupled to the acetylenic 
precursor 26 to undergo a hydrative cyclization using ruthenium catalysis 
leading to the carbon skeleton of cylindricin C (29). 
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Br
C6H13
BocHN CO2Me
I
Zn*, CuCN /2 LiCl
44%
C6H13
CO2Me
BocHN
N
OH
O
Me
C6H13
26
27
28 29
Scheme 8. Zn/Cu-mediated C-C bond formation in the synthesis of cylindricin C (29). 
 
This chapter details with our investigation on the potential use of amino acid-
derived organozinc reagents in the formation of sp-sp3 C-C bonds with the aim to 
prepare new acetylene-containing amino acids (Scheme 5). These unsaturated 
amino acids should then serve to prepare orthogonally protected diaminosuberic 
acid derivatives. 
 
3.2  Starting materials 
 
(S)-Serine was protected in two steps to give 31, which is a suitable precursor to 
form the iodinated counterpart 27.14 Initial attempts to form the iodide using 
triphenylmethylphosphonium iodide failed, but treatment with 
triphenylphosphine, iodine and imidazole, as shown in Scheme 9, eventually 
yielded the desired compound 27 in reasonable yield.  
 
OH
CO2HH2N
(S)-serine
OH
CO2MeBocHN
I
CO2MeBocHN
OH
CO2MeH2N
a b c
2730 31  
Scheme 9. Reagents and conditions: a) SOCl2, MeOH, reflux; b) Boc2O, Et3N, THF (99%, 2 steps); 
c) PPh3, imidazole, I2, CH2Cl2 (72%).  
 
An alternative approach relied on tosylation of 31 and subsequent nucleophilic 
attack of NaI, but this gave compound 27 in a much lower yield due to 
elimination. 
As a coupling partner, racemic 2-amino-4-pentynoic acid (32) was chosen to probe 
our approach (Scheme 10). Standard protecting group introduction delivered 
compound 34 which was subjected to the halogenation conditions. While a 
combination of iodine and morpholine gave no reaction, treatment with a 
catalytic amount of silver nitrate and N-bromosuccinimide (NBS) successfully 
provided the bromoacetylene 35 in 72% yield. Eventually this latter method 
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proved a reliable and convenient method for introducing the halide substituents 
on the acetylene under mild conditions.  
CO2HH2N CO2MeBocHN CO2MeBocHN
Br
a b c
CO2MeH2N
32 33 34 35  
Scheme 10. Reagents and conditions: a) SOCl2, MeOH, reflux; b): Boc2O, Et3N, THF (88%, 2 
steps); c) AgNO3, NBS, acetone (72%). 
 
This reaction also proceeded well with N-iodo instead of N-bromosuccinimide, but 
the resulting iodoacetylene appeared to be unstable and fully decomposed in 
several hours. The bromide on the other hand was stable and did not show any 
decomposition upon storage at 0 °C for weeks. 
 
3.3  Benchmark studies 
 
In preparing the acetylenic amino acids (viz. 36 and 37), one could on the one 
hand start from serine-derived iodide 27 and 1-bromo-1-heptyne, and on the 
other hand from 1-iodopentane and 35 (Scheme 11). Both will lead to the same 
compound, but start from different amino acids. Since 1-iodoheptane cannot 
undergo β-elimination and is commercially available, initial experiments were 
performed on the latter pathway.  
 
BocHN CO2Me
I
Me
Br
BocHN CO2Me BocHN CO2Me
Br
I
(  )4 (  )n (  )6
Me Me
a a
36 (n=4)
37 (n=6)
3527
 
Scheme 11. Reagents and conditions: a) Zn*, CuCN/2·LiCl, DMF. 
 
In all cases, so-called Riecke zinc (indicated with Zn*: zinc (99.998%) treated with 
1,2-dibromoethane at elevated temperatures, followed by treatment with 
Me3SiCl) was used to form the initial organozinc species upon addition of the 
iodide under vigorous stirring. The first attempts in dry THF resulted in no 
reaction at all, but with DMF as a solvent the desired organozinc species were 
readily formed.  
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This species must then be transmetallated with copper cyanide. Upon mixing, 
copper(I) cyanide and lithium chloride form a green soluble  complex within a few 
minutes. After three hours, stirring of the organozinc compound was 
discontinued and the zinc was allowed to settle. DMF was added to the 
CuCN/LiCl mixture and cooled to –18 °C, after which the organozinc reagent was 
added using a syringe. After five minutes, bromoacetylene 35 was added and the 
resulting mixture was allowed to warm to room temperature during the night. A 
successful conversion into the product could be readily observed in 1H−NMR 
since the newly formed methylene adjacent to the acetylene function shifts to δ 
2.65 ppm, a rather unique position in most NMR-spectra. After several test 
reactions, the yield was optimized to 75% yield. 
The addition of palladium catalysts has also been reported for these reactions, 
but in our hands did not change the outcome of the coupling. Furthermore, it has 
also been shown that the stoichiometric amounts of CuCN/2LiCl may be replaced 
by a catalytic amount of CuBr•SMe2.15 In this case, however, the catalytic 
procedure only led to decomposition. 
 
3.4  New acetylenic amino acids 
 
A small series of alkyl iodides was used to probe the viability of this method as 
shown in Scheme 12. In all cases, the desired products 38-40 were formed, with 
the primary iodides giving somewhat lower yields than the secondary iodide. In 
case the reaction was not carefully conducted under fully inert conditions, 
elimination was observed resulting in recovered bromoacetylene and the 
dehydroalanine derivative 41.16 
 
BocHN CO2Me
Br
BocHN CO2Me
38, n = 1, 49%
39, n = 2, 30%
R
Ph
40, 81%
CO2MeBocHN
(  )n
a
35
41  
Scheme 12. Reagents and conditions: a) Zn*, CuCN/2·LiCl, R-I, DMF. 
 
In summary, building block 35 can be used to provide a range of allyl 
functionalized acetylenic amino acids based on coupling of brominated 2-amino-4-
pentynoic acid (35) with virtually any aliphatic iodide. 
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This first approach is somewhat hampered through the limited availability of 2-
amino-4-pentynoic acid. In that sense, the alternative pathway, starting from 
readily available enantiopure serine, has a clear advantage. Thus, upon reaction 
of 27 with the required metals, coupling reactions with halogenated commercially 
available acetylenes were carried out (Scheme 13). For example, use of 
brominated Me3Si-acetylene (42) yielded adduct 43 in 52% yield, which is a 
useful precursor for ring-closing alkyne metathesis (see: Chapter 5).17 
 
BocHN CO2Me
I
BocHN CO2Me
R
a
27  
Bromide   Product                        (isolated yield) 
SiMe3
Br
42  
SiMe3
43
BocHN CO2Me
(52%)
 
OTBS
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44  
OTBS
45
BocHN CO2Me
(61%)
 
O
BnO
BnO
BnO
OBn
Br
46  
 
O
BnO
BnO
BnO
OBn
47
CO2Me
BocHN
(52%)
 
Br
I
48  
49
I
BocHN CO2Me
(41%)
 
Scheme 13. Reagents and conditions: a) Zn*, CuCN/2·LiCl, R-Br, DMF. 
 
Other interesting bromoacetylenes are sugar-derived acetylenes such as 46. 
Coupling with 27 led to the glycoamino acid 47, containing a stable linkage that 
might be isosteric with the naturally occurring labile acetal function. Considering 
the mild conditions, one could envision that this approach might be followed to 
make more complicated stable mimics of biologically relevant glycopeptides.18 We 
proved that the optical purity was retained under these mild coupling conditions 
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while previous methods involved strong basic conditions and amino acid 
protection to reach the same compounds.19 
Interestingly, a similar approach was independently pursued in the group of 
Isobe (Scheme 14).20 Describing an identical coupling of the same iodide with the 
α-configured acetylenic glucose derivative, the anomeric glycoamino acid 51 was 
obtained.  
 
O
OBn
BnO
BnO
BnO
I
CO2MeBocHNH
Br
O
OBn
BnO
BnO
BnO
H
NHBoc
CO2Me
27
50 51
 
Scheme 14. Reagents and conditions: a) Zn*, CuCN/2·LiCl, R-Br, DMF (40%). 
 
A fourth example involving bromide 54 led to the ester-substituted acetylenic 
amino acid 55. In fact, one could consider 55 as a rigidified derivative of glutamic 
acid which could be used in the active site of peptide systems where glutamic 
acids usually display a dominant role. 
CO2tBuBocHN
I
CO2tBuBocHN
CO2EtBr
CO2tBuBocHN
CO2Et
a b
52 53 55
54
 
Scheme 15. Reagents and conditions: a) i: O3, CH2Cl2 then NaBH4, MeOH; ii: PPh3, I2, imidazole, 
CH2Cl2 (20%, 2 steps); b) Zn*, CuCN/2·LiCl, 54, DMF (27%). 
 
Sterically encumbered allylglycine tert-butyl ester (52) was transformed to 
homoserine via ozonolysis.21,22 Treatment with triphenylphosphine and iodine 
provided the desired precursor 53 in a disappointing yield of 27%.23 Using the 
optimized organozinc conditions, reaction with bromide 54 afforded product 55 in 
an isolated 27% yield.24 Presumably 54 also can undergo Michael-addition, which 
may cause the low yield.  
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3.5 Direct isostere synthesis 
 
Having established a general protocol for the coupling of serine-derived iodides 
with bromoacetylenes, we focused our efforts on the formation of unsaturated 
diaminosuberic acid derivatives. Several differently protected iodides were made 
and coupled with orthogonally protected bromoacetylenes (Scheme 16).  
 
CO2R3RHN
R1O2C NHR2
CO2R3RHN
R1O2C NHR2
Br
I 64   Boc    Me   Boc      Me    61
65   Boc    Me   Ph2C= Me    43
66   Boc    Me   Ns        Me     -
67   Trt      Me   Boc      Me     -
68   Cbz    tBu   Fmoc   Bn      -
69   Cbz    tBu   Boc      Me     -
70   Fmoc Allyl  Boc      Me     -
71   Boc    Allyl  Boc      Me    35
72   Boc     Bn    Fmoc   Bn      -
73 Fmoc  Bn    Boc      Me -
R R3 R2 R1
R         R3
27   Boc     Me
56   Boc     Bn
57   Boc     Allyl
58   Fmoc  Allyl
59   Cbz     tBu
R1         R2
35    Me         Boc
60    Me         Ns
61    tBu         Fmoc 
62    Bn          Fmoc
63    Ph2C=    Me
+
yield
(%)
 
Scheme 16. Reagents and conditions: Zn*, CuCN/2·LiCl, DMF. 
 
Initially, the reactions were performed with rac-35 derivatives and (S)-serine-
derived iodides, both in tert-butyl carbamate- and methyl ester-protected form. 
This coupling under identical conditions eventually gave rise to a gratifying yield 
of 61% of 64 as a mixture of the two possible diastereoisomers. The non-
orthogonal isostere 65 also resulted in a reasonable yield of 43%. This example 
has the main advantage that the propargyl unit can be made according to 
asymmetric protocols as outlined in chapter 2. 
Attempts to utilize Ns- or Trt-groups (66 and 67) were unsuccessful due to the 
nature of the protecting group. Use of Cbz (68 and 69), Bn (72 and 73) and Fmoc 
(68, 70, 72 and 73) were also to no avail. In some cases, only unidentifiable side-
products were formed in low yield. On the other hand, an allyl ester such as 71 
could be coupled in 35% yield. 
These attempts to find a generic protocol for orthogonal protection led us to 
conclude that this is not possible in a straightforward manner. Apart from the 
difficult syntheses and side-reactions that take place in a number of cases, yields 
are generally rather low when coupling two amino acid fragments using this 
methodology.  
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Figure 3. 
 
Somewhat in contrast, in case a homoserine-derived iodide was used, a facile 
conversion to orthogonally protected 74 (Figure 3) was achieved in 59% yield, 
albeit as a mixture of all possible diastereoisomers. 
 
3.6  Conclusions 
 
The investigations concerning organozinc couplings of acetylenes provided 
interesting pathways for the synthesis of new amino acids under mild, non-
racemizing conditions. Since the amino acid moiety can either act as the 
electrophile or nucleophile, a wide range is open for its application. This is 
confirmed by several interesting examples which appeared in literature during 
the course of this research. 
However, the ultimate goal of synthesizing fully orthogonally protected 
diaminosuburic acid derivatives proved to be difficult to reach. Despite these 
setbacks, a reaction based on a homoserine-derived iodide provided an example of 
such a molecule in satisfactory yield.  
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3.8  Experimental section  
 
For general experimental details, see: Section 2.8. 
 
Methyl 2-[(tert-butoxycarbonyl)amino]-3-hydroxypropanoate (31)25.  
To a suspension of (S)-serine (2.00 g, 19.0 mmol) in MeOH (25 
mL) was added dropwise SOCl2 (4.00 mL, 52.8 mmol) and the 
resulting clear solution was refluxed for 2 h. The volatiles were 
OH
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removed in vacuo and Et3N (6.00 mL, 42.7 mmol) in THF (50 mL) was added. To 
this solution Boc2O (5.92 g, 27.1 mmol, lumps in frozen form) was added and the 
resulting mixture was stirred overnight at room temperature. After evaporation 
further purification using flash chromatography (50% EtOAc in heptane) yielded 
31 as a clean oil (4.13 g, 18.8 mmol, 99%). An alternative method uses K2CO3 
(3.97 g, 26.4 mmol) and Boc-Ser-OH (4.92 g, 24.0 mmol) which were suspended in 
DMF (25 mL) at 0 °C and vigorously stirred. After 10 min, MeI (3.03 mL, 48.2 
mmol) was added dropwise and stirring was continued for 2 h. Water (40 mL) 
was added and the reaction mixture was extracted using EtOAc (3 × 40 mL). The 
organic layer was washed (brine, 25 mL), dried and evaporated, yielding 
protected amino acid 31 (3.57 g, 16.1 mmol, 66%). 1H−NMR (300 MHz, CDCl3) δ 
5.49−5.34 (bs, 1H, NH), 4.44−4.32 (m, 1H, CαH), 4.00−3.86 (m, 2H, CH2OH), 3.78 
(s, 3H, OMe), 2.37−2.22 (m, 1H, OH), 1.46 (s, 9H, Boc); 13C−NMR (75 MHz, 
CDCl3) δ 171.4, 155.7, 80.0, 63.1, 55.6, 52.4, 28.1. 
 
General procedure for bromination: 
Methyl (2S)-5-bromo-2-[(tert-butoxycarbonyl)amino]-4-pentynoate (35).  
To a solution of N-bromosuccinimide (5.64 g, 31.5 mmol) and 2-
tert-butoxycarbonylamino-4-pentynoic acid methyl ester (34,6.81 
g, 31.4 mmol) in acetone (90 mL) was added AgNO3 (10.0 mg, 
0.06 mmol). The mixture was stirred for 1 h and monitored 
using TLC (Note: Rf-values differ ~ 0.02 or less). Water (100 mL) was added and 
the mixture was extracted using pentane (3 × 75 mL). The organic layers were 
combined and washed (brine, 50 mL), dried (Na2SO4) and evaporated, yielding 35 
as a yellowish solid (7.20 g, 25.5 mmol, 85%). [α]D = +39.4 (c = 1.46, CH2Cl2); Mp 
= 55 °C; 1H−NMR (300 MHz, CDCl3) δ 5.35 (d, J = 7.7 Hz, 1H, NH), 4.47−4.32 (m, 
1H, CαH), 3.76 (s, 3H, OMe), 2.73 (d, J = 5.0 Hz, 2H, CH2), 1.44 (s, 9H, Boc); 
13C−NMR (75.5 MHz, CDCl3) δ 171.0, 155.0, 80.3, 74.6, 52.7, 51.9, 41.7 (C≡CBr), 
28.3, 24.1; IR ν 2977, 1747, 1714, 1507, 1366, 1248, 1163, 1058 cm−1; HRMS (EI): 
calculated for C7H8NO4Br (M − Boc)+, 248.96367, found 248.96357.  
 
Methyl 5-bromo-2-[(4-nitrophenyl)sulfonyl]amino-4-pentynoate (60).  
Using the general procedure for bromination 2-[4-
nitrophenylsulfonylamino]-4-pentynoic acid methyl ester (347 mg, 
1.11 mmol) was transformed in its corresponding bromide 60 (427 
mg, 1.09 mmol, 98%). 1H−NMR (300 MHz, CDCl3) δ 8.06−8.03 (m, 
1H, ArH), 7.91−7.87 (m, 1H, ArH), 7.74−7.71 (m, 2H, 2 × ArH), 6.40 (bd, J = 8.7 
CO2MeBocHN
Br
Br
CO2MeNsHN
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Hz, 1H, NH), 4.34−4.28 (m, 1H, CαH), 3.57 (s, 3H, OMe), 2.76 (d, J = 5.1 Hz, 2H, 
C≡CCH2); 13C−NMR (75.5 MHz, CDCl3) δ 169.5, 133.8, 133.0, 130.2, 125.6, 73.1, 
54.8, 53.0, 29.5, 24.8; IR ν 3305, 3094, 2955, 1742, 1708, 1538, 1355, 1167 cm−1. 
 
tert-Butyl (2S)-5-bromo-2-[(9H-9-fluorenylmethoxy)carbonyl]amino-4-
pentynoate (61). Using the general procedure for bromination 
2-(9-fluorenyl-methoxycarbonyl)amino-4-pentynoic acid tert-
butyl ester (371 mg, 0.95 mmol) was brominated, resulting in 
61 as a white solid (358 mg, 0.76 mmol, 81%). 1H−NMR (300 
MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H, 2 × ArH), 7.58 (d, J = 7.5 Hz, 2H, 2 × 
ArH), 7.37 (t, J = 7.2 Hz, 2H, 2 × ArH), 7.29 (t, J = 7.2 Hz, 2H, 2 × ArH), 5.65 (bd, 
J = 7.5 Hz, 1H, NH), 4.43−4.33 (m, 3H, OCH2, CαH), 4.22 (t, J = 6.9 Hz, 1H, 
FmocαH), 2.76 (d, J = 4.2 Hz, 2H, C≡CCH2), 1.49 (s, 9H, Boc); 13C−NMR (75.5 
MHz, CDCl3) δ 168.8, 155,2, 143.5, 141.0, 127.5, 126.9, 124.9, 119.8, 82.9, 74.8, 
67.2, 52.8, 47.2, 28.1, 24.2.  
 
Benzyl (2S)-5-bromo-2-[(9H-9-fluorenylmethoxy)carbonyl]amino-4-
pentynoate (62). (S)-2-(9-fluorenyl-methoxycarbonyl)amino-4-
pentynoic acid (594 mg, 1.77 mmol), dissolved in DMF (15 mL) 
was treated with K2CO3 (273 mg, 1.95 mmol) and benzyl 
bromide (362 mg, 2.12 mmol) and stirred overnight. After 
partitioning between H2O (30 mL) and heptane (40 mL) the aqueous phase was 
extracted with heptane (2 × 30 mL). The combined organic layers were washed 
(brine, 20 mL), dried (Na2SO4) and evaporated which yielded 310 mg of the 
benzyl ester. Using the general method for bromination this solid was 
transformed into its corresponding bromide 62, a white solid (287 mg, 0.61 mmol, 
35%, 2 steps). [α]D = 7.4 (c = 1.15, CH2Cl2); 1H−NMR (400 MHz, CDCl3) δ 7.77 (d, 
J = 7.3 Hz, 2H, ArH-Fmoc), 7.61 (d, J = 7.3 Hz, 2H, ArH-Fmoc), 7.43−7.31 (m, 
9H, 5 × OBn, 4 × ArH-Fmoc), 5.65 (bd, J = 8.7 Hz, 1H, NH), 5.24 (q, J = 15.1 Hz, 
2H, ArCH2O), 4.48−4.52 (m, 1H, CαH), 4.43−4.38 (m, 2H, CH2O-Fmoc), 4.25 (t, J 
= 7.3 Hz, 1H, CαHFmoc), 2.83 (d, J = 4.4 Hz, CH2, BrC≡CCH2); 13C−NMR (75.5 
MHz, CDCl3) δ 170.0, 155.4, 143.7, 141.1, 134.9, 128.5, 128.4, 128.2, 127.6, 127.0, 
125.0, 119.9, 74.4, 67.5, 67.1, 52.4, 46.9, 23.8; IR ν 2977, 1747, 1714, 1506, 1366, 
1248, 1163, 1068 cm−1; HMRS (FAB)+ calcd for C27H23O4NBr 504.08105, found 
504.0810. 
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1-(2-Bromo-1-ethynyl)-2-iodobenzene (48).25 To a solution of 
phenylacetylene (1.50 g, 14.9 mmol) in THF (15 mL) was added, at 
below −40 °C, butyllithium (16.5 mL, 2.2 M in hexane). The 
mixture of lithium phenylacetylene and butyllithium thus obtained was cooled to 
−70 °C and a solution of tBuOK (3.2 g, 28 mmol) in THF (20 mL) was added over 
30 min, while maintaining the temperature of −70 °C. After stirring for an 
additional period of 30 min at this temperature, the cooling system was removed. 
The temperature was allowed to rise to 5 °C, after which a further amount of 
tBuOK (1.70 g, 15 mmol) in THF (10 mL) was added to destroy any unreacted 
alkyllithium. A fresh solution of MgBr2 (obtained by slowly adding 1,2-
dibromoethane (9.81 g, 52.2 mmol) to a stirred suspension of magnesium (1.82 g, 
67 mmol) and 15 mL of refluxing diethyl ether) was added at 0 °C and stirring at 
25 °C was continued for 1 hour. Iodine (5.2 g, 21 mmol) was added and the 
reaction was quenched after 45 min by addition of a cold 2 M HCl solution (20 
mL). The reaction mixture was extracted using pentane (3 × 30 mL), washed 
using aqueous saturated sodium thiosulfate, dried (Na2SO4) and evaporated. 
Further purification using column chromatography (2% EtOAc in heptane) 
afforded the desired compound (2.83 g, 1.24 mmol, 67%) as yellowish oil. 
1H−NMR (300 MHz, CDCl3) δ 7.84 (dt, J = 1.2 Hz, 8.1 Hz, 1H, IC=CH), 7.46 (dq, 
J = 1.8 Hz, 7.8 Hz, 1H, Ar), 7.30 (dt, J = 1.2 Hz, 7.5 Hz, 1H, Ar), 7.02 (dq, J = 1.5 
Hz, 7.5 Hz, 1H, Ar), 3.39 (s, 1H, C≡CH); 13C−NMR (75.5 MHz, CDCl3) δ 138.7, 
138.5, 133.4, 129.9, 127.7, 127.6, 100.4, 80.9. Using the general method for 
bromination 1-ethynyl-2-iodo-benzene (1.01 g, 4.45 mmol) was transformed into 
its corresponding bromide 48 (1.179 g, 3.85 mmol, 86%) as an oil. 1H−NMR (300 
MHz, CDCl3) δ 7.81 (dd, J = 0.9 Hz, 8.1 Hz, 1H, IC=CH), 7.43 (dd, J = 1.2 Hz, 7.2 
Hz, 1H), 7.28 (dt, J = 1.2 Hz, 7.5 Hz, 1H), 7.01 (dt, J = 1.5 Hz, 7.8 Hz, 1H); 
13C−NMR (75.5 MHz, CDCl3) δ 138.6, 138.5, 133.5, 133.2, 129.7, 1277, 100.5, 54.1 
(CBr). 
 
(2-Bromo-1-ethynyl)(trimethyl)silane (42).25 Using the 
general procedure for bromination (1-ethynyl)(trimethyl)silane (1.00 g, 10.2 
mmol) was transformed, resulting after distillation in product 42 (1.14 g, 6.4 
mmol, 63%). 1H−NMR (CDCl3, 300 MHz) δ 0.19 (s, 9H, SiMe3); 13C−NMR (75 
MHz, CDCl3) δ 104.0, 41.9, -0.2. 
 
1-Bromo-1-heptyne.25 Using the general procedure for 
bromination 1-heptyne (1.50 g, 15.0 mmol) was transformed to its 
Br
I
SiMe3Br
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Chapter 3 
 62 
corresponding bromide (2.592 g, 14.8 mmol, 99%). 1H−NMR (300 MHz, CDCl3) δ 
2.20 (t, J = 7.0 Hz, 2H, C≡CCH2), 1.54−1.27 (m, 6H, 3 × CH2), 0.90 (t, J = 7.0 Hz, 
3H, Me); 13C−NMR (75 MHz, CDCl3) δ 80.3, 38.6 (CBr), 32.7, 29.5, 21.3, 20.6, 
15.0. 
 
General procedure for iodination: 
Methyl (2R)-3-iodo-2-[(tert-butoxycarbonyl)amino]propanoate (27).25  
To a stirred solution of Boc-Ser-OMe (30, 5.50 g, 25.0 mmol) in 
CH2Cl2 (100 mL) were added iodine (7.00 g, 27.6 mmol), 
imidazole (1.88 g, 27.6 mmol) and PPh3 (7.70 g, 29.4 mmol) and 
the resulting yellow solution was stirred overnight. After evaporation of the 
volatiles compound 27 was isolated using flash chromatography (20% EtOAc in 
heptane), yielding the desired product as white solid (5.94 g, 18.1 mmol, 72%). 
1H−NMR (400 MHz, CDCl3) δ 5.38 (bs, 1H, NH), 4.46−4.41 (m, 1H, CαH), 3.81 (s, 
3H, OMe), 3.61−3.55 (m, 2H, CH2I), 1.44 (s, 9H, Boc); 13C (75.5 MHz, CDCl3) δ 
171.9, 157.2, 81.0, 58.6, 57.0, 30.0, 8.1. 
 
Benzyl (2R)-2-[(tert-butoxycarbonyl)amino]-3-iodopropanoate (56).25 
Using the general procedure Boc-Ser-OBn (500 mg, 1.69 mmol) 
was transformed, yielding 56 as a white solid (380 mg, 0.94 mmol, 
55%). 1H−NMR (300 MHz, CDCl3) δ 7.46 (s, 5H, Ar), 5.45 (bd, J = 
7.3 Hz, 1H, NH), 5.29 (d, J = 1.9 Hz, 2H, OCH2Ar), 4.67−4.59 (m, 1H, CαH), 3.66 
(t, J = 3.8 Hz, 2H, CH2I), 1.53 (s, 9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 169.0, 
154.4, 134.5, 128.3 (2 ×), 105.9, 80.4, 67.9, 53.7, 28.3, 7.6. 
 
Allyl (2R)-2-[(tert-butoxycarbonyl)amino]-3-iodopropanoate (57).  
Using the general procedure Boc-Ser-Allyl (753 mg, 3.10 mmol) 
was iodinated and isolated as white solid 57 (697 mg, 1.96 
mmol, 64%). 1H−NMR (300 MHz, CDCl3) δ 5.93 (ddt, J = 6.8 Hz, 
21.4 Hz, 1H, C=CH), 5.37 (app dq, J  = 1.5 Hz, 17.1 Hz, 1H, C=CH2), 5.27 (app dq, 
J = 1.2 Hz, 10.6 Hz, 1H, C=CH2), 5.35 (bs, 1H, NH), 4.74−4.61 (m, 2H, OCH2), 
4.54−4.50 (m, 1H, CαH), 3.63−3.53 (m, 2H, CH2I), 1.45 (s, 9H, Boc); 13C−NMR 
(75.5 MHz, CDCl3) δ 169.2, 154.8, 131.2, 119.3, 80.4, 66.6, 53.5, 28.2, 7.7; IR ν 
2924.1, 2852.4, 1716.0, 1497.0, 1163.8 cm−1. 
I
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Allyl 2R)-2-[(9H-9-fluorenylmethoxy)carbony]amino-3-iodopropanoate 
(58). Using the general procedure Fmoc-Ser-Allyl was 
converted to its corresponding iodide 58, which was obtained 
as white crystals (618 mg, 1.32 mmol, 70%). [α]D = +9.6 (c = 
0.23, CH2Cl2); 1H−NMR (300 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H, 2 × ArH), 
7.62 (d, J = 7.5 Hz, 2H, 2 × ArH), 7.41 (t, J = 7.2 Hz, 2H, 2 × ArH), 7.36−7.30 (m, 
2H, 2 × ArH), 6.00−5.88 (m, 1H, CH=C), 5.67 (bd, J = 7.2 Hz, 1H, NH), 5.41−5.30 
(m, 2H, C=CH2), 4.71 (d, J = 5.4 Hz, 2H, AllylCH2O), 4.64−4.58 (m ,1H, CαH), 
4.48−4.35 (m, 2H, CH2O), 4.26 (t, J = 7.2 Hz, 1H, CH-Fmoc), 3.63 (d, J = 3.6 Hz, 
2H, CH2I); 13C−NMR (75.5 MHz, CDCl3) δ 169.0, 154.9, 143.7, 141.3, 131.1, 127.8, 
127.1, 125.1, 120.0, 119.6, 67.4, 66.9, 54.0, 47.1, 7.6; IR ν 3406.4, 3063.5, 2948.5, 
1710.6, 1515.7, 1448.4, 1313.7, 1187 cm−1; HRMS (FAB)+ calcd for C21H21O4NI 
478.05153, found 478.0515. 
  
tert-Butyl (2R)-2-[(benzyloxy)carbonyl]amino-3-iodopropanoate (59).25  
A mixture of DCC (16.5 g, 80.0 mmol), tBuOH (7.60 g, 105 mmol) 
and copper-(I)-chloride (150 mg, 1.49 mmol) was stirred for 3 
days.26 The green suspension was then diluted with dry CH2Cl2 
(20 ml) and the N-protected amino acid (6.00 g, 25.1 mmol) in CH2Cl2 (30 ml) was 
added dropwise. The reaction was finished in 1 hour. Precipitated urea was then 
removed by filtration. The organic layer was washed using saturated NaHCO3 
solution (3 × 50 ml), dried (MgSO4) and concentrated in vacuo. Crude NMR 
revealed no further purification was necessary 1H−NMR (300 MHz, CDCl3) δ 
7.37−7.30 (m, 5H, Ar), 5.65 (bs, 1H, NH), 5.12 (s, 2H, ArCH2O), 4.36−4.29 (m, 2H, 
CαH), 3.93 (s, 2H, CH2OH), 2.21 (bs, 1H, OH), 1.48 (s, 9H, CMe3). Using the 
general protocol for iodination the crude amino acid was transformed to product 
59, an offwhite solid (9.05 g, 22.4 mmol, 89%, 2 steps). 1H−NMR (300 MHz, 
CDCl3) δ 7.37−7.28 (m, 5H, Ar), 5.60 (bd, J = 7 Hz, 1H, NH), 5.14 and 5.13 (AB, J 
= 12 Hz, 2H, ArCH2O), 4.41 (dt, J = 3.5 Hz, 7 Hz, 1H, CαH), 3.59 (d, J = 3.5 Hz, 
2H, CH2I), 1.50 (s, 9H, CMe3); 13C−NMR (75.5 MHz, CDCl3) δ 168.1, 155.4, 136.1, 
128.6, 128.1, 83.6, 67.1, 54.0, 28.0, 8.4. 
 
tert-Butyl 2-[(tert-butoxycarbonyl)amino]-4-iodobutanoate (53).25  
A solution of 2-tert-butoxycarbonylamino pent-4-enoic acid tert-
butyl ester (52, 934 mg, 3.40 mmol) was dissolved in CH2Cl2 (50 
mL) and cooled to −78 °C. O3 was bubbled through the solution 
and when a blue color remained visible, the ozone-generator was 
I
CO2AllylFmocHN
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turned off allowing oxygen to remove traces of ozone. NaBH4 (169 mg, 4.60 mmol) 
and MeOH (5 mL) were added and the temperature was allowed to warm to room 
temperature. The mixture was quenched with water (15 mL) and extracted with 
CH2Cl2 (2 × 30 mL), the combined organic layers were washed (brine), dried 
(MgSO4) and evaporated. Further purification using flash chromatography (25% 
EtOAc in heptane) yielded the desired alcohol (257 mg, 0.93 mmol) in 27%. 
1H−NMR (300 MHz, CDCl3) δ 5.32 (d, J = 6.9 Hz, 1H, NH), 3.62 (m, 2H, CH2OH), 
2.06 (m, 1H, CH2), 1.50 (m, 1H, CH2), 1.40 (s, 9H, Boc), 1.38 (s, 9H, CMe3); 
13C−NMR (75.5 MHz, CDCl3) δ 172.2, 156.8, 82.5, 80.5, 58.4, 51.3, 36.7, 28.5, 
28.2. Using general iodination conditions the amino acid (257 mg, 0.93 mmol) 
was transformed to its corresponding iodide 53 (250 mg, 0.88 mmol, 69.5%). 
1H−NMR (300 MHz, CDCl3) δ 5.08−5.01 (m, 1H, NH), 4.22−4.12 (m, 1H, CαH), 
3.20−3.10 (m, 2H, CH2I), 2.44−2.29 (m, 1H, CH2), 2.22−2.05 (m, 1H, CH2), 1.47 (s, 
9H, Boc), 1.44 (s, 9H, CMe3); 13C−NMR (75.5 MHz, CDCl3) δ 169.0, 154.9, 82.4, 
82.3, 54.9, 37.8, 28.3, 27.9, 0.57. 
 
General procedure for organozinc couplings 
Methyl 2-[(tert-butoxycarbonyl)amino]-5-cyclohexyl-4-pentynoate (40).  
Zinc dust (116 mg, 1.408 mmol) was weighed into a 20 mL 
flask, which was repeatedly evacuated (with heating using a 
heat gun) and flushed with argon. Dry DMF (0.5 mL, 
distilled from CaH2) and 1,2-dibromoethane (9.2 μL, 0.106 
mmol) were added and the flask was heated at 80 °C for 40 
min. The reaction mixture was allowed to cool to room temperature, 
trimethylsilyl chloride (4 μL, 0.035 mmol) was added and the resulting mixture 
was stirred vigorously for a further 30 min under argon. Iodocyclohexane (69 μl, 
0.528 mmol) was added and stirred at room temperature for 3 h more after which 
stirring was ceased to settle the zinc. CuCN (41 mg, 0.46 mmol) and LiCl (40 mg, 
0.92 mmol) were heated to 150 °C for 2 h and cooled to room temperature. 
Addition of DMF (1 mL) formed a soluble CuCN·2LiCl complex within 5 min. 
After cooling the Cu-complex to –15 °C, the organozinc reagent was added 
dropwise followed by bromoacetylene (rac)-35 (116 mg, 0.35 mmol). The mixture 
was allowed to stir overnight at room temperature. Water was added and the 
suspension was extracted using heptane, washed (brine), dried (MgSO4) and 
concentrated. Purification using flash column chromatography (10% EtOAc in 
heptane) yielded 40 (100 mg, 81%) as a colorless oil. 1H−NMR (300 MHz, CDCl3) 
δ 5.28 (d, J = 7.7 Hz, 1H, NH), 4.43−4.38 (m, 1H, CαH), 3.73 (s, 3H, OMe), 
CO2MeBocHN
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2.69−2.63 (m, 2H, C≡CCH2), 2.13 (m, 1H, CC≡CH), 1.73−1.22 (m, 10H, 5 × CH2), 
1.43 (s, 9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 171.4, 155.0, 88.1, 79.9, 73.8, 52.3, 
32.7, 32.7, 28.8, 28.2, 25.8, 24.6, 23.1; IR ν 3355, 2929, 2852, 2359, 2337, 1749, 
1717, 1498, 1447, 1365, 1251, 1181, 1060 cm−1; HRMS (EI): calculated for 
C17H27NO4 309.1940, found 309.1937. 
 
Methyl 2S-[(tert-butoxycarbonyl)amino]-4-decynoate (36).  
Using the general method of zincactivation, Serine derived 
iodide 27 (125 mg, 0.37 mmol) was treated with 1-bromo-1-
heptyne (66 mg, 0.38 mmol). Purification using flash 
chromatography (25% EtOAc in heptane) yielded product 36 (68 
mg, 0.27 mmol, 60%) as an oil. 1H−NMR (300 MHz, CDCl3) δ 5.27 (bd, 1H), 4.41 
(m, 1H), 3.75 (s, 3H), 2.69−2.64 (m, 2H), 2.13−2.09 (m, 2H), 1.46 (s, 9H), 
1.40−1.18 (m, 8H), 0.87 (t, J = 6.9 Hz, 3H). 
 
Methyl 2S-[(tert-butoxycarbonyl)amino]-4-dodecynoate (37).  
Using the general method of zincactivation, 1-iodide heptane 
(177 mg, 0.79 mmol) was treated with (rac)-35 (220 mg, 0.719 
mmol). Purification using flash chromatography (25% EtOAc in 
heptane) yielded product 37 (134 mg, 0.41 mmol) in 57%. 
1H−NMR (400 MHz, CDCl3) δ 5.28 (bd, J = 8.3 Hz, 1H, NH), 4.44−4.38 (m, 1H, 
CαH), 3.74 (s, 3H, OMe), 2.76−2.58 (m, 2H, CHCH2C≡C), 2.14−2.09 (m, 2H, 
C≡CCH2), 1.44 (s, 9H, Boc), 1.33−1.21 (m, 8H, aliphatic chain), 0.87 (t, J = 6.8 Hz, 
3H, Me); 13C−NMR (75 MHz, CDCl3) δ 171.5, 155.1, 84.0, 80.0, 73.8, 52.4, 52.3, 
31.7, 28.8, 28.7, 28.3, 23.1, 22.6, 18.6, 14.0; IR ν 2927, 2856, 1747, 1714, 1501, 
1365, 1165 cm−1; HMRS (FAB)+ calcd for C18H32O4N 326.23313, found 326.2331. 
 
2-tert-Butoxycarbonylamino-7-phenyl-hept-4-ynoic acid methyl ester 
(38). Following the general procedure for organozinc 
coupling, phenethyl iodide (233 mg, 1.00 mmol) was 
combined with (rac)-35 (212 mg, 0.69 mmol) to result in 38 
as an amorphous solid (90 mg, 0.27 mmol, 39%). 1H−NMR 
(300 MHz, CDCl3) δ 7.35−7.15 (m, 5H, Ar), 5.25−5.20 (m, 1H, NH), 4.45−4.40 (m, 
1H, CαH), 3.73 (s, 3H, OMe), 2.99−2.93 (m, 2H, C≡CCH2), 2.80−2.32 (m, 4H, 2 × 
CH2), 1.47 (s, 9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 171.4, 155.1, 140.6, 128.8, 
128.4, 126.2, 83.0, 79.9, 74.8, 52.4, 52.2, 35.0, 28.3, 23.0, 20.8; EI-MS m/z: 331 
(M)+. 
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2-tert-Butoxycarbonylamino-8-phenyl-oct-4-ynoic acid methyl ester (39). 
 Using the general procedure for organozinc coupling 1-
iodo-3-phenylpropane (267 mg, 1.08 mmol) was combined 
with (rac)-35 (217 mg, 0.71 mmol) to yield 39 as an 
amorphous solid (72 mg, 0.21 mmol, 29%). 1H−NMR (300 MHz, CDCl3) δ 
7.35−7.15 (m, 5H, Ar), 5.34 (bd, J = 7.6 Hz, 1H, NH), 4.47−4.41 (m, 1H, CαH), 
3.76 (s, 3H, OMe), 2.79−2.67 (m, 4H, C≡CCH2, CH2Ar), 2.20−2.10 (m, 2H, 
C≡CCH2), 1.81−1.74 (m, 2H, CH2), 1.46 (s, 9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 
171.5, 155.1, 141.5, 128.4, 128.3, 125.8, 83.3, 80.0, 74.5, 52.4, 52.3, 34.3, 30.3, 
28.2, 23.1, 18.0; EI-MS m/z: 345 (M)+. 
 
 Methyl 2S-[(tert-butoxycarbonyl)amino]-5-(1,1,1-trimethylsilyl)-4-
pentynoate27 (43). Using the general method of 
zincactivation, Serine derived iodide 27 (200 mg, 0.60 mmol) 
was treated with bromoethynyl-trimethyl-silane (215 mg, 1.2 
mmol). Purification using flash chromatography (25% EtOAc in heptane) yielded 
product 43 (95 mg, 0.32 mmol, 52%). 1H−NMR (300 MHz, CDCl3) δ 5.29 (bd, J = 8 
Hz, 1H, NH), 4.48−4.46 (m, 1H, CαH), 3.77 (s, 3H, OMe), 2.78 (dd, J = 5 Hz, 17 
Hz, 1H, C≡CCH2), 2.69 (dd, J = 5 Hz, 17 Hz, 1H, C≡CCH2), 1.46 (s, 9H, Boc), 0.14 
(s, 9H, SiMe3); 13C−NMR (75 MHz, CDCl3) δ 171.3, 155.2, 127.6, 100.8, 80.1, 52.4, 
52.1, 28.2, 24.2, 0.1. 
 
Methyl 2S-[(tert-butoxycarbonyl)amino]-7-[1-(tert-butyl)-1,1-
dimethylsilyl]oxy-4-heptynoate (45). Using the 
general method of zincactivation, Serine derived iodide 
27 (400 mg, 1.20 mmol) was treated with (4-bromo-but-3-
ynyloxy)-tert-butyl-dimethyl-silane (266 mg, 1.01 mmol). Purification using flash 
chromatography (25% EtOAc in heptane) yielded product 45 (231 mg, 0.60 mmol, 
59%) as an oil. 1H−NMR (300 MHz, CDCl3) δ 5.28 (bd, J = 9.3 Hz, 1H, NH), 
4.45−4.38 (m, 1H, CαH), 3.75 (s, 3H, OMe), 3.66 (t, J = 7.2 Hz, 2H, CH2O), 
2.77−2.57 (m, 2H, C≡CCH2Cα), 2.39−2.29 (m, 2H, C≡CCH2CH2O), 1.45 (s, 9H, 
Boc), 0.88 (s, 9H, CMe3), 0.06 (s, 6H, 2 × SiMe); 13C−NMR (75 Mhz, CDCl3) δ 
171.1, 155.1, 100.7, 88.1, 80.1, 52.7, 52.1, 28.3, 28.2, 25.8, 23.8, 18.6, −5.3; IR ν 
3416, 2976, 1746, 1712, 1498, 1161 cm−1; EI-MS m/z: 606 (M)+ 386, 312, 272, 228, 
168, 94, 89. 
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Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(2S,3S,4R,5R,6S)-3,4,5-
tri(benzyloxy)-6-[(benzyloxy)methyl]tetrahydro-2H-2-pyranyl-4-
pentynoate (47). Using the general procedure for zinccouplings, sugar-moiety 
46 (73 mg, 0.14 mmol) was coupled with 27 (140 
mg, 0.42 mmol) to deliver 47 as a white solid (54 
mg, 0.07 mmol, 52%). 1H−NMR (400 MHz, CDCl3) 
δ 7.38−7.25 (m, 18H, ArH), 7.14−7.12 (m, 2H, 
ArH), 5.31 (d, J = 8.7 Hz, 1H, NHBoc), 4.96 (d, J = 10.7 Hz, 1H), 4.89 (d, J = 11.0 
Hz, 1H), 4.82 (d, J = 4.9 Hz, 1H), 4.80 (s, 1H), 4.78 (d, J = 4.9 Hz, 1H), 4.61 (d, J = 
12.0 Hz, 1H), 4.54 (d, J = 12.2 Hz, 1H), 4.52 (d, J = 10.8 Hz, 1H), 4.49−4.44 (m, 
1H, CαH), 4.02 (d, J = 9.1 Hz, 1H), 3.74 (dd, J = 1.9 Hz, 11.9 Hz, 1H), 3.67 (s, 3H, 
OMe), 3.62−3.54 (m, 3H), 3.44−3.40 (m, 1H), 2.87−2.77 (m, 2H, C≡CCH2), 1.42 (s, 
9H, Boc); 13C−NMR (75 Mhz, CDCl3) δ 171.0, 154.2, 138.4, 138.0, 137.9, 137.8, 
128.7, 127.9, 127.8 (2 ×), 127.6, 127.5, 127.3, 85.9, 82.2, 80.9, 80.8, 80.6, 78.8, 
77.5, 77.1, 76.5, 75.6, 75.2, 74.9, 73.4, 69.8, 68.6, 28.2, 27.8, 23.2; IR ν 3353, 3031, 
2876, 2240, 1749, 1718, 1455, 1089 cm−1; MS (FAB): m/z 750 (M + H)+. 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-(2-iodophenyl)-4-
pentynoate (49). Using the general procedure for 
organozinc couplings 27 (643 mg, 1.96 mmol) was coupled 
with 1-(2-Bromo-1-ethynyl)-2-iodobenzene 48 (643 mg, 1.62 
mmol) resulting in 49 as an amorphous solid (293 mg, 0.68 
mmol, 42%). 1H−NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.0 
Hz, 1H, ArH), 7.39 (d, J = 7.7 Hz, 1H, ArH), 7.27 (t, J = 7.9 Hz, 1H, ArH), 6.97 (t, 
J = 7.6 Hz, 1H, ArH), 5.57 (bd, J = 8.1 Hz, 1H, NHBoc), 4.60−4.54 (m, 1H, CαH), 
3.79 (s, 3H, OMe), 3.08−2.93 (m, 2H, C≡CCH2), 1.44 (s, 9H, Boc); IR ν 2950.6, 
2929.4, 2888.9, 1747.2, 1714.4, 1504.2, 1367.3, 1249.7, 1160.9, 1101.2, 1056.8, 
837.0 cm−1; HRMS (CI): calculated for C17H20NO4I 430.04370, found 430.03937. 
 
7-(tert-Butyl) 1-ethyl 6-[(tert-butoxycarbonyl)amino]-2-heptynedioate 
(55). Using the general method of zincactivation, homoserine 
derived iodide 53 (112 mg, 0.29 mmol) was treated with bromo-
propynoic acid ethyl ester (54,66.7 mg, 0.377 mmol). Purification 
using flash chromatography yielded 55 (26.0 mg, 0.073 mmol, 
28%) as an oil. 1H−NMR (300 MHz, CDCl3) δ 5.09−4.99 (m, 1H, 
NH), 4.19 (q, J = 7.2 Hz, 2H, CH2O), 2.43−2.36 (m, 2H, C≡CCH2), 2.17−2.06 (m, 
1H, CH2), 1.95−1.81 (m, 1H, CH2), 1.46 (s, 9H, Boc), 1.43 (s, 9H, CMe3), 1.29 (t, J 
O
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BnO
OBn BocHN
CO2Me
CO2Et
BocHN CO2tBu
BocHN CO2Me
I
Chapter 3 
 68 
= 7.1 Hz, 3H, Me); 13C−NMR (75 MHz, CDCl3) δ 170.1, 155.3, 153.6, 87.7, 82.3, 
80.9, 73.4, 81.8, 53.3, 31.1, 28.3, 27.9, 15.2, 14.0; IR ν 3376, 2977, 2236, 1712, 
1504, 1367, 1253, 1154 cm−1;  HRMS (CI) calculated for C18H30NO6 356.20737, 
found 356.20741 (M + H)+. 
 
Dimethyl (2S)-2-[(tert-butoxycarbonyl)amino]-7-[(diphenylmethylene) 
amino]-4-octynedioate (65). Using the general 
method of zinc-activation, 27 (250 mg, 0.76 mmol) was 
coupled with bromide 63 resulting in 65 (158 mg, 0.32 
mmol, 43%). 1H−NMR (300 MHz, CDCl3) δ 7.65-7.23 
(m, 5H, Ar), 5.33-5.26 (m, 1H, NH), 4.40-4.34 (m, 1H, CαHNH), 4.28 (dd, J = 5.4 
Hz 8.0 Hz, 1H, CαH), 3.73 (s, 3H, OMe), 3.63 (d, J = 5.1 Hz (diasteromers), 3H, 
OMe), 2.88−2.60 (m, 4H, 2 × C≡CCH2), 1.44 (s, 9H, Boc). 
 
Dimethyl (2S)-2,7-di[(tert-butoxycarbonyl)amino]-4-octynedioate (64).  
Using the general method of zinc-activation, 27 (750 mg, 
2.27 mmol) was coupled with 35 (581 mg, 1.90 mmol). 
After flash chromatography (40% EtOAc in heptane), 
product 64 was obtained as a sticky oil (497 mg, 1.16 
mmol, 61%). 1H−NMR (300 MHz, CDCl3) δ 5.62 (bd, J = 8.6 Hz, 1H, NH), 5.43 
(bd, J = 7.6 Hz, 1H, NH), 3.79 (s, 3H, OMe), 3.78 (s, 3H, OMe), 2.73−2.57 (m, 4H, 
C≡CCH2), 1.44 (s, 18H, 2 × Boc); 13C−NMR (75 MHz, CDCl3) δ 171.5, 171.3, 155.0 
(2 ×), 80.0, 79.9, 77.9 (C≡), 52.5, 52.0, 28.2, 28.1, 23.4, 23.1; IR ν 3381.5, 2976.0, 
1745.2, 1713.5, 1506.0, 1365.6, 1164.5, 1058.6 cm−1. 
 
1-Allyl 8-methyl (2S)-2,7-di[(tert-butoxycarbonyl)amino]-4-octynedioate 
(71). Using the general method of zinc-activation, 57 
(250 mg, 0.703 mmol) was reacted with 35 (237 mg, 
0.775 mmol). After purification using flash 
chromatography (25% EtOAc in heptane) product 71 
was isolated as a clear sticky oil (113 mg, 0.25 mmol, 35%). 1H−NMR (300 MHz, 
CDCl3) δ 5.92−5.80 (m, 1H, C=CH), 5.60 (m, 1H, NH), 5.41 (m, 1H, NH), 
5.35−5.17 (m, 2H, =CH2), 4.66−4.62 (m, 2H, OCH2), 4.41 (m, 2H, 2 × CαH), 3.75 
and 3.73 (2 × s, 3H diastereomers, OMe), 2.68−2.55 (m, 4H, 2 × C≡CCH2), 1.40 
and 1.40 and 1.3772 (3 × s, 18H diastereomers); 13C−NMR (75 MHz, CDCl3) δ 
171.2, 170.4, 155.0, 131.5, 118.8, 79.7, 66.0, 55.5, 52.0, 28.2, 28.1, 23.3, 23.0; IR ν 
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3383.5, 2976.5, 1743.4, 1712.5, 1502.3, 1366.0, 1161.9 cm−1; HMRS (FAB)+ calcd 
for C22H35O8N2 455.23934, found 455.2398. 
 
9-(tert-Butyl) 1-methyl 2-[(tert-butoxycarbonyl)amino]-8-[(9H-9-
fluorenylmethoxy)carbonyl]amino-4-
nonynedioate (74). Using the general method of 
zinc-activation, homoserine derived iodide 53 (470 
mg, 0.93 mmol) was treated with 35 (214 mg, 0.70 
mmol). Purification using flash chromatography 
(20% EtOAc in heptane) yielded amorphous solid 74 (250 mg, 0.41 mmol, 59%). 
1H−NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H, 2 × ArH), 7.61 (d, J = 7.5 
Hz, 2H, 2 × ArH), 7.38 (t, J = 7.2 Hz, 2H, 2 × ArH), 7.31 (t, J = 7.2 Hz, 2H, 2 × 
ArH), 5.75−5.39 (m, 2H, 2 × NH, diastereoisomers), 4.46−4.33 (m, 5H,  2 × CαH, 
CH-Fmoc), 4.23 (t, J = 5.4 Hz, 2H,  FmocCH2O), 3.75 (s, 3H, OMe), 2.63−2.69 (m, 
2H, C≡CCH2Cα), 2.19−2.25 (m, C≡CCH2), 2.09−1.97 (m, 1H, CH2), 1.74−1.86 (m, 
1H, CH2), 1.48 (s, 9H, Boc), 1.43 (s, 9H, CMe3); 13C−NMR (75 Mhz, CDCl3), 171.4 
(2 ×), 155.8 (2 ×), 143.9, 141.3, 127.7, 125.1, 119.9, 82.3 (2 ×), 77.2 (2 ×), 66.9, 
53.7, 52.4, 52.3, 47.1, 32.0, 28.3, 28.0, 23.1, 15.2; IR ν 3342, 2978, 2250, 1714, 
1504, 1157, 738 cm−1; EI-MS m/z: 606 (M)+.  
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4  TOWARD TRIAZOLE-BASED CYSTINE 
MIMICS  
 
4.1  Introduction 
 
During the course of our investigations, new developments in acetylene 
chemistry culminated in 2002 in two independent contributions describing a 
catalytic system which enhances azide-alkyne 1,3-dipolar cycloadditions resulting 
in [1,2,3]-triazoles. 
 
 
R
N3 R' N
N
N R'
R
N
N
N
R R'
++
1 2 3 4
(1,4-product) (1,5-product)
100 oC
N
N
N R'
R 3
(1,4-product)
Cu(I)
25 oC
 
Scheme 1. Huisgen cyclization leads to two regioisomers vs Cu(I)-catalyzed variant 
 
This so-called Huisgen reaction generally requires harsh conditions (refluxing in 
toluene) and produces a mixture of the two possible regioisomeric 1,4- (3) and 1,5-
triazoles (4). The first contribution of the group of Meldal describes a screening of 
metal complexes that are able to catalyze this particular cycloaddition.1,2 They 
found that copper(I) species gave selectively access to the 1,4-isomer in high 
yield. Furthermore, the application of this catalytic system to functionalize solid-
phase bound peptides was described. They also state that the [1,2,3]-triazole 
moiety can be regarded as a peptide isostere that, when incorporated into a 
peptide, both displays hydrogen-bonding capabilities and mimics the amide 
backbone. 
The second contribution from the Sharpless group described an identical reaction 
using a copper(I) catalyst.3 They showed that an unprecedented level of 
selectivity and reliability was reached in this reaction, even in the creation of 
covalent links between densely functionalized building blocks. Interestingly, the 
conditions applied by the Sharpless group involve water as the primary solvent.  
An added value of this reaction – currently commonly known as the ‘click-
reaction’ – may lie in new generic applications for linking of different fragments 
under mild, so-called bio-orthogonal conditions.4 Especially the azide combines 
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selective and high reactivity with stability in aqueous and/or oxygenated 
systems.  
The copper(I)-mediated mechanism follows presumably the pathway outlined in 
Figure 1.5 Recently, a thorough investigation has provided the insight that a 
dimeric copper species 8 may be responsible for the catalytic cycle. This may 
explain the greatly enhanced reactivity of a second azide in diazide-containing 
species.6 A pre-organized catalyst thus eventually gives rise to the formation of 
ditriazoles over statistically expected mixtures, even when a 10-fold excess of 
diazide is used.  
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Figure 1. Proposed mechanism of the click-reaction. 
 
First, the copper(I)-catalyst forms a π-complex with the acetylene (6) and 
subsequently replaces the acidic proton of the acetylene. The azide coordinates to 
the copper via the negatively charged nitrogen atom (8), followed by attack and 
subsequent formation of the new intermediate 9. This slightly bent allene-like 
structure then rearranges to form the copper-triazole species 10. Finally, 
copper(I) exchange with an acidic proton delivers the triazole (3) and the 
copper(I) species that can enter the next cycle.  
 
During the course of our investigation many examples of intramolecular 
cyclization appeared.7 For example, Gin et al. used the copper-mediated 1,3-
dipolar cycloaddition to obtain the dimeric cyclodextrin 12 in 80% yield (and 15% 
of its trimer). Later, even trimeric cyclodextrins8 and C2-symmetric cyclic 
peptides9 were reported (Scheme 2). 
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Scheme 2. Reagents and conditions: CuI, DBU, 50 °C then Pd/C, NH4HCO2 (80%, 2 steps). 
 
Head-to-tail peptide cyclizations were also investigated by Finn et al. (Scheme 
3).10 While long-term exposure of the immobilized azido-acetylene 13 or 14 to 
classic Huisgen cyclization conditions gave no reaction, Cu-catalysis provided the 
desired dimeric head-to-tail cyclization products (15, 16) 
. 
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Scheme 3. Reagents and conditions: a) i: CuI, ii: TFA. Peptide 1: Lys-Ala-Ile-Arg-Gly-Asp-Thr-
Phe-Ala (15), 76 membered ring; Peptide 2: Lys-Met-Asn-Asp-Hys-Ala-Ile-Arg-Gly-Asp-Thr-Phe-
Ala-Thr-Arg-Ala-Glu (16) 124 membered ring. 
 
Most recently, a ring closure was established in the Burgess group through an 
intramolecular click-reaction to form a β-turn mimic (Scheme 4).11 Remarkably, 
variation of the side chains R1 and R2 had a large influence on the 
monomer/dimer ratio, of 50% of the former, while the maximum isolated yield 
was 14%.  
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Scheme 4. Reagents and conditions: Slow addition to CuI, DiPEA, THF, 25 °C, 14 h. 
 
Another example of ‘intramolecular’ applications by the Ghadiri group shows the 
compatibility of triazoles with peptide-containing systems.12 They introduced 
triazole-containing dipeptides mimics 21 in cyclic octapeptides 20 which, 
analogous to the corresponding cyclopeptides,13 formed an extended network 
resulting in the nanotubes 19 (scheme 5).  
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Scheme 5. Nanotube 19 based on triazole-containing cyclopeptides 20. 
 
Further studies by the Ghadiri group utilized dipeptide-mimics of types 21 in α-
helical coiled coils to alter the secondary and quaternary structures for enhanced 
thermodynamic stability.14 This example also proves that the triazole unit can be 
successfully applied in peptides as a conformational mimic of the amide bond.  
Figure 2 displays our computational results for electron densities around the 
amide and triazole and illustrates the similarity between the two. The direction 
and also magnitude of the dipole moments are with 3.92 and 4.83 Debye 
respectively almost identical. This demonstrates the capability of the triazole to 
act as a hydrogen bond acceptor. 
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Figure 2. Electron potential surfaces for an amide (left) and a triazole (right).15  
 
In this chapter, the use of azide/acetylene 1,3-dipolar cycloadditions to form 
conformationally restricted β-turn mimics 22 is investigated (Scheme 6). The 
synthesis of suitable precursors 23 and the application of ring contractions are 
discussed. 
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Scheme 6. Conformational restriction via intramolecular click-reactions. 
 
4.2  Intermolecular studies 
 
In order to test the click-reaction on amino acid-type structures, various azides 
were reacted with acetylenes using the Sharpless conditions (in situ reduction of 
Cu(II) with sodium ascorbate). The source of Cu(I) via in situ reduction is 
convenient, since copper(I) salts (CuI or CuOTf) are generally more difficult to 
handle. Furthermore, the formation of undesired byproducts such as Glaser type 
homocoupled acetylenes is suppressed under these reductive conditions.  
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Scheme 7. Reagents and conditions: a) i: Boc2O, Et3N, THF, ii: MsCl, CH2Cl2, iii) NaN3, DMF, 60 
°C (54%, 3 steps); b: Cu(OAc)2, Na-ascorbate, H2O, tBuOH (2 : 1). 
 
Transformation of 2-aminoethanol to the desired precursor 25 was readily 
performed in reasonable yield via Boc-protection, mesylation and nucleophilic 
substitution using sodium azide. When the organic components (dissolved in 
tBuOH) and the Cu(OAc)2/sodium ascorbate couple (dissolved in water) were 
combined,16 the solution turned bright yellow. After workup the organic phase 
contained the triazole 26 as a single product in good yield (84%). Glycine derived 
ethyl ester 24 was subjected to identical conditions, resulting in 27 as a single 
product. 
 
To further extend this methodology, several amino acids were combined in order 
to obtain isosteres that might be of use as cross-links in peptide synthesis (see 
also: Sections 3.5 and 5.1). Starting from suitably protected 28a (PG = Boc, R = 
Me) of 28b (PG = Fmoc, R = H), click reactions were carried out under the 
aforementioned conditions with different azides (Scheme 8). Remarkably, 
coupling of 28a with Boc-protected azidoalanine was unsuccessful and also other 
partners gave variable results. According to 1H−NMR, compound 31 was formed, 
but could not be recovered from the water layer. As for the corresponding methyl 
ester protected product 32; the product could be obtained in reasonable yield. 1,3-
Dipolar cycloaddition of the Fmoc-protected propargylglycine 28b to give 30 and 
33 proceeded well. These preliminary results gave us the confidence that we 
should be able to apply such a strategy in a intramolecular fashion.  
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Scheme 8. Reagents and conditions: CuSO4, Na-ascorbate, H2O, tBuOH (2 : 1). 
 
4.3  Citrulline derivatives 
 
As partly described in Section 3.4, rigidified glutamic acid or citrulline 
derivatives are biologically interesting building blocks. Similar derivatives may 
also be obtained by linking the amino acid moiety with the side chain functional 
group using the click-reaction, resulting in a rigid triazole spacer. An 
investigation combining azidoalanine 34 (obtained by diazotransfer on 
enantiopure 2,3-diaminopropanoic acid) with propargylurea gave,17 however, no 
positive results when standard click-conditions were applied (Scheme 9). In 
contrast, the Boc-protected amino azide 25 gave 78% of the desired product. This 
led us to protect the free acid as a tert-butyl ester (36, obtained using the Kunz-
conditions),18 which under the same conditions gave rise to product 38 in 87% 
yield. 
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37 R = CO2H no reaction
38 R = CO2tBu (87%)  
Scheme 9. Reagents and conditions: a) Cu(OAc)2, Na-ascorbate, H2O, tBuOH (2 : 1); b) DCC, 
tBuOH, CuCl, 3 days (88%).  
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In comparison to citrulline, the side chain of urea derivative 38 is rather long. A 
shorter side chain in which the triazole may act as a hydrogen bridge acceptor 
was envisioned as shown in Scheme 10. Azide 36 was reacted with ethyl 
propiolate, after which the acid-labile protective groups were removed. Upon 
treatment with ammonia (25% aqueous solution) and subsequent Fmoc-
protection, the desired amino acid 40 was obtained (44%, 4 steps). En passant, 
this example successfully demonstrated the possibility of conjugated acetylenes 
participating in the copper-catalyzed 1,3-dipolar cycloaddition. 
 
CO2tBuBocHN
N3
CO2tBuBocHN
N
NN
CO2Et
CO2Et
CO2HFmocHN
N
NN
CONH2a b
36 39 40
 
Scheme 10. Reagents and conditions: a) Cu(OAc)2, Na-ascorbate, H2O, tBuOH (2 : 1)(88%); b) i: 
TFA, ii: NH4OH, iii) FmocOSu (51%, 3 steps). 
 
4.4  Peptide transformations 
 
Having established a proper protocol for intermolecular click-reactions on amino 
acid derivatives, our attention shifted to the corresponding intramolecular 
cycloadditions. Common approaches to introduce rigidification in peptides 
require non-polar solvents in which the peptide folding may be different from the 
folding in an aqueous environment. To the best of our knowledge, no examples of 
introduction of artificial peptide-stabilization in aqueous solvents are known.  
We then set out to investigate, whether the latter could be achieved with this 
click-reaction. Two oligopeptides, 43 and 44 (based on experiences as detailed in 
Section 5.4) were made using the required acetylene and azide handles. Both 
peptides 43 and 44 were constructed using standard solid phase reaction 
protocols. To a Wang-resin, Fmoc-protected propargylglycine (42) was coupled 
yielding 41 with a loading of 0.75 mmol/g. While in principle any amino acid 
would suffice, side-chain protected asparagine was chosen as the N-terminal 
amino acid in 43 and 44. Alternating subsequent deprotection, standard peptide 
coupling and eventual cleavage of the unprotected N-terminus resulted in both 
43 and 44 in good overall yields of 79 and 66%, respectively. Unfortunately, 
treatment of peptides 43 and 44 under the typical diazotransfer conditions with 
triflic azide furnished solely undefined products.17  
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Scheme 11. Reagents and condtions: a) DIC, HOBt, DMAP, Fmoc-(S)-2-amino-4-pentynoic acid 
(42); b) DIC, HOBt, Fmoc-AA-OH, DMF; c) 0.1 M HOBt, 20% piperidine in DMF; d) 1% TFA in 
CH2Cl2; e) FmocOSu, Et3N, MeCN, H2O (96%); f) TfN3, CuSO4, CH2Cl2, H2O, MeOH. 
 
It was then suspected that the active copper(II)-catalyst for the azide-activation 
could also be involved in coordination to the acetylene, possibly leading to 
acetylene decomposition or undesired polymerization. Other model-systems such 
as 47 were initially made using Boc-protection and also these proved to be 
incompatible with triflic azide treatment.  
To still be able to probe the viability of such an approach, dipeptide 47, a 
potential β-turn mimic precursor as discussed in Sections 1.2 and 5.3, was 
prepared via coupling of (S)-2-amino-6-heptynoic acid methyl ester and Fmoc-
Orn(N3)-OH with Castro’s reagent in a moderate yield of 47% (Scheme 12). 
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Scheme 12. Reagents and conditions: a) TfN3, CuSO4, CH2Cl2, H2O, MeOH (95%); b) SOCl2, 
MeOH, reflux (99%); c) PyBOP, DiPEA, CH2Cl2 (47%); d) Cu(OAc)2, Na-ascorbate, H2O, tBuOH (2 : 
1) 
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Unfortunately, subsequent submission to copper(I) (in situ formed via reaction of 
copper(II) acetate with sodium ascorbate) did not result in a [2+3]-cycloaddition. 
In addition, subjection of 47 to copper(I) iodide in the presence of 2,6-lutidine at 
variable temperatures had no good results either. Presumably, the anticipated 
bicyclic system is too strained to be formed under these conditions so that 
alternative reaction pathways leading to polymerization may prevail. 
 
Despite these drawbacks, we intended to further pursue these types of cyclization 
reactions. In order to be able to faster generate peptide cyclization precursors, we 
changed to solid phase synthesis strategies involving acetylene- and azide-
containing amino acids. This required a synthesis of the latter compounds, which 
was carried out starting from protected (S)-2-amino-4-pentynoic acid and azide 
functionalized ornithine, made using the aforementioned diazotransfer 
procedure. (Scheme 13). Several oligopeptides were thus synthesized and 
subjected to the copper-promoted 1,3-dipolar cycloaddition conditions.  
O
NHFmoc
O
CbzHN
H
N
O
NHAc
O
HN
CO2H
N3
X
41 49
a b
CbzHN
H
N
O
NHAc
O
HN
CO2H
N
N N
(  )2
50  
Scheme 13. Reagents and conditions: a) standard solid phase Fmoc-chemistry, followed by 
cleavage with TFA; b) Cu(OAc)2, Na-ascorbate, H2O, tBuOH (2 : 1).  
 
The first example was tripeptide 49,19 the ornithine residue may act as a β-turn 
inducer, allowing the acetylene and the azide to interact in the desired manner. 
Unfortunately, this cyclization did not provide any identifiable products.  
In order to maximize the chance for the two ends to react with each other, next 
the robust β-hairpin sequence based on Asn-Pro-Asn-Ala was chosen.20 The 
asparagine can form an additional H-bridge over the β-turn, resulting in a rather 
stable β-hairpin that is also frequently encountered in nature. Hence, the fully 
deprotected peptides 53 and 54 could be examples of conformational fixation in 
an aqueous environment. Construction of a small oligopeptide with two terminal 
1,3-dipolar cycloaddition components would provide the required flexibility 
necessary for cyclization. 
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Using the aforementioned Fmoc-solid phase synthesis protocols, both the 6-mer 
51 and the 8-mer 52 were prepared, starting from the Fmoc-protected 
propargylglycine functionalized Wang-resin 41 (Scheme 14). The portionwise 
piperidine treatment for Fmoc-deprotection was performed in the presence of 0.1 
M HOBt to suppress aspartimide formation.21,22 Using standard DIC/HOBt 
activation the suitably protected amino acids were consecutively attached. The N-
terminal residue was made via diazotransfer on 2-amino Boc protected 2,4-
diaminobutyric acid (55) and 56 was subsequently used in the solid phase 
synthesis.23 Upon cleavage from the resin the trityl and N-terminal Boc-group 
were removed. Due to the reactive nature of the thus created cations and the 
presence of the acetylene, additives such as iPr3SiH and 1,2-ethanedithiol were 
added to the cleavage cocktail. After the usual workup mass spectroscopy 
confirmed the presence of 51 and 52, while IR and NMR-spectroscopy confirmed 
the presence of the azide and the acetylene, respectively. 
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Scheme 14. Reagents and conditions: a) standard solid phase (Fmoc) chemistry; b) Cu(OAc)2, Na-
ascorbate, H2O, tBuOH (2 : 1) or 2,6-lutidine, DiPEA, CuI in deoxygenated MeCN; c) TfN3, CuSO4, 
CH2Cl2, H2O, MeOH (95%). 
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Initially, in situ reduced copper(II) in a 1 mM aqueous solution was used for the 
cyclization. Although some conversion took place in case of 52, the resulting polar 
product was difficult to separate from residual copper salts, which is necessary 
for 1H−NMR analysis. Analytical HPLC showed that the starting peptide had 
been consumed, but a clear product peak could not be observed. Probably, either 
decomposition or polymerization might have taken place under these reaction 
conditions. Utilization of microwave irradiation solely resulted in decomposed 
products. An alternative copper(I) source in the form of CuI did not result in any 
recoverable peptides for both 51 and 52. Focusing on 52, more classical conditions 
such as refluxing in degassed toluene in the presence of CuBr (up to 1 equiv) and 
DBU showed no conversion at all, as based on LCMS analysis. 
As a possible explanation for these failures, it was reasoned that chelation by the 
peptide to the copper catalyst (as observed with 35 to 37) could diminish the 
copper catalysis. Hence, oligopeptide 52 was pretreated with Ac2O to convert free, 
reactive amines into amides and subsequently exposed to CuI, but also this  did 
not change the outcome of the reaction. 
 
4.5 Contraction strategies 
 
A novel method to prepare strained, cyclic peptides is currently being developed 
in the group of Hiemstra/van Maarseveen at the University of Amsterdam.24 In 
this concept, a ‘hinge’ moiety is used which initially facilitates cyclization, and in 
a later stage can be activated for ring contraction (Scheme 15).  
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Scheme 15. Concept of ring contraction. 
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The phenolic moiety present in precursor 57 has been developed to serve those 
two purposes. After cyclization, Boc-deprotection triggers intramolecular amide 
bond formation, resulting in a ring contraction. The application of such a 
contraction might provide the targeted cyclic peptide systems 58.  
Since cyclization to 50 so far has been unsuccessful, we reasoned that 
oligopeptide 57 could be a nice example to demonstrate the viability of this 
methodology. The synthesis commenced with (S)-2-amino-4-pentynoic acid (28), 
which upon esterfication and subsequent coupling to Cbz-Orn(Boc)-OH, yielded 
dipeptide 59 (Scheme 16). After TFA-mediated removal of the Boc-group, the 
resulting amine was condensed with aldehyde 61 in the presence of 20 equiv of 
sodium sulfate as dehydration agent and the resulting imine reduced with excess 
sodium triacetoxyborohydride.25 Subsequent Boc-protection using 1.2 equiv of 
Boc2O led to compound 60 in 23% overall yield.  
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Scheme 16. Reagents and conditions: a) i: SOCl2, MeOH; ii: PyBOP, DiPEA, Cbz-Orn(Boc)-OH 
(88%, 2 steps); b) i: TFA; ii: 40, Na2SO4; iii: NaB(OAc)3H; iv: Boc2O (23%, 4 steps). 
 
To reach the target molecule, esterfication between the phenolic moiety and an 
azido amino acid was required (Scheme 17). However, due to steric hindrance of 
the phenolic substituents, reagents such as DCC and DIC appeared ineffective in 
this esterfication. Fortunately, it was found that acyl fluorides were particularly 
useful to effect this transformation. Thus, Fmoc-Orn(N3)-OH (45) was 
transformed into the corresponding acid fluoride using either TFFH 
(tetramethylfluoroformamidinium hexafluorophosphate) or cyanuric fluoride.26 
An excess of the acid fluoride was then added to phenol 60, but remarkably 
dipeptide 60 was recovered in a quantitative manner. Further attempts were 
abandoned due to lack of starting material and the complexity of the synthetic 
route. 
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Scheme 17. Reagents and conditions: a) TFFH, CH2Cl2 or cyanuric fluoride, pyridine, CH2Cl2 
 
4.6 Conclusions 
 
In this chapter the application of copper catalyzed 1,3-dipolar cycloaddition is 
investigated. Several relative simple substrates are indeed easily modified using 
these conditions and thus a small library of amino acids was made, including 
mimics of citrulline. However, more advanced intramolecular applications were 
not successful. Small flexible tri- or tetrapeptides were not recovered after 
catalysis. The 6- and 8-mer sequences, which should by design adopt a suitable β-
turn conformation, failed to undergo a 1,3-dipolar cycloaddition. The use of a 
wide variety of reagents also did not change the outcome. This shows that such 
an approach is far from trivial, although more recently successful examples have 
emerged in literature.9,11 
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4.8 Experimental section 
 
For general experimental details, see: Section 2.8. 
 
tert-Butyl N-(2-azidoethyl)carbamate (25).27 To a solution of 
2-amino-ethanol (1.50 g, 24.6 mmol) and Boc2O (5.90 g, 27.0 mmol) in 1,4-dioxane 
(60 mL) was added a solution of NaHCO3 (4.13 g, 49.9 mmol) in H2O (60 mL). The 
BocHN
N3
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resulting mixture was refluxed for 2 h. After cooling down the organic solvents 
were stripped off using vacuum evaporation. The aqueous suspension was then 
extracted using Et2O and the combined organic layers were washed (brine), dried 
(Na2SO4) and evaporated. The resulting Boc-protected 2-aminoethanol was 
obtained as yellow oil (3.74 g, 23.3 mmol) which was directly used for the 
subsequent step. The oil was dissolved in CH2Cl2 (75 mL) and Et3N (3.9 mL, 26 
mmol) was added. After cooling to 0 °C, MsCl (2.90 g, 25.4 mmol) was added 
dropwise and the resulting solution was stirred for 2 h at 0 °C. After warming to 
ambient temperature, H2O (50 mL) was added dropwise and the resulting 
aqueous layer was extracted using CH2Cl2 (2 × 50 mL). The combined organic 
layers were washed (brine), dried (Na2SO4) and evaporated. The resulting crude 
mesylated oil (6.40 g) was dissolved in DMF (75 mL) and sodium azide (3.24 g, 49 
mmol) was added. The mixture was stirred at 60 °C overnight. After cooling down 
water (100 mL) was added and the mixture was extracted with heptane (3 × 75 
mL). The combined organic layers were washed (brine), dried (Na2SO4) and 
evaporated, yielding the desired compound 25 (2.51 g, 13.6 mmol, 54%, 3 steps). 
1H−NMR (400 MHz, CDCl3) δ 4.81 (bs, 1H, NHBoc), 3.42 (t, J = 5.1 Hz, OCH2), 
2H), 3.30 (q, J = 5.4 Hz, 2H, NCH2), 1.46 (s, 9H, Boc). 
 
3-Azido-(S)-2-tert-butoxycarbonylamino-propionic acid (34). 
A solution of sodium azide (6.36 g, 97.8 mmol) in distilled H2O (20 
mL) and CH2Cl2 (20 mL) was cooled on an ice bath. Triflyl 
anhydride (5.52 g, 19.6 mmol) was added slowly over 5 min while 
stirring continued for 2 h. The mixture was placed in a separatory funnel and the 
CH2Cl2 phase removed. The aqueous portion was extracted with CH2Cl2 (2 × 10 
mL). The organic fractions, containing the triflyl azide, were pooled and washed 
once with aqueous saturated Na2CO3 and used without further purification. 
The amino acid Boc-DAP-OH (2.00 g, 9.80 mmol) was combined with K2CO3 (2.00 
g, 14.8 mmol), Cu(OAc)2 (catalytic amount), distilled H2O (20 mL) and MeOH (30 
mL). The previously synthesized triflyl azide in CH2Cl2 (40 mL) was added, and 
the mixture was stirred at ambient temperature overnight. Subsequently, the 
organic solvents were removed under reduced pressure, and the aqueous slurry 
was diluted with H2O (50 mL). This was acidified to pH = 6 with concentrated 
HCl and extracted with EtOAc (2 × 30 mL) for removal of the sulfonamide 
byproduct. The aqueous phase was then acidified to pH = 2 with concentrated 
HCl. The product was obtained from EtOAc extractions (3 × 30 mL). The organic 
extracts were combined, dried (MgSO4), and evaporated to dryness giving 34 as a 
N3
CO2HBocHN
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pale oil (1.92 g, 8.34 mmol, 85%) with no need for further purification. 1H−NMR 
(500 MHz, DMSO-D6) δ 6.89 (bd, 1H, NH), 4.13 (ddd, J = 6.3 Hz, 6.3 Hz, 7.4 Hz, 
1H, CαH), 3.37 (m, 2H, CH2N3), 1.39 (s, 9H, Boc); 13C−NMR (125 MHz, DMSO-D6 
δ 170.6, 154.8, 53.3, 50.8, 27.8; IR ν 3329 br, 2980, 2106 str, 1714 cm−1; HRMS 
m/e calcd for C8H18N5O4 + (M + NH4)+: 248.1359, found: 248.1356. 
 
3-Azido-(S)-2-tert-butoxycarbonylamino-propionic acid tert-butyl ester 
(36).27 A mixture of DCC (2.84 g, 13.0 mmol), tBuOH (1.30 g, 17.6 
mmol) and copper-(I)-chloride (15 mg, 0.15 mmol) was stirred for 
3 days. The green suspension was then diluted with dry CH2Cl2 
(5 mL) and the Boc-Ala(N3)-OH (34, 1.00 g, 4.34 mmol) in CH2Cl2 (5 mL) was 
added dropwise. The reaction was finished in 3 h as monitored by TLC. 
Precipitated urea was then removed by filtration. The organic layer was washed 
using saturated. NaHCO3 solution (3 × 10 ml), dried (MgSO4) and concentrated 
in vacuo, yielding tert-butyl ester protected amino acid 36 (1.10 gram, 3.84 mmol, 
88%). 1H−NMR28 (400 MHz, CDCl3) δ 5.35 (bd, J = 6.6 Hz, 1H, NH), 4.36−4.31 
(m, 1H, CαH), 3.73−3.63 (m, 2H, CH2N3), 1.49 (s, 9H, Boc), 1.46 (s, 9H, Boc); 
13C−NMR (75 MHz, CDCl3) δ 83.1, 80.7, 55.0, 52.8, 27.3, 27.5. 
 
Fmoc-Orn(N3)-OH (45).27 Following the general procedure for 
diazotransfer as described above, Fmoc-Orn-OH (1.00 gram, 2.55 
mmol) was converted to its corresponding azide 45 (924 mg, 2.41 
mmol, 95%). 1H−NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.3 Hz, 
2H, Fmoc), 7.59−7.53 (m, 2H, Fmoc), 7.39 (t, J = 7.3 Hz, 2H, Fmoc), 7.33−7.26 (m, 
2H, Fmoc), 5.40 (bd, J = 6.8 Hz, 1H, NH), 4.46−4.31 (m, 1H, CαH), 4.20 (t, J = 6.4 
Hz, 1H, CαH-Fmoc), 4.12 (q, J = 7.3 Hz, 2H, CH2O), 3.35−3.26 (m, 2H, CH2N3), 
2.01−1.54 (m, 4H, 2 × CH2); 13C−NMR (75 MHz, CDCl3) δ 173.3, 155.9, 143.6, 
140.6, 140.5, 127.5, 127.4, 126.9, 125.1, 120.0, 119.9, 65.7, 53.6, 50.4, 46.9, 46.8, 
28.3, 25.3; IR ν 3383, 3317, 3065, 2951, 2098, 1705, 1525, 1450, 1393, 1235, 1195 
cm−1. 
 
tert-Butyl N-[2-(4-pentyl-1H-1,2,3-triazol-1-yl)ethyl]carbamate (26). To a 
stirred solution of tert-butyl N-(2-
azidoethyl)carbamate (150 mg, 0.92 mmol) and 
heptyne (266 mg, 2.77 mmol) in tBuOH (5 mL) was 
added a premixed solution of Cu(OAc)2 (36 mg, 0.18 mmol) and sodium ascorbate 
(73 mg, 0.37 mmol) in H2O (5 mL). After vigorously stirring overnight, the 
N3
FmocHN CO2H
N
N
N
NHBoc
Me
N3
CO2tBuBocHN
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mixture diluted with H2O (10 mL) and extracted with CHCl3 (3 × 7 mL), yielding 
26 as a yellowish solid (217 mg, 0.77 mmol, 84%). 1H−NMR (400 MHz, CDCl3) δ 
7.27 (s, 1H, ArH), 4.87 (s, 1H, NHBoc), 4.43 (t, J = 5.8 Hz, 2H, NCH2), 3.62 (q, J = 
5.8 Hz, 2H, ArCH2), 2.71 (t, J = 7.6 Hz, 2H, NHCH2), 1.71−1.31 (m, 6H, 3 × CH2), 
1.43 (s, 9H, Boc), 0.90 (t, J = 7.1 Hz, 3H, CH2Me); 13NMR (75.5 MHz, CDCl3) δ 
155.2, 147.9, 120.8, 79.4, 49.4, 40.2, 31.2, 28.9, 28.1, 25.4, 22.2, 13.8; IR ν 3255, 
2953, 2929, 2869, 1701, 1544, 1454, 1365, 1175, 972 cm−1; HRMS (EI) m/z calcd 
for C14H26N4O2 282.2056, found 282.20607. 
 
Ethyl 2-(4-pentyl-1H-1,2,3-triazol-1-yl)acetate (27). 
Following a general protocol as shown for 26, N3-Gly-
OEt (130 mg, 1.00 mmol) and heptyne (192 mg, 2.00 
mmol) were combined. After workup, the addition of hexane caused the desired 
product 27 (193 mg, 0.86 mmol, 86%) to crystallize as white needles. 1H−NMR 
(400 MHz, CDCl3) δ 7.41 (s, 1H, ArH), 5.15 (s, 2H, ArCH2CO), 4.28 (q, J = 7.1 Hz, 
2H, OCH2), 2.75 (t, J = 7.6 Hz, 2H, ArCH2), 1.71−1.63 (m, 2H, CH2CH2Ar), 
1.40−1.30 (m, 4H, 2 × CH2), 1.26 (t, J = 7.1 Hz, 3H, Me), 0.89 (t, J = 7.1 Hz, 3H); 
13NMR (75.5 MHz, CDCl3) δ 165.8, 148.3, 121.3, 62.0, 50.5, 31.2, 28.8, 25.4, 22.2, 
13.9, 13.8; IR ν 2929, 2860, 2095, 1751, 1216, 773 cm−1; MS (EI) m/z calcd for 
C11H19N3O2 225.1477, found 226.1547 (M + H)+. 
 
(2S)-methyl 2-[(tert-butoxycarbonyl)amino]-3-[1-(2-ethoxy-2-oxoethyl)-
1H-1,2,3-triazol-4-yl]propanoate (32). Following a 
general protocol as shown for 26, (S)-2-tert-
butoxycarbonylamino-4-pentynoic acid methyl ester (28, 
100 mg, 0.44 mmol) and N3-Gly-OEt (57 mg, 0.44 mmol) 
were reacted. After isolation, 32  was yielded as a yellowish solid (40 mg, 0.112 
mmol, 26%). 1H−NMR (400 MHz, CDCl3) 7.52 (s, 1H, ArH), 5.51 (bd, J = 16.4 Hz, 
1H, NHBoc), 5.13 (s, 2H, CH2N), 4.70−4.57 (m, 1H, CαH), 4.26 (q, J = 14 hz, 2H, 
CH2Ar), 3.73 (s, 3H, OMe), 3.27 (d, J = 10.8 Hz, 2H, OCH2), 1.43 (s, 9H, Boc), 1.30 
(t, J = 14 Hz, 3H, CH3); 13C−NMR (75.5 MHz, CDCl3) δ 171.5, 165.8, 155.0, 143.0, 
123.2, 80.0, 62.4, 53.1, 52.5, 50.9, 28.4, 14.3; IR ν 3384, 2979, 1747, 1711, 1509, 
1214, 1165 cm−1. 
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(2R)-3-(1-2-[(tert-butoxycarbonyl)amino]ethyl-1H-1,2,3-triazol-4-yl)-2-
[(9H-9-fluorenylmethoxy)carbonyl]aminopropanoic acid (30).  
To a stirred solution of (R)-2-amino-4-pentynoic acid 
(400 mg, 3.54 mmol) in H2O (4 mL) were added Et3N 
(0.50 mL, 3.56 mmol) and FmocOSu (1.19 g, 3.53 
mmol) which was dissolved in MeCN (10 mL). The 
pH of this mixture was maintained pH = 9.0 for 10 minutes by manual addition 
of Et3N. After 15 more minutes N3-Et-NHBoc (25, 580 mg, 3.54 mmol), 
Cu(OAc)2·2H2O (18.0 mg, 0.044 mmol) and Na-ascorbate (35.0 mg, 0.088 mmol, 
0.4 equiv) were added. After 10 seconds, the suspension colored bright yellow. 
The mixture was stirred overnight. The pH was lowered to 6 and the organic 
solvents were stripped in vacuo. After further lowering the pH (< 2), extraction 
using EtOAc (3 × 10 mL), subsequent washing of the combined organic layers 
(brine, 15 mL), drying (MgSO4) and evaporation, a brown solid was yielded. Flash 
chromatography (5% MeOH and 2% AcOH in CH2Cl2) resulted in 30 in off-white 
crystals (1.372 g, 2.63 mmol, 81%, 2 steps). 1H−NMR (400 MHz, CDCl3) δ 7.75 (d, 
J = 7.8 Hz, 2H, Fmoc), 7.59 (d, J = 7.3 Hz, 2H, Fmoc), 7.42−7.35 (m, 3H, Fmoc + 
triazole-H), 7.31 (dt, J = 1.0 Hz, 7.8 Hz, 2H, FMoc), 6.00 (bs, 1H, NH), 4.95 (bs, 
1H, NHBoc), 4.70−4.62 (m, 1H, CαH), 4.43−4.32 (m, 4H, CH2O, CH2NAr), 4.22 (t, 
J = 6.4 Hz, 1H, Fmoc-αH), 3.60−3.55 (m, 2H, CH2NHBoc), 3.40−3.30 (m, 2H, 
CH2CAr), 1.42 (s, 9H, Boc); 13NMR (75.5 MHz, CD3OD) δ 176.3, 156.3, 156.1, 
143.2, 143.1, 140.5, 126.8, 126.2, 124.3, 124.3, 78.7, 66.3, 49.4, 39.8, 27.3, 27.1; IR 
ν 2985.7, 2899.7, 1715.5, 1406.0, 1227.2, 1054.7 cm−1. 
 
(2S)-3-[1-(carboxymethyl)-1H-1,2,3-triazol-4-yl]-2-[(9-
fluorenylmethoxy)carbonyl]aminopropanoic acid (33).  
Using the previously described protocol, (S)-2-amino-4-
pentynoic acid (500 mg, 4.42 mmol) was protected 
subsequently combined with N3-Gly-OMe (508 mg, 4.42 
mmol), yielding 33 as off-white crystals (720 mg, 1.60 
mmol, 38%). 1H−NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.8 Hz, 2H, Fmoc), 7.59 (d, 
J = 7.3 Hz, 2H, Fmoc), 7.42−7.35 (m, 3H, Fmoc + ArH), 7.31 (dt, J = 1.0 Hz, 7.8 
Hz, 2H, Fmoc), 5.87 (bd, J = 6.8 Hz, NH), 5.14 (t, J = 21.0 Hz, 2H, Ar-
CH2CO2Me), 4.68−4.63 (m, 1H, CαH), 4.51−4.36 (m, 2H, CH2O), 4.22 (t, J = 6.4 
Hz, 1H, Fmoc-αH), 3.78 (s, 3H, OMe), 3.47−3.32 (m, 2H, CH2Ar); 13NMR (75.5 
MHz, CD3OD) δ 176.2, 170.6, 160.3, 147.2, 147.1, 144.4, 130.7, 130.1, 128.3, 
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127.8, 122.9, 70.3, 57.3, 55.5, 53.8, 51.0, 31.1; HRMS (EI) m/z calcd for 
C23H22N4O6 450.15393, found 450.15604.  
 
tert-Butyl N-[2-(4-[(aminocarbonyl)amino]methyl-1H-1,2,3-triazol-1-
yl)ethyl]carbamate (34). Using the general procedure, 
tert-butyl 2-azidoethylcarbamate (200 mg, 1.26 mmol) 
was combined with 1-(prop-2-ynyl)urea (123 mg, 1.26 
mmol). Further purification (5% MeOH in CH2Cl2) 
yielded the desired urea 34 (251 mg, 0.98 mmol 78%). 1H−NMR (400 MHz, 
CDCl3) δ 7.56 (s, 1H, C=CH), 6.24 (s, 1H, NHCONH2), 5.42 (s, 1H, NHBoc), 4.91 
(m, 2H, CH2NAr), 4.45 (t, J 4.9 Hz, 2H, CH2NHCONH2), 4.42−4.35 (m, 2H, 
CONH2), 3.60 (q, J = 5.4 Hz, 2H, CH2NHBoc), 1.43 (s, 9H, Boc); 13NMR (75.5 
MHz, CD3OD) δ 163.8, 160.1, 126.4, 82.6, 63.8, 53.3, 43.8, 38.7, 23.3, 17.7. 
 
[1-(tert-butoxycarbonyl )amino-2-(5-ureidomethyl-[1,2,3]triazol-1-yl)-
ethyl]-carbamic acid tert-butyl ester (38). Using 
the general procedure Boc-Ala(N3)-OtBu (36, 200 mg, 
0.70 mmol) was combined with 1-(prop-2-ynyl)urea (68 
mg, 0.69 mmol). Further purification (5% MeOH in 
CH2Cl2) yielded the desired urea 38 (235 mg, 0.61 mmol) in 87%. 1H−NMR (400 
MHz, CDCl3) δ 7.57 (s, 1H, ArH), 6.30 (bs, 1H, NHCONH2), 5.57 (bs, 1H, NHBoc), 
4.92−4.85 (m, 2H, CH2NAr), 4.77−4.70 (m, 2H, NH2), 4.59−4.53 (m, 1H, CαH), 
4.44−4.40 (m, 2H, ArCH2N), 1.44 (s, 9H, Boc), 1.43 (s, 9H, Boc); 13NMR (75.5 
MHz, CDCl3) δ 167.7, 158.9, 154.9, 145.5, 12c3.2, 83.6, 80.5, 54.3, 51.1, 50.6, 35.4, 
28.4, 28.0; IR ν 3348, 2978, 2934, 1708, 1657, 1367, 1152, 1053, 732 cm−1; HRMS 
(EI) m/z calcd for C16H29N5O5 385.2199, found 385.21968. 
 
Ethyl 1-3-(tert-butoxy)-2-[(tert-butoxycarbonyl)amino]-3-oxopropyl-1H-
1,2,3-triazole-4-carboxylate (39). Using the general 
procedure Boc-Ala(N3)-OtBu (1.08 g, 3.94 mmol) was 
coupled to propynoic acid ethyl ester (580 mg, 5.91 mmol), 
resulting in triazole 39 (1.33 g, 3.45 mmol, 88%). 1H−NMR 
(400 MHz, CDCl3) δ 8.05 (s, 1H, C=CH), 5.46 (d, J = 6.8 Hz, 1H, NH), 4.79−4.76 
(m, 2H, OCH2), 4.52−4.43 (m, 1H, CαH), 4.36−4.28 (m, 2H, NCH2), 1.39 (s, 9H, 
Boc), 1.36 (s, 9H, Boc), 1.32 (t, J = 7.0 Hz, 3H, CH3); 13C−NMR (75 MHz, CDCl3) δ 
167.0, 160.0, 154.6, 139.5, 128.3, 83.6, 80.3, 61.0, 53.9, 50.1, 28.0, 27.7; IR ν 
3358.3, 2977.9, 2933.7, 2358.8, 1717.9, 1511.1, 1152.6, 1041.1 cm−1.  
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General procedure for the loading of Wang-resin. 
A batch of resin was allowed to swell in dry DMF. 
After removal of the DMF, fresh dry DMF was 
added, followed by the amino acid (2 equiv), DIC 
(2 equiv), HOBt (4 equiv) and DMAP (2 equiv). After 16 h the solution was 
removed and washed thrice with DMF. Then Ac2O (10% in DMF) was added in 
order to cap all remaining free sites. After removal of the solution the resin was 
washed twice using MeOH, twice with CH2Cl2 and twice with Et2O in order to 
remove all traces of DMF and dried. The loading was determined by measuring 
weight or Fmoc-titration. 
 
General procedure for amino acid coupling using Fmoc-NH-Resin. 
The Fmoc-protected amino acid loaded resin was treated with 20% piperidine and 
0.1 M HOBt in DMF (15 mL) for 5 min and subsequently the solvent was 
removed (by filtration). This procedure was repeated three times. The resin was 
washed using DMF (3 × 1 min). Having removed the Fmoc, the resin was treated 
with DIC (3.3 equiv, 1 M in DMF), HOBt (3.3 equiv, 1 M in DMF), the Fmoc-AA-
OH (3 equiv) and DMF and ‘stirred’ for approximately 40 min . The coupling was 
qualitatively monitored using the Kaiser test.29 When completed, the solvent was 
again removed by filtration and washed with DMF (3 × 1 min). 
 
General procedure for the cleavage from the Wang-resin. 
The resin was washed twice using MeOH, twice with CH2Cl2 and twice with Et2O 
in order to remove all traces of DMF. Then 1% of ethanedithiol, 1% of H2O and 
1% of iPr3SiH in TFA were added and the resin was mixed for 4 h. After 
filtration, the filtrate was concentrated, dissolved in MeOH and treated with 
Et2O, causing the peptide-chain to precipitate from the solution. The solid 
peptide was dissolved in dioxane and freeze-dried under vacuum, yielding a 
white solid. 
O
O
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H2N-Asp(Bn)-Pro-Ala-Prg30-OH (43). Using 
standard solid phase chemistry, the Wang-resin (0.832 
g, 0.75 mmol/g) was functionalized. After cleavage with 
TFA (50% in CH2Cl2) and evaporation under a stream 
of N2, the solid was taken up in dioxane and freeze-
dried, yielding 43 as a white solid (240 mg, 0.49 mmol, 
79%). 1H−NMR (400 MHz, CD3OD) δ 7.31 (s, 5H, Ar), 5.10 (s, 2H, CH2O), 
4.57−4.50 (m, 1H, CαH), 4.47−4.40 (m, 1H, CαH), 4.37−4.33 (m, 1H, CαH), 
4.23−4.14 (m, 1H, CαH), 3.67−3.54 (m, 1H, CH2N), 3.50−3.41 (m, 1H, CH2N), 
3.10−2.96 (m, 1H, CH2CO2Bn), 2.92−2.82 (m, 1H, CH2CO2Bn), 2.67−2.56 (m, 2H, 
C≡CCH2), 2.27 (s, 1H, C≡CH), 2.26−2.15 (m, 1H, CH2), 1.94−1.77 (m, 3H, CH2), 
1.27 (d, J = 6.8 Hz, 3H, Me); HRMS (EI) m/z calcd for C24H30N4O7 486.21145, 
found 523.21987. 
 
Cbz-Orn(Asp(Bn))-Prg-OH (44). Following the general 
protocol, the Wang-resin (900 mg, 0.75 mmol/g) was 
functionalized. After cleavage with TFA (50% in CH2Cl2) 
and evaporation under a stream of N2, the solid was taken 
up in dioxane and freeze-dried, yielding 44 as  a white 
solid (253 mg, 0.44 mmol, 66%). 1H−NMR (400 MHz, 
DMSO-D6) δ 7.36−7.22 (m, 10H, 2 × Ar), 5.11 (s, 2H, 
CH2O), 4.98 (s, 2H, CH2O), 4.37−4.28 (m, 1H, CαH), 4.11−3.99 (m, 2H, 2 × CαH), 
3.41−2.92 (m, 2H, NCH2), 2.88−2.80 (m, 2H, CH2CO), 2.60−2.51 (m, 2H, 
C≡CCH2), 2.06 (s, 1H, C≡CH), 1.69−1.38 (m, 4H, 2 × CH2); ); HRMS (EI) m/z 
calcd for C29H34N4O8 566.2377, found 566.24065. 
 
Fmoc-Orn(N3)-hhPrg-OMe (47). To a suspension of 
(S)-2-amino-6-heptynoic acid (56 mg, 0.39 mmol) in 
MeOH (5 mL) was added dropwise SOCl2 (75 µL, 1.00 
mmol) and the mixture was refluxed for 2h. After 
cooling to room temperature, the solvents were stripped 
off yielding the methyl ester 46 as a HCl-salt. The solids were resuspended in 
CH2Cl2 (10 mL) and in the following order DiPEA (163 µL, 0.90 mmol), Fmoc-
Orn(N3)-OH (150 mg, 0.39 mmol) and PyBOP (226 mg, 0.43 mmol) were added 
upon which the resulting mixture was stirred overnight. After evaporation 
further purification was performed using flash chromatography (66% EtOAc in 
heptane), yielding dipeptide 47 (95 mg 0.19 mmol, 47%) as a white solid. 
N
O HN
N
H
O
H2N CO2H
O Me
BnO2C
CbzHN
NH
O
NH2
CO2Bn
O H
N CO2H
N3
FmocHN N
HO
CO2Me
Chapter 4 
 92 
1H−NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.8 Hz, 2H), 7.57 (m, 2H), 7.37 (t, J = 
7.3 Hz, 2H), 7.30−7.26 (m, 2H), 7.12−7.16 (bd, 1H, NH), 5.88 (m, 1H, NHFmoc), 
4.60−4.54 (m, 1H, CαH), 4.44−4.39 (m, 1H, CαH), 4.39−4.32 (m, 2H, CH2O), 
4.21−4.18 (m, 1H, CαH-Fmoc), 3.74 (s, 3H, OMe), 3.35−3.22 (m, 1H, CH2N3), 
3.18−3.03 (m, 1H, CH2NHBoc), 2.21−2.16 (m, 2H, C≡CCH2), 2.00−1.50 (m, 8H, 4 
× CH2); 13C−NMR (75 MHz, CDCl3) δ 172.2, 171.9, 156.1, 143.6, 143.5, 141.0, 
127.5, 126.8, 124.9, 119.7, 83.1, 68.9, 66.9, 60.2, 53.3, 52.1, 51.6, 46.9, 39.0, 30.6, 
29.9, 26.0, 24.2, 17.7, 14.0; IR ν 3297.7, 3065.5, 2952.7, 2098.2, 1702.9, 1659.3, 
1525.2, 1477.9, 1386.8, 1233.8, 1193.4 cm−1; HRMS (EI) m/z calcd for C28H31N5O5 
517.23252, found 517.2301. 
 
Cbz-Orn(Orn(N3)Ac)-Prg-OH (49). Following the 
general protocol, Wang-resin (600 mg, 0.75 mmol/g) was 
functionalized. Before cleavage the Fmoc-group was 
removed and the free amine was capped with Ac2O. After 
cleavage with TFA (50% in CH2Cl2) and evaporation 
under a stream of N2, the solid was taken up in dioxane 
and freeze-dried, yielding 49 as a white solid (178 mg, 0.33 mmol, 73%). 13NMR 
(75.5 MHz, CD3OD) δ 172.5, 172.0, 171.3, 171.0, 156.3, 131.4, 127.6, 127.1, 126.9, 
78.2, 70.8, 66.0, 54.1, 52.9, 50.8, 50.4, 38.0, 35.4, 30.1, 29.1, 28.9, 25.1, 24.9, 21.0, 
20.8; HRMS (EI) m/z calcd for C25H33N7O7 543.2441, found 566.2349 (M + Na)+. 
 
Cbz-Orn(Boc)-Prg-OMe (59). To a suspension of (S)-2-
amino-4-pentynoic acid (200 mg, 1.77 mmol) in MeOH (25 
mL) was added dropwise SOCl2 (300 µL, 3.8 mmol) and 
the mixture was refluxed for 2h. After cooling to room 
temperature, the solvents were stripped off yielding the methyl ester as a HCl-
salt. The solids were resuspended in CH2Cl2 (20 mL) and in the following order 
DiPEA (670 µL, 3.94 mmol), Cbz-Orn(Boc)-OH (670 mg, 1.83 mmol) and PyBOP 
(1 g, 1.85 mmol) were added and the resulting mixture was stirred overnight. 
After evaporation and further purification using flash chromatography (66% 
EtOAc in heptane), dipeptide 59 was obtained (750 mg, 1.58 mmol, 88%) as a 
white solid. 1H−NMR (400 MHz, CDCl3) δ7.34−7.29 (m, 5H, Ar), 7.11 (bd, J = 7.5 
Hz, 1H, NH), 5.69 (bd, J = 7.5 Hz, 1H, NHCbz), 5.10 (s, 2H, OCH2), 4.77 (bs, 1H, 
NHBoc), 4.72−4.67 (m, 1H, CαH-Prg), 4.40−4.35 (m, 1H, CαH-Orn), 3.75 (s, 3H, 
OMe), 3.24−3.05 (m, 2H, CH2N), 2.75−2.71 (m, 2H, C≡CCH2), 1.99 (t, J = 2.6 Hz, 
1H, C≡CH), 1.92−1.51 (m, 4H, 2 × CH2), 1.42 (s, 9H, Boc). 
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Cbz-Orn(2-hydroxy-4-methoxy-benzyl)-Prg-OMe 
(60). Previously obtained dipeptide 59 (750 mg, 1.58 
mmol) was dissolved in EtOAc (2 mL) and 2 M HCl (in 
EtOAc, 10 mL) was added. The resulting mixture was 
stirred for 45 min and evaporated. The deprotected 
HCl-salt was then redissolved in CH2Cl2 (20 mL) and 
Et3N (220 μL, 1.58 mmol) was added. The resulting 
mixture was stirred for 30 min and evaporated. The precipitates were 
resuspended in dry THF (30 mL) and Na2SO4 (4.40 g, 31 mmol), 2-hydroxy-4-
methoxy-benzaldehyde (240 mg, 1.58 mmol) and NaHCO3 (252 mg, 3.2 mmol) 
were added, leaving the mixture for several hours to dehydrate (solution turning 
yellow). When imine formation was completed, NaB(OAc)3H (2.00 g, 9.6 mmol) 
was added and the reaction was allowed to stir overnight. The solution became 
clear/flocky white. The borane remainder was carefully quenched using aqueous 
saturated ammonium chloride (2 mL) prior to extraction with aqueous saturated 
NaHCO3 (10 mL) and Et2O (3 × 50 mL). The remaining oil thus obtained was 
treated with CH2Cl2 (10 mL) and Boc2O (413 mg, 1.91 mmol) for 16 h. Remainder 
of the Boc2O was removed with imidazole. Further purification was performed 
using flash chromatography (3% MeOH in CH2Cl2), yielding the desired product 
60 (222 mg, 0.36 mmol, 23%, 4 steps)  as a semi-solid. 1H−NMR (400 MHz, 
CDCl3) δ 7.38−7.33 (m, 5H), 6.96 (d, J = 8.4 Hz, 1H), 6.72 (ds, 1H), 6.48 (d, J = 2.4 
Hz, 1H), 6.35 (dd, J = 2.4 Hz, 8.0 Hz, 1H), 5.31 (bs, 1H), 5.12 (s, 2H), 4.71−4.67 
(m, 1H), 4.25−4.21 (m, 1H), 4.21 (s, 2H), 3.78 (s, 3H), 3.74 (s, 3H), 3.22−3.17 (m, 
2H), 2.77−2.73 (m, 2H), 2.01 (t, J = 2.6 Hz, 1H), 1.86−1.79 (m, 1H), 1.63−1.57 (m, 
3H), 1.45 (s, 9H). 13NMR (75.5 MHz, CDCl3) δ 170.8, 170.0, 160.9, 157.0, 155.7, 
136.1, 131.9, 128.3, 128.1, 127.9, 115.2, 105.4, 102.3, 81.6, 78.0, 72.0, 67.2, 55.3, 
54.4, 52.9, 50.7, 46.8, 46.1, 31.3, 30.1, 28.5, 28.0, 27.4, 23.8, 22.3. 
 
H2N-hAla(N3)-Asn-Pro-Asn-Ala-Prg-OH (51). 
Using standard solid phase chemistry (2.31 g, 
1.73 mmol) the oligopeptide (723 mg, 1.15 mmol, 
67%) was obtained as a white fluffy solid. 
13NMR (75.5 MHz, D2O) δ 173.8, 173.74, 173.3, 
173.1, 172.6, 171.2, 170.1, 168.0, 79.0, 71.7, 66.2, 
60.7, 52.9, 51.0, 50.9, 50.1, 49.4, 49.3, 48.1, 48.0, 47.9, 47.8, 46.4, 35.9, 35.7, 29.7, 
29.2, 24.2, 21.3, 20.5, 16.5; HRMS (EI) m/z calcd for C25H37N11O9 635.2776, found 
658.2623 (M + Na)+. 
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H2N-hAla(N3)-Ala-Asn-Pro-Asn-Ala-Ala-
Prg-OH (52). Using standard solution 
phase chemistry on wang-resin (1.71 g, 1.3 
mmol) the oligopeptide (700 mg, 0.90 
mmol, ~69%) was obtained as a white 
fluffy solid. HRMS (ESI) m/z calcd for 
C31H48N13O11 778.35962, found 778.36131 (M + H)+. 
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5  TOWARD ACETYLENE-BASED CYSTINE 
MIMICS 
 
5.1 Introduction 
 
Compared to the rich history of investigations into olefin metathesis, its alkyne 
metathesis counterpart has drawn much less attention.1 Despite the great 
similarity of the mechanism and the potential transformations, relatively few 
examples involving alkyne metathesis have appeared in literature pursued by a 
limited number of research groups. The main features of alkyne metathesis, 
compared to olefin metathesis, include the inherent absence of (E)/(Z) mixtures 
and the surprisingly strong bias for cyclization. These advantages are 
compensated by the relative sensitivity and difficult accessibility of suitable 
catalysts. Since general acceptance of new methodology usually very much 
depends on its ease of use, alkyne metathesis may only become a widely used tool 
in case commercially available, air-stable catalysts emerge. The latter situation 
was encountered in the olefin metathesis field, which reached wide acceptance 
with the emergence of the ‘air-stable’ 1st generation Grubbs catalyst in 1995,2 
while Schrock’s superior, but air-labile catalyst was already available since 
1990.3 
Nevertheless, recent developments culminated in 1999 in the first example of a 
total synthesis based upon ring-closing alkyne metathesis (RCAM) from the 
Fürstner group, being the synthesis of nakadomarin (2) (Scheme 1).4  
 
N
O
N
H
H
H
HN
O
SO2Ph
O
HN
O
SO2Ph
O
Me
Me
(tBuO)3W
Me
Me
Me
1
2 3 4  
Scheme 1. Retrosynthesis of nakadomarin, featuring RCAM as the key step. 
 
The earliest reports of alkyne metathesis date from the late 1960s,5 when 
heterogeneous catalysts (e.g. silica-bound tungsten oxide) catalyzed alkyne 
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metathesis reactions at 400 °C.6 During these early days, especially olefin 
metathesis was drawing much attention in the chemical community in terms of 
application, suitable catalysts and mechanism. In analogy with the proposed 
Chauvin mechanism for olefin metathesis,7 Katz and coworkers came up with a 
similar mechanism for alkyne metathesis,8 now involving alkylidyne complexes 
(Scheme 2). This mechanism implies that initiators for metathesis should be 
found among alkyl-substituted metal-carbyne complexes (5) and that the 
catalytic cycle involves the formation and ring-opening of metallacyclobutadiene 
species. 
M
R1
RMe
M
RMe
R1
M
Me
R R1
R1 = Me, alkyl
5
6 7
 
Scheme 2. Mechanism of alkyne metathesis as proposed by Katz.  
 
It was not until well-defined metal alkylidyne complexes such as 
[(tBuO)3W≡CCMe3] (1) became available, that the first alkyne metathesis 
reactions were successfully carried out, thus confirming the mechanistic 
hypothesis. The Schrock group was the first to report the synthesis of the 
tungsten-catalyst 1 and demonstrated its application in the cross-metathesis of 3-
heptyne, as shown in Scheme 3.9  
 
Me
Me Me
Me
+
alkyne
metathesis
Me
Me8 9 10  
Scheme 3. Alkyne metathesis-mediated exchange of alkyl substituents. 
 
In these early examples, it was already observed that only internal acetylenes 
(RC≡CR1) successfully undergo the alkyne metathesis process, whereas terminal 
acetylenes (RC≡CH) are much more prone to undergo polymerization reactions 
and therefore cannot be used in alkyne metathesis.10 Moreover, it was observed 
that alkyne metathesis catalysts displayed excellent chemoselectivity for alkynes 
and did not react with olefins in the molecule.11 
Toward acetylene-based cystine mimics 
 99
The group of Fürstner further developed the scope of RCAM and initiated a 
program to search for alternative catalysts in the late nineties.12 As a result, 
sterically hindered trisamidomolybdenum(III) complexes of the general type 
[Mo{(tBu)(Ar)N}3] (11) were found to react with CO, NO, N2O and also N2 in a 
stoichiometric fashion (Scheme 4).13 Due to this remarkable reactivity, the 
Fürstner group set out to apply species of type 11 in alkyne metathesis. Although 
complex 11 was inactive on test substrates, the addition of CH2Cl2 or other 
halogen sources (TMSCl) resulted in an efficient and rapid alkyne metathesis 
reaction. This novel catalyst, when activated, outperformed existing protocols in 
many respects, independent of its use in RCAM, homo-alkyne dimerization or 
cross-alkyne metathesis.14 However, drawbacks remain such as sensitivity to 
oxygen, moisture and acidic protons of e.g. alcohols and acids. Even secondary 
amide protons suffice to inactivate the catalyst, rendering it useless for 
application of RCAM in for example peptides. 
 
Ar(R)N Mo
N(R)Ar
N(R)Ar N2
1 atm
-35 °C Ar(R)N
Mo
N(R)Ar
N(R)Ar
N
N
Ar(R)N
Mo
N(R)Ar
N(R)Ar
Ar(R)N
Mo
N(R)Ar
N(R)Ar
N
N
Ar(R)N
Mo N(R)Ar
N(R)Ar
Ar(R)N Mo
N(R)Ar
N(R)Ar
N
NAr(R)N
Mo
Ar(R)N
Ar(R)N
N2
11 12
13
1415  
Scheme 4. Reaction of molybdenum-catalyst 11 with molecular nitrogen.  
 
As mentioned before, despite the broad scope of ring-closing metathesis (RCM), 
ring-closing alkyne metathesis has specific advantages over olefin metathesis, 
especially the lack of formation of geometrical isomers. This is exemplified by 
RCM examples in the synthesis of carbocyclic analogues of cyclic peptides, where 
generally mixtures of (E)- and (Z) isomers are obtained.15 These carbon analogues 
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are generally designed as synthetic mimics to attain a metabolically (and 
chemically) stable β-turn peptide as compared to nature’s disulfide bridges.  
As shown in Section 1.4, Grubbs successfully demonstrated the application of 
RCM for the formation of carbon analogues of cystine.16 Generally these are made 
by incorporation of two unsaturated amino acids in peptides and subsequent 
metathesis. 
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Figure 1. Balaram’s tetrapetide (16) and Grubbs carbon mimic (17) 
 
In Chapter 3 has already been indicated that we were interested in the synthesis 
of acetylene-bridges as stable cross-links in peptide units. This can either be 
achieved via incorporation of an acetylene-containing diaminosuberic acid 
fragment in a peptide, or via incorporation of monomeric RCAM precursors in a 
peptide, followed by RCAM after the peptide has been synthesized. While the 
former approach (Scheme 5, path a) has been detailed in Chapter 3,17 we now 
wish to detail the latter pathway.  
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Scheme 5. Fixation of a peptide β-turn via an unsaturated all carbon cross-link.  
 
The use of RCAM for peptide chemistry was already demonstrated in our group 
by Wolf (see Section 3.1).18 Using this approach by building peptides containing 
unsaturated amino acids (viz. 21) and applying RCAM (Scheme 5, path b), we 
intend to make constrained peptides (20).19 Interestingly, this approach was later 
also pursued by the Liskamp group. 20 
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These general studies to employ acetylene-containing amino acids and ring-
closing alkyne metathesis as an approach to prepare stable β-turn elements 
involves the synthesis of the RCAM catalyst, the synthesis of suitable 
oligopeptides with varying length and motifs and a study of the conformational 
behavior of the β-turn-containing peptides. 
 
5.2  Synthesis of an RCAM catalyst 
 
Since alkyne metathesis catalysts are not commercially available, we set out to 
prepare the tungsten-catalyst 1 following the published procedures (Scheme 6).21 
The synthesis commenced with freshly prepared lithium dimethylamide, which 
was reacted at –60 °C with tungsten(IV) chloride. After warming up to room 
temperature and additional refluxing for two hours, evaporation and subsequent 
vacuum sublimation yielded 22 as red-brown crystals.  
 
(tBuO)3W
Me
Me
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Me2N
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NMe2
NMe2
NMe2
a b c
 
Scheme 6. Reagents and conditions: a) LiNMe2, THF, –60 °C to rt (44%); b) tBuOH (66%); c) 
neopentyne, heptane (44%). 
 
Then, ligand exchange with tert-butanol and subsequent recrystallization in 
heptane yielded the complex 23.22 This compound was subjected to neopentyne23 
to cleave the dimeric species, yielding catalyst 1 which was obtained in pure form 
by sublimation. Due to the fact that the catalyst readily decomposes at elevated 
temperatures, a low pressure was required (Tsub = 45 °C at 0.01 mbar). 
Eventually, catalyst 1 was obtained as clear pale yellow crystals, which were 
collected from the sublimation condensor in a glove box in an overall yield of 13%.  
 
5.3 Benchmark studies 
 
Given the delicacy of the RCAM process and our initial lack of experience with 
this particular catalyst and reactions, we were looking for a conversion that 
would allow us to benchmark our results. A suitable target reaction we 
envisioned, was the cyclization of dipeptide 28 to the cycloalkyne 24, which is an 
acetylene variant of the cyclic dipeptide 25 (Scheme 7). Katzenellenbogen had 
previously demonstrated that this olefin acts as a β-turn mimic,24 and 
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preliminary results on this particular cyclization had already been obtained in 
our lab.25 
The precursor synthesis commenced with enantiomerically pure (S)-2-amino-6-
octynoic acid (29), which was either protected at the nitrogen atom with a Boc 
group (26) or reacted at the acid function to give the corresponding methyl ester 
27. Both amino acids were then coupled via a mixed anhydride to form the 
dipeptide 28 in 87% yield. 
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Scheme 7. Reagents and conditions; a) Boc2O, NaHCO3, 1,4-dioxane/H2O (1 : 1), 100 °C (85%); b) 
SOCl2, MeOH, reflux (100%); c) iBuOCOCl, Et3N, Et2O, CH2Cl2, 0 °C (87%); d) PhMe, 1, 80 °C, 3 h 
(72%). 
 
This RCAM precursor was now subjected to the ring-closing metathesis 
conditions (10% of 1, toluene, 80 ºC, 3 h) to give the desired cycloalkyne 24 in 72% 
yield. Generally these results were found to be reliable giving yields between 70 
and 80%. This gratifying result clearly demonstrates the potential of ring-closing 
alkyne metathesis, even in combination with highly functionalized substrates 
such as these amino acids. Furthermore, this result encouraged us to investigate 
ring-closing alkyne metathesis in larger peptide systems. 
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5.4  Tetramer cyclization 
 
Having established a reliable protocol for RCAM reactions on dipeptides, we now 
set out to apply this reaction on larger structures. Initially, we chose to work 
with tetrapeptides that we would like to stabilize via the formation of acetylene 
linkages.26 We deliberately chose to work with solution phase strategies, since for 
the desired length (four to five amino acid residues) this is more suitable to 
prepare gram amounts of material. The sequence commenced with (S)-2-amino-4-
hexynoic acid (30), which was treated with MeOH under acidic conditions to form 
the corresponding methyl ester. Next, it was reacted as a free amine with Boc-
Aib-OH (42)27 in the presence of Castro’s reagent (PyBOP)28 and DiPEA in 
CH2Cl2 to give 34 in 89%. Alternating Boc deprotection using hydrochloric acid in 
EtOAc and the previously described coupling protocol involving subsequently 
Boc-protected proline and 32 gave eventually the fully protected tetrapeptide 38 
in 38% overall yield after silica gel flash chromatography.  
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Scheme 8. Reagents and conditions: a) NaHCO3, Boc2O, 1,4-dioxane/H2O (1 : 1), 100 °C; b) i: 
SOCl2, MeOH ii: PyBOP, DiPEA, 42, CH2Cl2; c) i; 2 M HCl in EtOAc, 45 min ii: PyBOP, DiPEA, 
Boc-Pro-OH, CH2Cl2 (58%); d) i; 2 M HCl in EtOAc, 45 min ii: PyBOP, DiPEA, 32 or 33, CH2Cl2, 
e) 2 M NaOH, Boc2O (65%). 
 
RCAM of 38 using tungsten-catalyst 1 (9 mol%, chlorobenzene or toluene, 80 °C, 
3 h)29 did not result in the desired cyclic peptide. While the corresponding olefin 
derivative is known to readily cyclize,30 this specific tetrapeptide failed to 
undergo cyclization despite numerous attempts using a variety of conditions. 
Chapter 5 
 104
Alternative sequences (made according to Scheme 8) based on elongated 
acetylene handles using (S)-2-amino-5-heptynoic acid (39) or the (R)-instead of 
(S)-proline-containing diastereomers 40 and 41 also never gave rise to any 
cyclized products. Most likely, dimers, or oligomers were formed instead via 
intermolecular pathways since the acetylenic 
methyl groups (δ ~1.74, t, J = 2.4 Hz) were clearly 
consumed according to 1H−NMR. Presumably, the 
Pro-Aib-based turn sequence is too rigid to allow 
approach of the two acetylenes in a manner 
suitable to effect cyclization.  
 
In order to reduce the rigidity of the system, 
similar tetramers were synthesized containing alanine residues instead of Aib. 
For example, in an alternative synthetic sequence (Scheme 9), the (S)-alanine-
based tetrapeptide 45 was synthesized in six steps in an overall yield of 62%.  
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Scheme 9. Reagents and conditions: a) i: SOCl2, MeOH ii: PyBOP, DiPEA, Boc-Ala-OH, CH2Cl2 
(59%); b) i; 2 M HCl in EtOAc, 45 min ii: PyBOP, DiPEA, Boc-Pro-OH, CH2Cl2 (62%);c) i;2 M HCl 
in EtOAc, 45 min ii: PyBOP, DiPEA, 32, CH2Cl2 (76%), d) PhMe, 1, 80 °C, 3 h (72%). 
 
Upon application of RCAM on this tetrapeptide using 10% of catalyst 1 in toluene 
at 80 °C, the reaction was finished within one hour. In the same fashion, (R)-
alanine derivative 49 and (R) Proline derivative 51 were constructed (Scheme 10) 
and subjected to initial RCAM conditions, resulting in similar recoveries of the 
cyclized diastereoisomers 50 and 52. Similarly, the pentapeptide 53 was 
transformed into cyclic compound 54, albeit in only 36% yield.  
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Scheme 10. Reagents and conditions: a) i: SOCl2, MeOH ii: PyBOP, DiPEA, Boc-(R)-Ala-OH, 
CH2Cl2 (51%); b) i; 2 M HCl in EtOAc, 45 min ii: PyBOP, DiPEA, Boc-Pro-OH, CH2Cl2 (57%); c) i; 
2 M HCl in EtOAc, 45 min ii: PyBOP, DiPEA, 32, CH2Cl2 (76%), d) PhMe, 1, 80 °C, 3 h (70%); e) 
PhCl, 1, 80 °C, 3 h (57%); f) PhCl, 1, 80 °C, 3 h (36%).  
  
Since both (R)- and (S)-alanine-based tetramers successfully underwent 
cyclization and the amino isobutyric acid derivatives did not, spatial distortion 
can be ruled out as plausible reason for the failure of cyclizing 38-41. 
Presumably, the Aib-Pro sequence gives a too rigid β-turn and thus prevents 
successful RCAM. This is remarkable, since RCM on its olefin counterpart was 
successful.30  
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5.5  Conformational NMR-studies 
 
Upon cyclization of the tetrapeptides, a constrained peptide is formed. This can 
be observed with 1H−NMR, in which apart from the disappearance of the methyl 
groups, all α-protons and amide protons dramatically shift due to mutual 
interactions in the ring system (Figure 3). 
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Figure 2. Chemical shifts. 
 
 
Figure 3. Selected region of the 1H−NMR spectrum before (a) and after (b) ring closure of 
compound 45.  
 
At this stage, compounds 46, 50 and 54 were analyzed by 1H−NMR and 
compared with their cystine-containing counterparts 55 (Figure 2). The precursor 
of the latter cyclic peptide was readily prepared following peptide synthesis 
protocols as outlined for the synthesis of the linear peptides, but employing 
suitably protected Cystiene derivatives instead of (S)-2-amino-4-hexynoic acid 
derivatives ((S)-30). Oxidation of the Cysteine residues was readily accomplished 
under standard conditions (I2, MeOH, DMF, ascorbic acid, citrate buffer) to afford 
the target cyclic peptide 55 in 55% overall yield. 
Relevant 1H−NMR NOE signals observed for the different peptides are depicted 
in Figure 4. Comparison of the NOESY spectra of 54 and 55 revealed several 
similarities. In both cases Hc/Hd interactions were present, indicating a trans-
a 
b 
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amide bond at this side of the molecules. Furthermore, NOEs between Ha/Hb and 
Hb/He suggest a β-turn as the major structural motif for both protected peptides. 
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Figure 4. 1H−NMR-correlations. 
 
Figure 5. ROESY’s of RCAM-products Boc-Mpg31-Pro-Ala-Mpg-OMe 46 (left) and its 
diastereoisomer 50 (right). Markings indicate the additional correlations revealed by ROESY 
overlaying COSY.  
 
The most remarkable difference entails the presence of an NOE between NH-Boc 
and the NH- and α-protons of the glycine residue in 54, all of which are absent in 
cystine analogue 55. Presumably, the rigid acetylene bridge forces these protons 
to be in close proximity. The methyl ester of the shorter tetramers 46 and 50 also 
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correlates to the NH-Boc, which confirms the closer proximity relative to the 
cystine-bridged peptides.  
Attempts to study the involvement of amide protons in H-bonding through either 
temperature-dependent chemical shift studies (spectra were recorded in DMSO-
d6) or solvent titration studies were abortive for both 54 and 55 due to overlap of 
the amide signals and the aromatic protons. 
These structural analyses demonstrate that replacement of a disulfide bridge 
with an acetylene moiety renders the cyclic peptides more rigid, favoring 
additional interstrand proton-proton interactions. 
 
5.6  Alternative β-turn mimics 
 
The presence of β-turns is one of the factors responsible for β-sheet formation. 
New β-turn inducing moieties have emerged in literature during the past few 
years. Examples of these mimics are the aforementioned cyclic dipeptide 24 by 
Katzenellenbogen, but also backbones based on the sugar derivative 56 (Scheme 
11) are known to act as a β-hairpin inducer.32 In a preceding project was shown 
how a sugar-based β-turn motif, functionalized with two 2-amino-hex-4-ynoic acid 
(30) units, can undergo RCAM to form 57. 
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Scheme 11. Reagents and conditions: PhCl, 1, 80 °C (25%).  
 
However, these sugar amino acid moieties are obtained after rather extensive 
synthetic sequences and therefore less convenient for use as a β-turn inducer. In 
contrast, a recent paper by Nowick described the use of commercially available 
ornithine as a β-turn inducer (59) and compared it to the (R)-Pro-Gly moiety 
(58).33 The latter moieties, a well-known β-turn inducer, were incorporated in 
several β-hairpin sequences based on Arg-Trp-Gln-Tyr-Val-Ava-Lys-Phe-Thr-Val-
Gln-NH, replacing Ava at the β-turn position.34 
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Figure 6. Ornithine as β-turn inducer as compared to Gly-(R)-Pro. 
 
The results showed that replacement led to only little deviation for the amide 
protons. This strongly suggests that the ornithine-induced turn (viz. 59) is 
comparable to the (R)-Pro-Gly (viz. 58) turn in promoting β-hairpin formation in 
peptides. Apart from the fact that a shorter peptide synthesis is required, it also 
provides an additional functional group for further functionalization, rendering 
this approach rather attractive.  
HN
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61
62
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FmocHN
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CO2Me
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FmocHN
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CO2HBocHN
(R)-32
NH
O
NHBocMe
a
b c
d
O(R)-30 60
 
Scheme 12. Reagents and conditions: a) NaHCO3, Boc2O, 1,4-dioxane/water (1 : 1), 100 °C (99%); 
b) i: SOCl2, MeOH, reflux; ii:) Fmoc-Orn(Boc)-OH, PyBOP, DiPEA, CH2Cl2; c) i: 2M HCl in EtOAc, 
45 min; ii PyBOP, DiPEA, (R)-32, CH2Cl2 (24%, 4 steps); d) PhMe, 1, 80 °C, 3 h (38%). 
 
Orthogonal protection of both ornithine amine functional groups allows selective 
coupling on the side chain. Initial condensation using Castro’s reagent in 
presence of DiPEA with suitably protected (R)-30 with Fmoc-Orn(Boc)-OH was 
followed by selective acidic (hydrochloric acid in EtOAc) deprotection of the side 
chain protecting Boc-group. After the second condensation using Castro’s reagent 
and DiPEA with Boc-protected (R)-2-amino-hex-4-ynoic acid ((R)-32) tripeptide 
61 was made in an overall yield of 24%. Ring-closing alkyne metathesis using 
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standard conditions (10 mol% catalyst, toluene, 80 °C) gave rise to the cyclized 
product 62 in reasonable yield. This system could provide an interesting handle 
for future peptide systems. It must be noted however that the absence of the 
internal hydrogenbond leads to a more flexible turn.  
 
5.7  Larger oligopeptides 
 
Having established reliable RCAM protocols for the synthesis of tetrameric and 
pentameric cyclic peptides, we wished to extend this methodology for the 
synthesis of more extended acetylene cross-linked β-hairpin structures. Because 
for this purpose solution phase synthesis would become too laborious, we 
switched to solid phase strategies, which can easily provide larger oligopeptide 
structures. We showed previously that RCAM could not be successfully 
performed on the resin, so we chose to do this crucial cyclization reaction after 
cleavage from the resin.  
A solid phase peptide synthesis procedure was designed aimed at providing a 
small library of peptides of variable length, with each member containing 
acetylene residues on both ends. We chose to work with a 2-chlorotrityl-
functionalized resin due to the well-known very mild cleavage conditions, which 
would allow side chain protection. Using Fmoc-protection (S)-30 was efficiently 
protected in 96% to yield the desired building block 63 for solid phase chemistry 
peptide synthesis. 
Cl
Cl
a, b, c, d
alternating b and c
Me
H2N CO2H
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FmocHN CO2H
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AAn = Gly-Glu(OtBu)-Gly-Ala (64)
AAn = Ala-Pro-Ala-Gly (65)
AAn = Gly-Ala-Pro-Ala-Gly-Ala (66)
AAn = Ala-Gly-Ala-Pro-Ala-Gly-Ala-Gly (67)
AAn = Ala-Gly-Ala-Gly-Ala-Pro-Ala-Gly-Ala-Gly-Ala-Gly (68)
n
n
 
Scheme 13. Reagents and conditions: a) CH2Cl2, Fmoc-(S)-2-amino-hex-4-ynoic acid (63); b) DIC, 
HOBt, Fmoc-AA-OH, DMF; c) 0.1 M HOBt, 20% piperidine in DMF; d) 1% TFA in CH2Cl2; e) 
FmocOSu, Et3N, CH3CN, H2O (96%); f) CH2N2 in Et2O or SOCl2 in MeOH. 
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A modest oligopeptides-library was thus synthesized and after cleavage protected 
as the corresponding methyl esters using either diazomethane or mildly acidic 
MeOH.35 Characterization using MALDI-TOF mass spectroscopy and 13C−NMR 
spectroscopy confirmed the successful synthesis of final oligopeptides. The spacer 
between the β-turn and acetylenic amino acids consist of alternating alanine and 
glycine residues. These sequences are often encountered in β-sheet motifs present 
in spider silk and are also chemically inert.36  
Attempts to apply our previously developed RCAM conditions on these substrates 
revealed a major drawback of larger peptides. Virtually all of these larger 
peptides were very poorly soluble in toluene. Several attempts such as preheating 
of the peptide in the solvent, applying a high dilution and using halogenated 
solvents as co-solvent were to no avail, since in any of these cases no RCAM 
products could be observed. This led us to conclude that RCAM is only suitable 
for small oligopeptides (up to five amino acids) and that alternative approaches 
are required for larger peptides.  
 
5.8  Conclusions 
 
In this chapter an overview of ring-closing alkyne metathesis as a tool to 
introduce conformational restriction in peptides has been given. Fairly 
straightforward construction of dipeptide, tripeptide and tetrapeptides equipped 
with unsaturated amino acids and subsequent RCAM under inert conditions gave 
rise to good yields. Using 2D NMR-spectroscopy conformational features of the 
resulting products were measured and the acetylene bridge was confirmed to give 
a more rigid turn than a comparable cystine-based system. Extending RCAM to 
larger oligopeptides gave problems with the nature of peptide-systems. Solubility 
problems with inert solvents and diminished activity due to chelating effects of 
the peptide around the transition metal could not be overcome. This obviously is 
a limiting factor in such applications of RCAM. 
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5.10  Experimental section 
 
For general experimental details, see: Section 2.8.  
 
(NMe2)3W≡W(NMe2)3 (22). Using Schlenk conditions, dimethylamide 
(50.0 mL, 2 M in THF, 100 mmol) was cooled to –40 °C and BuLi (58.1 
mL, 1.6 M in hexane, 93.8 mmol) was added dropwise. After raising the 
temperature to room temperature and stirring for 18 h, the mixture was 
evaporated in vacuo. The resulting white solids were dissolved in THF (60 mL), 
cooled to –60 °C and transferred to a suspension of WCl4 (7.37 g, 23.3 mmol) in 
Et2O (at 0 °C). The reaction was allowed to warm to room temperature and 
stirred for 18 h. After additional refluxing for 2 h, the mixture was evaporated 
and the resulting brown solid was transferred in a glove box to a sublimation 
flask for further purification. Sublimation (110 °C, 0.01 mbar) yielded 3 as a red-
brown solid (3.24 g, 6.1 mmol) in 44% yield. 
 
(tBuO)3W≡W(OtBu)3 (23). Using Schlenk conditions, tungsten 
hexa(dimethylamine) (3.23 g, 6.10 mmol) was dissolved in KBP37 
40 mL) and freshly distilled tBuOH (20 mL) was added. After 
stirring for 16 h, the dark red mixture was evaporated in vacuo. The darkbrown 
solids were dissolved in KBP (40 mL) and concentrated to approximately 20 mL 
so that most of the compound precipitated. Upon heating, all material dissolved 
again and after standing for 18 h at –30 °C a large precipitate was formed. The 
solvent was removed using a canula and the remaining solids were dried using 
high-vacuum, yielding dark red crystals (2.70 g, 3.35 mmol, 66%).  
 
(tBuO)3W≡CtBu (1).38 Using Schlenk conditions, tungsten 
hexa-tert-butanol (2.70 g, 3.35 mmol) was dissolved in KPB 
(100 mL) and freshly distilled and degassed 4,4-dimethyl-2-pentyne was added 
dropwise. The reaction was stirred for 16 h and evaporated in vacuo. Further 
purification using sublimation (45 °C, 0.01 mbar)39 yielded faint yellow crystals 
(1.41 g, 3.06 mmol) in 44% yield. 
 
(S)-2-[(tert-Butoxycarbonyl)amino]-6-octynoic acid 
(26). To a solution of (S)-2-amino-oct-6-ynoic acid (2.00 g, 
12.9 mmol) in dioxane/water (1/1, 150 mL) sodium 
bicarbonate (2.16 mg, 25.1 mmol) and Boc2O (4.28 g, 19.6 mmol) were added. The 
W(NMe2)3
W(NMe2)3
WtBuO
tBuO
tBuO
W
OtBu
OtBu
OtBu
(tBuO)3W
Me
Me
Me
CO2HBocHN
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reaction mixture was heated at reflux temperature for 2 h. The dioxane was 
evaporated and the aqueous layer was acidified with 2 M HCl and extracted 
using EtOAc (3 × 75). The organic layer was washed (brine,150 mL), dried 
(MgSO4) and evaporated. After purification of the crude product using flash 
chromatography (85% EtOAc, 1% AcOH in heptane), Boc-hhMpg-OH 26 (2.19 g, 
8.57 mmol, 75%) was obtained as a clear oil.  1H−NMR (300 MHz, CDCl3) δ 8.28 
(bs, 1H, OH), 5.11 (bd, J = 7.8 Hz, 1H, NH), 4.32−4.24 (m, 1H, CαH), 2.19−2.12 
(m, 2H, C≡CCH2), 2.01−1.87 (m, 2H, CH2), 1.75 (s, 3H, C≡CMe), 1.62−1.51 (m, 
2H, CH2), 1.43 (s, 9H, CMe3); 13C−NMR (75 MHz, CDCl3) δ 176.1, 155.2, 80.1, 
78.0, 76.1, 53.4, 31.6, 28.3, 24.9, 18.5, 3.5; IR ν 2928, 1712, 1511, 1394, 1367, 
1163 cm−1; HMRS (FAB+) calcd for C13H22O4N 256.15488, found 256.1549. 
 
(2R)-2-[(tert-Butoxycarbonyl)amino]-5-hexynoic acid (33) . 
Using the previously described protocol, H2N-hMpg-OH 31 (150 
mg, 1.06 mmol) was converted to Boc-hMpg-OH (212 mg, 0.88 
mmol, 83%), a white solid. [α]D = –10.7 (c = 1.13, CH2Cl2); 
1H−NMR (300 MHz, CDCl3) δ 5.21−5.15 (bs, 1H, NH), 4.44−4.30 
(m, 1H, CαH), 2.32−2.25 (m, 2H, C≡CCH2), 2.14−2.03 (m, 1H, CH2), 1.96−1.86 (m, 
1H, CH2), 1.78 (s, 3H, C≡CMe), 1.47 (s, 9H, CMe3); 13C−NMR (75 MHz, CDCl3) δ 
176.5, 155.3, 81.6, 80.2, 77.0, 52.9, 31.4, 28.3, 15.3, 3.6; IR ν 2975, 1712, 1511, 
1247, 1161 cm−1; HMRS (FAB+) calcd for C12H20O4N 242.13923, found 242.1392. 
 
2-[(tert-Butoxycarbonyl)amino]isobutyric acid (Boc-Aib-OH, 
42).38 To a solution of H2N-Aib-OH (2-aminoisobutyric acid, 3.35 g, 
32.5 mmol) in aqueous 2 M NaOH (16 mL) was added a solution of Et3N (4.5 mL, 
32.5 mmol) and Boc2O (5.52 g, 25.3 mmol) in 1,4-dioxane (35 mL). The resulting 
mixture was stirred for 40 h. The dioxane was removed in vacuo and the aqueous 
solution was acidified to pH = 2 using 2 M HCl. The mixture was extracted using 
EtOAc (3 × 30 mL) and the organic layer were washed (brine), dried (MgSO4) and 
evaporation yielded the desired compound 42 (3.33 g, 16.4 mmol) as a white solid 
in 65%. 1H−NMR (300 MHz, CDCl3) δ 5.05 (bs, 1H, NH), 1.53 (s, 6H, 2 × Me), 1.45 
(s, 9H, Boc); 13C−NMR (100 MHz, CDCl3) δ 179.5, 155.0, 80.0, 56.1, 28.3, 25.4 (2 
×). 
CO2HBocHN
Me
BocHN CO2H
Me Me
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Boc-hhMpg-hhMpg-OMe (28). To a solution of Boc-
hhMpg-OH (616 mg, 2.30 mmol) and Et3N (0.36 mL, 2.56 
mmol) in Et2O at 0 °C was added dropwise isobutyl 
chloroformate (0.3 mL, 2.31 mmol). After warming to 
room temperature and stirring for 30 min the reaction 
mixture was filtered over a glass filter under a nitrogen 
stream. DiPEA (1.18 mL, 6.91 mmol) and (S)-2-amino-oct-6-ynoic acid methyl 
ester (475 mg, 2.31 mmol) were added and the reaction mixture was allowed to 
stir overnight. The mixture was evaporated in vacuo and purified using flash 
chromatography (40% EtOAc in heptane), yielding 28 as a white solid (814 mg, 
2.00 mmol, 87%). [α]D = +14.2 (Hg385, c = 1.0, CH2Cl2); 1H−NMR (400 MHz, 
CDCl3) δ 6.61 (d, J = 7.4 Hz, 1H, NH), 5.06 (d, J = 8.0 Hz, 1H, NHBoc), 4.83−4.78 
(m, 1H, CHNHBoc), 4.09−3.96 (m, 1H, CHCO2Me), 3.72 (s, 3H, OMe) 2.34−2.20 
(m, 4H, 2 × C≡CCH2), 1.95−1.82 (m, 2H, CH2), 1.77−1.62 (m, 8H, 2 × C≡CMe, 
CH2),), 1.58-1.45 (m, 4H, 2 × CH2), 1.42 (s, 9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 
172.4, 171.7, 155.6, 80.0, 78.3, 78.0, 77.4, 76.2, 54.1, 52.3, 71.8, 31.8, 31.5, 28.2, 
24.8, 24.7, 18.4, 18.3, 3.4 (2 ×); 15N−NMR (40.5 MHz, CDCl3) δ 123.7 (NHBoc), 
115.4 (NH); IR ν 2922, 2865, 2240, 1746, 1660, 1531, 1367, 1170 cm−1; HRMS 
(EI): calculated for C22H34N2O5 406.2468, found 406.2448. 
 
11-tert-Butoxycarbonylamino-12-oxo-azacyclododec-6-yne-2-carboxylic 
acid methyl ester (24). To a stirred solution of Boc-hhMpg-
hhMpg-OMe (33 mg, 81 µmol) and (tBuO)3W≡CtBu (5.5 mg, 6.9 
µmol) was added toluene (5 mL) and the reaction was heated to 
80 °C for 1.5 h. After cooling down and removal of the volatiles, 
purification using flash chromatography resulted in 24 as an off-white solid (22 
mg, 62 µmol, 77%). [α]D = –14.6 (c = 1.0, CH2Cl2); 1H−NMR (400 MHz, CDCl3) δ 
7.14 (d, J = 8.7 Hz, 1H, NH), 6.08 (d, J = 8.3 Hz, 1H, NHBoc), 4.78 (q, J = 6.8 Hz, 
1H, CαH) 4.27 (q, J = 7.9 Hz, 1H, CαH), 3.73 (s, 3H, OMe), 2.17−2.15 (m, 4H, 2 × 
C≡CCH2), 2.07−1.96 (m, 2H, CH2), 1.79−1.52 (m, 4H, 2 × CαCH2), 1.45 (s, 9H, 
Boc), 0.89−0.83 (m, 2H, CH2); 13C−NMR (100 MHz, CDCl3) δ 173.2, 171.8, 155.8, 
80.4, 80.2, 79.3, 53.8, 52.5, 51.2, 32.8 (2 ×), 28.1, 24.6, 24.2, 18.3 (2 ×); IR ν 3313, 
2931, 2865, 2249, 1744, 1667, 1520, 1366, 1170 cm−1; HRMS (EI): calculated for 
C18H28N2O5 352.1998, found 352.1984. 
 
BocHN
Me
H
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Representative procedure for the synthesis of the tetramers. 
Boc-Mpg-Pro-Ala-Mpg-OMe (45). To a 
stirred suspension of (S)-2-amino-hex-4-ynoic 
acid (30, 300 mg, 2.36 mmol) in MeOH (15 
mL) was slowly added SOCl2 (500 µL, 6.72 
mmol) and the resulting clear solution was 
refluxed for 2 h. After cooling to ambient temperature, the solvents were removed 
in vacuo. The crude methyl ester was resuspended in CH2Cl2 (15 mL) and DiPEA 
(1.0 mL, 5.9 mmol), PyBOP (1.43 g, 2.75 mmol) and Boc-Ala-OH (531 mg, 2.80 
mmol) were added. After stirring for 16 h, the product was evaporated and 
purified using flash chromatography (50% EtOAc in heptane) yielding 43 as a 
fluffy white solid (432 mg, 1.36 mmol, 59%). 1H−NMR (300 MHz, CDCl3) δ 6.84 
(bd, J = 7.9 Hz, 1h, CONH), 5.16 (bd, J = 7.3 Hz, 1H, NHBoc), 4.69−4.59 (m, 1H, 
CαH), 4.30−4.13 (m, 1H, CαH), 3.74 (s, 3H, OMe), 2.76−2.60 (m, 2H, C≡CCH2), 
1.72 (t, J = 2.5 Hz, 3H, C≡CMe), 1.42 (s, 9H, Boc), 1.35 (d, J = 7.3 Hz, Me). The 
solid was dissolved in 2 M HCl EtOAc (20 mL) and stirred for 30 min. After 
complete conversion (based on TLC), the solvents were stripped in vacuo and the 
HCl-salt was redissolved in CH2Cl2 (30 mL) and DiPEA (611 µL, 3.60 mmol), 
PyBOP (720 mg, 1.38 mmol) and Boc-Pro-OH (300 mg, 1.39 mmol) were added. 
The resulting solution was stirred overnight at ambient temperature. After 
evaporation and further purification, the desired tripeptide 44 was obtained (352 
mg, 0.86 mmol, 62%) as a colorless oil. 1H−NMR (400 MHz, CDCl3) δ 7.04 (bs, 1H, 
NH), 6.85 (bs, 1H, NH), 4.60−4.50 (m, 1H, CαH), 4.50−4.32 (m, 1H, CαH), 
4.29−4.10 (m, 1H, CαH), 3.70 (s, 3H, OMe), 3.47−3.23 (m, 2H, CH2N), 2.68−2.53 
(m, C≡CCH2), 2.23−1.75 (m, 4H, 2 × CH2), 1.68 (t, J = 2.4 Hz, 3H, C≡CMe), 1.39 
(s, 9H, Boc), 1.33 (d, J = 6.9 Hz, 3H, MeCαH). The previously made tripeptide 44 
(500 mg, 1.22 mmol) was dissolved in 2 M HCl EtOAc (20 mL) and stirred for 30 
min. After complete conversion (based on TLC) the solvents were stripped in 
vacuo and the HCl-salt was redissolved in CH2Cl2 (30 mL). DiPEA (550 µL, 3.24 
mmol) and 32 (309 mg, 1.35 mmol) were added and after 5 min, followed by 
PyBOP (700 mg, 1.35 mmol). After stirring overnight at room temperature, the 
volatiles were removed and the mixture was further purified using flash 
chromatography (100% EtOAc) yielding the desired tetramer 45 (550 mg, 1.02 
mmol, 76%) as white solid. 1H−NMR (400 MHz, CDCl3) δ 7.13 (bd, J = 7.3 Hz, 1H, 
NH-Mpg-OMe), 7.08 (bd, J = 7.5 Hz, 1H, NH-Ala), 5.35 (bd, J = 8.0 Hz, 1H, 
NHBoc), 4.62−4.54 (m, 3H, 3 × CαH), 4.47−4.40 (m, 1H, CαH-Ala), 3.81−3.78 (m, 
1H, CH2N), 3.72 (s, 3H, OMe), 3.72−3.66 (m, 1H, CH2N), 2.67−2.63 (m, 2H, 
Me
O
N
N
HO
Me
HN
O
Me
BocHN CO2Me
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C≡CCH2), 2.57−2.55 (m, 2H, C≡CCH2), 2.25 (m, 1H, CH2), 2.06−1.97 (m, 3H, 
CH2), 1.72 (t, J = 2.4 Hz, 6H, 2 × C≡CMe), 1.37 (s, 9H, Boc), 1.33 (d, J = 5.8 Hz, 
3H, Me); 13C−NMR (75 MHz, CDCl3) δ 173.3, 173.1, 172.4, 172.0, 156.4, 81.5, 
80.4, 80.2, 75.3, 74.8, 74.5, 61.7, 53.9, 52.7, 52.3, 50.4, 49.4, 29.6, 29.2, 26.5, 25.0, 
23.7, 18.8, 4.94, 4.88. IR ν 3293, 2926, 2362, 2341, 1742, 1642, 1520, 1450, 1369, 
1245, 1168, 1048, 847 cm−1; HRMS (FAB) m/z calcd for C26H48N4O7: 519.2819, 
found 519.2824 (M + H)+. 
 
General procedure for ring-closing alkyne metathesis of the tetramers. 
Methyl (3S, 8S, 11S, 14S)-3-[(tert-butoxycarbonyl)amino]-11-methyl-
2,10,13-trioxo-1.9.12-triazabicyclo[12.3.0]heptadec-5-yne-8-carboxylate 
(46). The reaction was performed under an Ar 
atmosphere in flame-dried glassware. To a solution of 
(tBuO)3W≡CtBu (1, 10 mg, 0.02 mmol) in dry C6H5Cl 
(5.5 mL) was added a solution of 45 (200 mg, 0.39 
mmol) in dry C6H5Cl (30 mL) and the reaction mixture was stirred at 80 °C for 3 
h. The solvent was concentrated and the crude mixture was purified by column 
chromatography (EtOAc) to give 46 as a crystaline solid (112 mg, 0.23 mmol) in 
62% yield. 1H−NMR (400 MHz, CDCl3) δ 7.63 (bd, 1H, NH-Mpg), 6.58 (bd, 1H, 
NH-Ala), 5.80 (bd, 1H, NHBoc), 4.81 (m, 1H, CαHCO2Me), 4.60 (m, 1H, 
CαHNHBoc), 4.31 (m, 1H, CαH-Pro), 4.17 (m, 1H, CαH-Ala), 3.82 (s, 3H, OMe), 
3.75−3.62 (m, 1H, NCH2), 3.61−3.56 (m, 1H, NCH2), 2.71−2.62 (m, 4H, 2 × 
C≡CCH2), 2.24−1.90 (m, 4H, 2 × CH2), 1.53 (d, 3H, J = 7.1 Hz, Me-Ala), 1.44 (s, 
9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 170.5, 170.3, 170.1, 169.6, 154.3, 79.6, 
78.2, 76.8, 61.7, 52.4, 50.9, 50.6, 50.2, 47.3, 29.5, 28.4, 28.1, 25.5, 22.6, 22.5; IR ν 
3311, 2926, 1745, 1643, 1504, 1444, 13678, 1163, 1061, 1030, 911, 734 cm−1; 
HRMS (FAB) m/z calcd for C22H32N4O7Na: 487.21687, found 487.21656 (M + 
Na)+. 
 
Boc-Mpg-Pro-Aib-Mpg-OMe (38). 
Following the example for tetramer 
synthesis, (S)-2-amino-hex-4-ynoic acid 
methyl ester (100 mg, 0.56 mmol) was 
coupled with Boc-Aib-OH (191 mg, 0.94 
mmol) yielding yellowish oil 34 (155 mg, 0.49 mmol, 88%). 1H−NMR (400 MHz, 
CHCl3) δ 7.13−7.04 (m, 1H, NH), 5.04 (s, 1H, NHBoc), 4.65−4.58 (m, 1H, CαH), 
3.71 (s, 3H, OMe), 2.72−2.56 (m, 2H, C≡CCH2), 1.70 (t, J = 2.4 Hz, 3H, C≡CMe), 
HN
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1.46 (s, 3H, Me-Aib), 1.45 (s, 3H, Me-Aib), 1.40 (s, 9H, Boc);13C−NMR (75 MHz, 
CDCl3) δ 174.3, 171.1, 154.4, 80.1, 78.9, 72.9, 56.6, 52.4, 51.0, 18.1, 25.3, 25.0, 
22.5, 3.4; IR ν 3311.2, 2977.6, 2935.1, 1783.8, 1714.4, 1666.2, 1506.1, 1160.9 cm−1; 
MS (EI) m/z: 326, 253, 158, 102, 88, 82, 58. The deprotected dipeptide (75 mg, 
0.33 mmol) was reacted with Boc-Pro in similar fashion, yielding 36 as a white 
solid (81 mg, 0.19 mmol, 58%). 1H−NMR (300 MHz, CDCl3) δ 7.40−7.27 (m, 1H, 
NH), 6.80 (bs, 1H, NH), 4.54−4.48 (m, 1H, CαH-Mpg), 4.15−4.06 (m, 1H, CαH-
Pro), 3.66 (s, 3H, OMe), 3.48−3.35 (m, 2H, CH2N), 2.72−2.56 (m, 2H, C≡CCH2), 
2.20−2.00 (m, 3H, CH2), 2.00−1.89 (m, 1H, CH2), 1.70 (t, J = 2.4 Hz, 3H, C≡CMe), 
1.47 (s, 3H, Me-Aib), 1.44 (s, 3H, Me-Aib), 1.40 (s, 9H, Boc). After deprotection of 
the tripeptide (147 mg, 0.34 mmol), 32 (106 mg, 0.47 mmol) was coupled which 
resulted in 38 as a white solid (134 mg, 0.25 mmol, 74%). 1H−NMR (400 MHz, 
CHCl3) δ 7.31−7.26 (m, 1H, NH), 7.16 (bd, J = 7.8 Hz, 1H, NH), 5.66 (bd, J = 7.3 
Hz, NH), 4.62 (m, 1H, CαH), 4.48 (m, 1H, CαH), 4.41 (m, 1H, CαH), 3.75 (s, 3H, 
OMe), 3.80−3.70 (m, 2H, CH2N), 2.66 (m, 2H, C≡CCH2), 2.54 (m, 2H, C≡CCH2), 
2.20−2.00 (m, 3H, CH2), 2.00−1.89 (m, 1H, CH2), 1.76 (s, 3H, C≡CMe), 1.76 (s, 3H, 
C≡CMe), 1.53 (s, 3H, Me-Aib), 1.49 (s, 3H, Me-Aib), 1.46 (s, 9H, Boc); 13C−NMR 
(75 MHz, CDCl3) δ 174.1, 174.0, 173.2, 171.5, 155.0, 80.0, 79.0, 78.6, 73.7, 73.4, 
60.7, 57.2, 52.4, 51.4, 50.8, 47.9, 40.0, 28.2, 27.6, 25.6, 25.7, 25.0, 24.7, 23.4, 22.2, 
3.1, 3.0; IR ν 3313.7, 2978.8, 1742.5, 1639.8, 1520.0, 1441.4, 1366.7, 1247.5, 
1167.7, 1051.4, 915.1, 846.1, 733.1 cm−1; HRMS (SIMS) m/z calcd for C27H40N4O7  
555.2795, found 555.2824 (M + Na)+. 
 
Boc-hMpg-Pro-Aib-hMpg-OMe (39). 
Following the general example of tetramer 
synthesis, H2N-hMpg-OMe (200 mg, 1.04 
mmol) was coupled with Boc-Aib-OH (250 mg, 
1.23 mmol) resulting in 35 as a clean oil. The 
crude product was deprotected, condensed 
with Boc-Pro-OH (181 mg, 0.84 mmol) and isolated yielding 37 as a white solid 
(188 mg, 0.45 mmol, 43%, 3 steps). Deprotection and subsequent condensation 
with Boc-hMpg-OH (125 mg, 0.51 mmol) resulted in tetrapeptide 39 as a white 
solid (137 mg, 0.24 mmol, 54%). 1H−NMR (300 MHz, CDCl3) δ 7.21 (bd, J = 6.3 
Hz, 1H, NH-hMpg), 6.79 (bs, 1H, NH-Aib), 5.38 (bd, J = 6.5 Hz, 1H, NHBoc), 
4.68−4.49 (m, 2H, 2 × CαH), 4.41−4.29 (m, 1H, CαH), 3.70 (s, 3H, OMe), 
3.78−3.69 (m, 2H, CH2N), 2.27−1.83 (m, 12H, 6 × CH2), 1.74 (t, J = 2.3 Hz, 6H, 2 
× C≡CMe), 1.54 (s, 3H, Me-Aib), 1.44 (s, 3H, Me-Aib), 1.42 (s, 9H, Boc); 13C−NMR 
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(75 MHz, CDCl3) δ 174.1, 172.6, 172.0, 171.0, 155.5, 80.3, 79.7, 77.8, 76.5, 76.4, 
60.3, 57.2, 52.2, 51.8, 51.2, 47.4, 31.8, 30.9, 28.1, 26.4, 25.1, 20.9, 15.22, 15.15, 
14.0, 3.3, 3.2; IR ν 3313.2, 2975.7, 1683.1, 1636.5, 1520.0, 1445.0, 1169.7, 1049.9, 
846.0 cm−1; MS (FAB): m/z (%): 583 (12), 561 (5), 461 (14), 265 (8), 154 (21), 149 
(9), 140 (9), 137(12), 136 (16), 98 (21), 77 (11), 70 (100), 58 (25), 57 (56). 
 
Boc-Mpg-(R)-Pro-Aib-Mpg-OMe (40). 
Using the standard peptide conditions 
previously described Boc-Aib-Mpg-OMe (34, 
155 mg, 0.48 mmol) was deprotected and 
condensed with Boc-(R)-Pro-OH (127 mg, 
0.59 mmol) resulting in the desired tripeptide (152 mg, 0.36 mmol, 76%). 
1H−NMR (300 MHz, CDCl3) δ 7.40−7.27 (m, 1H, NH), 6.80 (bs, 1H, NH), 
4.54−4.48 (m, 1H, CαH-Mpg), 4.15−4.06 (m, 1H, CαH-Pro), 3.66 (s, 3H, OMe), 
3.48−3.35 (m, 2H, CH2N), 2.72−2.56 (m, 2H, C≡CCH2), 2.20−2.00 (m, 3H, CH2), 
2.00−1.89 (m, 1H, CH2), 1.70 (t, J = 2.4 Hz, 3H, C≡CMe), 1.47 (s, 3H, Me-Aib), 
1.44 (s, 3H, Me-Aib), 1.40 (s, 9H, Boc); 13C−NMR (75.5 MHz, CDCl3) δ 174.2, 
171.9, 171.2, 155.4, 80.4, 78.4, 73.0, 60.7, 60.4, 56.6, 52.4, 46.9, 28.0, 25.2, 24.5, 
24.3, 21.8, 15.0, 3.2. The tripeptide (152 mg, 0.36 mmol) was deprotected and 
coupled to 32 (106 mg, 0.47 mmol) resulting in 40 as a white solid (134 mg, 0.25 
mmol, 71%). 1H−NMR (400 MHz, CDCl3) δ 7.14 (bd, J = 8.0 Hz, 1H, NH-Mpg-
OMe), 6.99 (s, 1H, NH-Aib), 5.65 (d, J = 7.6 Hz, 1H, NHBoc), 4.57 (q, J = 8.0 Hz, 
1H, CαH), 4.56 (q, J = 7.3 Hz, 1H, CαH), 4.36−4.33 (m, 1H, CαH), 3.70 (s, 3H, 
OMe), 3.80−3.71 (m, 2H, CH2N), 2.63−2.61 (m, 2H, C≡CCH2), 2.52−2.49 (m, 2H, 
C≡CCH2), 2.17−1.84 (m, 4H, 2 × CH2), 1.72 (s, 6H, 2 × C≡CMe), 1.48 (s, 3H, Me-
Aib), 1.45 (s, 3H, Me-Aib), 1.39 (s, 9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 174.2, 
171.7, 171.0, 170.7, 155.4, 80.0, 78.6, 78.2, 73.7, 73.3, 60.9, 57.0, 52.5, 51.6, 51.3, 
47.6, 28.4, 26.1 (2 ×), 25.9, 24.2, 22.2, 15.1, 14.1, 3,4, 3.3; IR ν 3314, 2980, 1743, 
1638, 1520, 1367, 1248, 1168 cm−1; HRMS (FAB) m/z calcd for C27H40N4O7 
555.2795, found 555.2939 (M + Na)+. 
 
Boc-hMpg-(R)-Pro-Aib-hMpg-OMe (41). 
Using standard peptide conditions previously 
described H2N-hMpg-OH (100 mg, 0.71 mmol) 
was coupled with Boc-Aib-OH (171 mg, 0.84 
mmol) resulting in a white solid (150 mg, 0.46 
mmol, 65%). 1H−NMR (300 MHz, CDCl3) δ 
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7.05 (bd, J = 6.6 Hz, 1H, NH), 4.97 (bs, 1H, NHBoc), 4.64−4.53 (m, 1H, CαH), 3.69 
(s, 3H, OMe), 2.20−2.10 (m, 2H, C≡CCH2), 2.07−1.78 (m, 2H, CH2Cα), 1.72 (t, J = 
2.4 Hz, 3H, C≡CMe), 1.46 (s, 3H, Me-Aib), 1.44 (s, 3H, Me-Aib), 1.40 (s, 9H, Boc); 
13C−NMR (75 MHz, CDCl3) δ 174.3, 172.3, 154.4, 80.1, 77.4, 76.4, 56.5, 52.1, 51.6, 
31.2, 28.1, 25.7, 25.0, 14.7, 3.4; IR ν 3317, 2978, 2924, 2468, 1749, 1682, 1655, 
1522, 1165 cm−1. The dipeptide (150 mg, 0.46 mmol) was then deprotected and 
condensed with Boc-(R)-Pro (118 mg, 0.55 mmol) yielding a white solid (147 mg, 
0.34 mmol, 70%). 1H−NMR (300 MHz, CDCl3) δ 7.43−7.30 (m, 1H, NH-hMpg), 
6.80 (bs, 1H, NH-Aib), 4.56−4.46 (m, 1H, CαH-hMpg), 4.13−4.08 (m, 1H, CαH-
Pro), 3.70 (s, 3H, OMe), 3.50−3.27 (m, 2H, CH2N), 2.20−1.80 (m, 8H, 4 × CH2), 
1.70 (t, J = 2.4 Hz, 3H, C≡CMe), 1.49 (s, 3H, Me-Aib), 1.43 (s, 3H, Me-Aib), 1.42 
(s, 9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 174.4, 172.6, 171.9, 155.4, 80.5, 77.2, 
76.2, 60.9, 56.9, 52.2, 51.9, 47.2, 30.7, 29.2, 28.1, 25.6, 24.9, 24.6, 15.2, 3.4. The 
tripeptide (147 mg, 0.34 mmol) was deprotected and coupled with Boc-hMpg-OH 
(104 mg, 0.43 mmol) yielding the desired tetrapeptide 41 (150 mg, 0.27 mmol, 
79%). 1H−NMR (300 MHz, CDCl3) δ 7.18 (bd, J = 7.6 Hz, 1H, NH-hMpg), 6.80 (bs, 
1H, NH-Aib), 5.46 (bd, J = 6.5 Hz, 1H, NHBoc), 4.63−4.46 (m , 2H, 2 × CαH), 
4.35−4.14 (m, 1H, CαH), 3.71 (s, 3H, OMe), 3.78−3.69 (m, 2H, CH2N), 2.27−1.83 
(m, 12H, 6 × CH2), 1.74 (t, J = 2.3 Hz, 6 H, × C≡CMe), 1.54 (s, 3H, Me-Aib), 1.44 
(s, 3H, Me-Aib), 1.43 (s, 9H, Boc); 13C−NMR (75 MHz, CDCl3) δ 174.6, 172.9, 
171.6, 171.1, 155.6, 79.9, 77.6, 77.4, 76.7, 76.2, 60.9, 57.0, 52.3, 51.4, 47.1, 31.4, 
31.2, 28.4, 28.3, 25.8, 24.8, 24.6, 15.2, 3.3 (2 ×); IR ν 3297.7, 2975.4, 1637.7, 
1524.0, 1444.3, 1366.0, 1246.4, 1168.3, 1047.1 cm−1; HRMS (FAB) m/z calcd for 
C29H45N4O7  561.3288, found 561.3376 (M + H)+. 
 
Methyl (3S, 8S, 11S, 14S)-3-[(tert-butoxycarbonyl)amino]- 11-[4-([(2-
bromobenzyl)oxy]carbonyloxy)benzyl]-[(2,10,13-trioxo-1,9,12-triaza-5,6-
dithiabicyclo[12.3.0]heptadecane-8-ylcarbonyl)amino]acetate (55). 
A solution of the suitably protected 
pentapeptide (73 mg, 0.072 mmol) in DMF 
(7.2 mL) was poured, in one portion, into a 
well-stirred solution of iodine (220 mg, 
0.86 mmol) in MeOH (65 mL). After 5 
min, a solution of ascorbic acid (166 mg, 
0.94 mmol) in citrate buffer  (pH = 5, 14.4 mL) was added, producing within 
about 15 s a colorless and slightly turbid solution. The solution was concentrated 
to ≈ 10 mL and then extracted with CH2Cl2, dried (MgSO4), and evaporated. The 
S S
HN
BocHN
N
O
N
H O
O
O(-2-Br-Cbz)
HN
O
CO2Me
Chapter 5 
 120
crude was purified by column chromatography (66% to 100% EtOAc in petroleum 
ether)  to give 55 (50 mg, 80%). [α]D = +42.3  (c = 0.14, CH2Cl2); 1H−NMR δ 7.62 
(d, J = 7.9 Hz, 1H,  Ar), 7.53 (d, J = 7.3 Hz, 1H, Ar), 7.53 (t, J = 7.4 Hz, 1H, Ar) 
7.26 (t, J = 7.0 Hz, 1H, Ar), 7.15 (m, 6H, Ar, NH-Gly, NH-Cys), 6.11 (d, J = 9.5 
Hz, 1H, NH-Tyr), 5.45 (d, J = 7.8 Hz, 1H, NH-Cys), 5.36 (q, J = 12.8 Hz, J = 17.4 
Hz, 2H, CH2Ph), 5.02  (bs, 1H, CαH-Tyr), 4.75 (t, J = 8.9 Hz, 1H, CαH-Cys), 4.59 
(m, 1H, CαH-Cys),  4.42 (m, 1H, CαH-Pro), 4.04 (dd, J = 5.6 Hz, J = 18.1 Hz, 1H, 
CαH-Gly), 3.98 (dd, J = 5.4 Hz, J = 18.2 Hz, 1H, CαH-Gly), 3.76 (s, 3H, OMe), 
3.71 (m, 1H, CH2N), 3.50 (dd, J = 5.5 Hz, J = 14.0 Hz, 1H, αH-Tyr), 3.44 (m, 1H, 
CH2N), 3.30 (q, J = 11.5 Hz, J = 15.7 Hz, 1H, CH2S), 3.14 (m, 2H, 2 × CH2S),  3.06 
(m, 2H, αH Tyr, CH2S), 2.28 (m, 1H, CH2), 2.05 (m, 1H, CH2), 1.93 (m, 2H, CH2), 
1.42 (s, 9H, Boc); 13C−NMR δ 170.8, 170.2, 169.7, 150.36, 134.0, 132.8, 130.1, 
129.9, 127.5, 120.9 (Ar), 80.7, 69.5, 62.1, 57.5, 52.2, 52.0, 51.3, 47.5, 41.1, 40.1, 
35.3, 33.8, 29.3, 28.1, 24.9; HRMS m/z calcd for C36H45BrN5O11S2 866.1740, 
found 866.1692 (M + H)+. 
 
Methyl (3S, 8S, 11S, 14S)-3-[(tert-butoxycarbonyl)amino]- 11-[4-([(2-
bromobenzyl)oxy]carbonyloxy)benzyl]-[(2,10,13-trioxo-1,9,12-triaza-
bicyclo[12.3.0]heptadec-5-yn-8-ylcarbonyl)amino]acetate (54).  
Using the general procedure for ring 
closing alkyne metathesis peptide 53 (200 
mg, 0.23 mmol) was reacted upon which 
54 was obtained (68 mg, 0.08 mmol, 36%). 
[α]D = –2.6 (c = 0.3, CH2Cl2); 1H−NMR δ 
8.15 (bs, 1H, NH-Gly), 7.89 (d, J = 7.9 Hz, 
1H, NH-Mpg), 7.61−7.06 (m, 8H, Ar), 6.54 (d, J = 7.0 Hz, 1H, NH-Tyr), 5.98 (d, J 
= 8.3 Hz, 1H, NH Boc), 5.35 (s, 2H, CH2Ph), 4.63 (bs, 1H, CαH-Mpg), 4.55 (bs, 1H, 
CαH-Mpg), 4.29 (bs, 1H, CαH-Tyr), 4.16 (t, J = 7.5 Hz, 1H, CαH-Pro), 4.10 (m, 
1H, CαH-Gly), 3.91 (m, 1H, CαH Gly), 3.74 (s, 3H, OMe), 3.72−3.53 (m, 3H, 2 × 
CH2N, CH2Ar), 3.32 (m, 1H, CH2Ar), 2.73−2.59 (m, 4H, 2 × C≡CCH2), 2.05 (m, 
2H, CH2), 1.95 (m, 1H, CH2), 1.84 (m, 1H, CH2), 1.40 (s, 9H, Boc); 13C−NMR δ 
172.3, 171.6, 170.9, 170.7, 170.4, 155.4, 155.3, 135.2, 132.8, 129.9, 127.5, 123.3, 
121.5, 121.0, 80.0, 78.8, 77.2, 69.5, 62.0, 56.8, 52.1, 51.7, 50.5, 47.1, 41.1, 34.6, 
28.6, 28.1, 25.5, 22.8, 21.7; HRMS m/z: calcd for C38H45BrN5O11: 826.2298, found 
826.2257 (M + H)+. 
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Boc-Mpg-Pro-(R)-Ala-Mpg-OMe (49). 
Using the general example of 
tetramersynthesis (S)-2-amino-hex-4-ynoic 
acid (30, 350 mg, 2.75 mmol) was condensed 
with Boc-(R)-Ala-OH (625 mg, 3.30 mmol) 
yielding 47 as a clean oil (438 mg, 1.44 mmol, 51%). 1H−NMR (300 MHz, CDCl3) 
δ 6.88 (bd, J = 8.0 Hz, 1H, NH), 5.09−4.98 (m, 1H, NHBoc), 4.71−4.62 (m, 1H, 
CαH-Mpg), 4.32−4.16 (m, 1H, CαH-Ala), 3.76 (s, 3H, OMe), 2.74−2.65 (m, 2H, 
C≡CCH2), 1.75 (t, J = 2.5 Hz, 3H, C≡CMe), 1.76 (s, 9H, Boc), 1.37 (d, J = 7.1 Hz, 
3H, Me-Ala); 13C−NMR (75 MHz, CDCl3) δ 171.5, 154.9, 79.9, 79.1, 74.1, 72.7, 
60.3, 52.4, 51.1, 28.1, 24.7, 23.4, 3.3. After deprotection and subsequent 
condensation with Boc-Pro-OH (362 mg, 1.68 mmol), 48 was recovered as a white 
solid (416 mg, 1.01 mmol, 72%). 1H−NMR (300 MHz, CDCl3) δ 7.09−6.48 (m, 2H, 
2 × NH), 4.66−4.50 (m, 2H, 2 × CαH), 4.30−4.20 (m, 1H, CαH), 3.74 (s, 3H, OMe), 
3.53−3.31 (m, 2H, CH2N), 2.71−2.63 (m, 2H, C≡CCH2), 2.24−1.80 (m, 4H, 2 × 
CH2), 1.74 (t, J = 2.4 Hz, 3H, C≡CMe), 1.44 (s, 9H, Boc), 1.38 (d, J = 6.9 Hz, 3H, 
Me-Ala). After deprotection the tripeptide (104 mg, 0.30 mmol) was condensed 
with 32 (75.2 mg, 0.33 mmol) providing 49 as a white foamy solid (88 mg, 0.17 
mmol, 57%). 1H−NMR (400 MHz, CDCl3) δ 7.15 (bd, J = 7.6 Hz, 1H, NH-Mpg), 
6.96 (bd, J = 7.6 Hz, 1H, NH-Ala), 5.35 (bd, J = 8.4 Hz, NHBoc), 4.59−4.50 (m, 
4H, 4 x αH), 3.89 (m, 1H, CH2N), 3.73 (s, 3H, OMe), 3.71 (m, 1H, CH2N), 
2.64−2.48 (m, 4H, C≡CCH2), 2.30−1.99 (m, 4H, 2 × CH2), 1.75 (s, 3H, C≡CMe), 
1.74 (s, 3H, C≡CMe), 1.41 (s, 9H, Boc), 1.35 (d, J = 7.2 Hz, 3H, Me); 13C−NMR (75 
MHz, CDCl3) δ 171.1, 170.8, 170.4, 168.9, 154.5, 79.7, 79.2, 79.0, 73.8, 72.5, 60.3, 
52.2, 51.0, 50.7, 48.2, 47.8, 28.124.7, 24.6, 23.5, 22.1, 17.9, 16.2, 3.4, 3.3; IR ν 
3317.2, 2976.3, 1744.8, 1641.8, 1525.9, 1443.6, 1367.2, 1248.8, 1166.9, 782.3 cm−1; 
HRMS (FAB) m/z calcd for C26H48N4O7 (M + H)+ 519.2819, found 519.2824. 
 
Methyl (3S, 8S, 11S, 14R)-3-[(tert-butoxycarbonyl)amino]-11-methyl-
2,10,13-trioxo-1.9.12-triazabicyclo[12.3.0]heptadec-5-yne-8-carboxylate 
(50). Following the general example for cyclization, 
Boc-Mpg-Pro-(R)-Ala-Mpg-OMe (49, 81 mg, 0.16 
mmol) was reacted, resulting in a recovery of 50 as a 
crystalline solid (51 mg, 0.11 mmol, 71%). 1H−NMR 
(400 MHz, CDCl3) δ 7.92 (bd, J = 8.2 Hz, 1H, NH), 
6.59 (bd, J = 8.3 Hz, 1H, NH), 5.89 (bd, J = 8.3 Hz, 1H, NHBoc), 4.87 (m, 1H, 
CαH), 4.62 (m, 1H, CαH), 4.45 (t, J = 7.6 Hz, 1H, CαH), 4.33 (t, J = 7.1 Hz, 1H, 
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CαH), ,3.83 (s, 3H, OMe), 3.65 (m, 1H, CH2N), 3.55 (m, 1H, CH2N), 2.72−2.56 (m, 
4H, C≡CCH2), 2.33, 2.05 (m, 4H),1.47 (d, J = 7.6 Hz, 3H), 1.44 (s, 9H, Boc); 
13C−NMR (75.5 MHz) δ 171.2, 170.5 (2 ×), 169.8, 154.5, 79.7, 78.3, 77.2, 61.3, 
52.6, 50.7 (2 ×), 50.3, 47.5, 28.4, 27.8, 26.0, 23.4, 23.0, 18.1; IR ν 3311.9, 2974.5, 
1744.0, 1639.3, 1510.6, 1445.4, 1165.9 cm−1.  
 
Boc-Mpg-(R)-Pro-Ala-Mpg-OMe (51). 
Following the general example for 
tetrapeptidesynthesis, Boc-Ala-Mpg-OMe 
(43, 89 mg, 0.28 mmol) was deprotected and 
condensed with Boc-(R)-Pro-OH (68 mg, 0.30 
mmol). Upon isolation the tripeptide (80 mg, 0.20 mmol, 69%) was obtained. After 
deprotection the tripeptide was coupled with 32 (50 mg, 0.22 mmol) resulting in 
the desired tetrapeptide 51 (95 mg, 0.18 mmol, 92%). 1H−NMR (400 MHz, CDCl3) 
δ 7.20 (bd, J = 7.3 Hz, 1H, NH), 7.12 (bd, J = 6.8 Hz, 1H, NH), 5.68 (bd, J = 6.8 
Hz, 1H, NH), 4.66−4.59 (m, 1H, CαH), 4.51−4.35 (m, 3H, 3 × CαH), 3.75 (s, 3H, 
OMe), 3.76−3.70 (m, 2H, CH2N), 2.71−2.63 (m, 2H, C≡CCH2), 2.55−2.48 (m, 2H, 
C≡CCH2), 2.22−2.06 (m, 3H, 2 × CH2), 2.01−1.93 (m, 1H, CH2), 1.76 (s, 3H, 
C≡CMe), 1.75 (s, 3H, C≡CMe), 1.43 (s, 9H, Boc), 1.45−1.41 (m, 3H, Me); 13C−NMR 
(75 MHz, CDCl3) δ 171.9, 171.3, 170.9, 169.9, 155.0, 78.8, 78.8, 78.0, 73.7, 73.0, 
65.6, 65.5, 52.5, 51.2, 49.4, 47.5, 28.3, 25.0, 22.5, 22.4, 17.4, 15.3, 3.5 (2 ×); IR ν 
3293.6, 2926.0, 1741.9, 1641.9, 1520.1, 1449.5, 1369.4, 1245.2, 1167.7, 846.7 cm−1; 
(FAB) m/z :541, 519, 419, 378, 307, 154, 136. 
 
Methyl (3S, 8S, 11R, 14S)-3-[(tert-butoxycarbonyl)amino]-11-methyl-
2,10,13-trioxo-1.9.12-triazabicyclo[12.3.0]heptadec-5-yne-8-carboxylate 
(52). Following the general procedure for RCAM 
tetrapeptide 51 (65 mg, 0.12 mmol) was cyclized 
which upon isolation resulted in 52 as a white solid 
(33 mg, 0.07 mmol, 57%). 1H−NMR (400 MHz, CDCl3) 
δ 7.26 (bd, J = 8.0 Hz, 1H, NH), 6.81 (bd, J = 9.4 Hz, 
1H, NH), 6.31 (bd, J = 10.3 Hz, 1H, NHBoc), 4.89−4.83 (m, 1H, CαH), 4.70−4.55 
(m, 2H, 2 × CαH), 4.16−4.09 (m, 1H, CαH), 3.80 (s, 3H, OMe), 3.67−3.56 (m, 2H, 
CH2N), 2.88−2.75 (m, 1H, C≡CCH2), 2.71−2.52 (m, 3H, C≡CCH2), 2.38−2.28 (m, 
1H, CH2), 2.22−2.12 (m, 1H, CH2), 2.03−1.83 (m, 2H, CH2), 1.46 (s, 9H, Boc), 
1.45−1.42 (m, 3H, Me).  
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Methyl (1S, 4S, 9S, 13R, 16S)-9-[(tert-butoxycarbonyl)amino]-16-(tert-
butyl-dimethyl-silanyloxy)-[(2,10-dioxo-17-oxa-3,11-diaza-
bicyclo[11.3.1]heptadec-6-yn-4-
ylcarbonyl)amino]acetate (57). Compound 57 
was prepared according to the general 
metathesis protocol yielding 57 in 25%. [α]D = –
3.1 (c = 0.1, CH2Cl2). 1H−NMR δ 7.51(d, 1H, NH-
Mpg-OMe), 7.49 (bs, 1H, NH-Gly), 6.82 (bs, 1H, 
NHSAA), 6.21 (d, 1H, NHBoc), 4.60 (m, 1H, CαH-Mpg-OMe), 4.45 (m, 1H, CαH-
Mpg), 4.12 (m, 1H, CαH-Gly), 3.98 (m, 1H, CαH-Gly), 3.78 (m, 2H, CH2N), 3.76 (s, 
3H, OMe), 3.63 (m, 2H, 2 × CαH-SAA), 3.38 (m, 1H, CHOTBS), 2.92 (m, 1H, 
C≡CCH2), 2.81 (m, 1H, C≡CCH2), 2.60 (m, 1H, C≡CCH2), 1.50 (s, 9H, Boc), 0.87 
(s, 9H, SiCMe3) 0.04 (s, 3H, SiMe), 0.02 (s, 3H, SiMe); 13C−NMR δ 169.8, 79.5, 
75.2, 69.1, 52.9, 52.5, 43.0, 41.5, 29.7, 28.3, 26.6, 25.7, 23.0 (2 ×), −4.8, −4.9; 
HRMS m/z: calcd for C29H49N4O9Si (M + H)+: 625.3268, found 625.3220. 
 
Fmoc-Orn([(R)-2-amino-hex-4-ynoic acid]-Boc)-[(R)-2-amino-hex-4-ynoic 
acid]-OMe (61). Following the general example for 
tetramer-synthesis (S)-30 (135 mg, 0.76 mmol) was 
condensed with Fmoc-Orn(Boc)-OH (345 mg, 0.76 
mmol) resulting in 60 as a white solid (490 mg, 0.85 
mmol, inseparable from PyBOP residues). 1H−NMR 
(400 MHz, CDCl3) δ 7.76 (d, J = 7.3 Hz, 2H, Fmoc), 
7.60 (d, J = 7.3 Hz, 2H, Fmoc), 7.39 (t, J = 7.3 Hz, 2H, 
Fmoc), 7.31 (t, J = 7.3 Hz, 2H, Fmoc), 7.20 (bs, 1H, NH), 6.77 (bs, 1H, NH), 5.59 
(bs, 1H, NH), 4.69−4.62 (m, 2H, CαH, NH), 4.44−4.33 (m, 3H, CH2O, CαH), 
4.26−4.19 (m, 1H, CαHFmoc), 3.78 (s, 3H, OMe), 3.30−3.15 (m, 2H, CH2N), 
2.72−2.64 (m, 2H, C≡CCH2), 1.81 (s, 3H, C≡CMe), 1.95−1.51 (m, 4H, 2 × CH2), 
1.44 (s, 9H, Boc). The crude dipeptide 60 was deprotected and upon condensation 
with 32 (144 mg, 0.66 mmol) 61 was obtained as a white solid (123 mg, 0.18 
mmol, 24%, 3 steps). 1H−NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.3 Hz, 2H, Fmoc), 
7.60 (d, J = 7.3 Hz, 2H, Fmoc), 7.39 (t, J = 7.3 Hz, 2H, Fmoc), 7.31 (t, J = 7.3 Hz, 
2H, Fmoc), 7.20 (bs, 1H, NH), 6.57 (bs, 1H, NH), 5.67 (bs, 1H, NH), 5.56 (bs, 1H, 
NH), 4.75−4.68 (m, 1H, CαH), 4.60−4.53 (m, 1H, CαH), 4.44−4.35 (m, 3H, CH2O, 
CαH), 4.28−4.18 (m, 1H, CαHFmoc), 3.78 (s, 3H, OMe), 3.64−3.63 (m, 1H, CH2N), 
3.22−3.08 (m, 1H, CH2N), 2.78−2.53 (m, 4H, 2 × C≡CCH2), 1.84−1.55 (m, 4H, 2 × 
CH2), 1.76 (s, 6H, 2 × C≡CMe), 1.45 (s, 9H, Boc); 13C−NMR (75 MHz, CD3OD) δ 
O
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171.8, 170.7, 170.0, 155.7, 154.8, 143.7, 143.6, 140.5, 127.5, 127.0, 125.2, 120.0, 
78.3, 77.4, 75.7, 75.5, 74.7, 65.8, 55.1, 54.1, 53.7, 53.0, 52.2, 51.6, 46.8, 29.6, 28.4 
(Boc), 25.9, 22.8, 21.8, 21.6, 3.51; IR ν 3297, 2972, 1655, 1529, 1250, 1166, 1053 
cm−1; HRMS (SIMS) m/z calcd for C38H46N4O8 (M + Na)+ 687.3394, found 
687.33885. 
 
Methyl (5S, 8S, 13S)13-[(tert-butoxycarbonyl)amino]-5-[(9H-9-
fluorenylmethoxy)carbonyl]amino-6,14-dioxo-1,7-diaza-10-
cyclotetradecyne-8-carboxylate (62). Using the 
general procedure for ring closing alkyne 
metathesis compound 61 (30.0 mg, 43 µmol) was 
cyclized. After chromatography (2% CH2Cl2 in 
MeOH) cyclized product 62 was obtained as a white 
crystalline solid (9.7 mg, 15 µmol, 38%). 1H−NMR (400 MHz, CDCl3) δ 7.75 (d, J 
= 7.0 Hz, 2H, 2 × ArH), 7.59 (d, J = 5.3 Hz, 2H, 2 × ArH), 7.39 (t, J = 7.3 Hz, 2H, 
2 × ArH), 7.29 (t, J = 7.3 Hz, 2H, 2 × ArH), 7.06 (bs, 1H, NH), 6.86 (bd, J = 6.8 
Hz, 1H, NH), 6.03 (bd, J = 9.0 Hz, 1H, NHFmoc), 5.59 (bs, 1H, NHBoc), 4.74−4.65 
(m, 1H, CαH), 4.53−4.47 (m, 1H, CαH), 4.42−4.34 (m, 3H, CH2O, CαH), 4.26−4.20 
(m, 1H, CαHFmoc), 3.82 (s, 3H, OMe), 3.04−2.85 (m, 2H, CH2NH), 2.77−2.31 (m, 
4H, 2 × C≡CCH2), 2.05−1.61 (m, 4H, 2 × CH2), 1.49 (m, 9H, Boc); 13C−NMR (75 
MHz, CD3OD) δ 171.8, 170.3, 169.9, 155.5, 154.4, 143.7, 143.6, 140.5, 127.5, 
126.9, 125.2, 120.0, 79.5, 79.0, 78.6, 65.8, 53.6, 53.1, 52.2, 51.4, 46.8, 37.2, 30.3, 
28.4, 25.6, 23.0, 20.2; IR ν 3338.7, 1713.1, 1650.6, 1025.0, 1003.8 cm−1. 
 
General procedure for the loading of 2-chlorotrityl chloride. 
Under inert conditions, a batch of resin was 
allowed to swell in dry CH2Cl2. After 
removal of the CH2Cl2, fresh dry CH2Cl2 
was added, followed by the Fmoc-protected 
amino acid (1.3 equiv) and DiPEA (2 equiv). 
After 40 min, DiPEA (2 equiv) and MeOH (5 mL) were added and the reaction 
was continued for 10 min. The resulting mixture was filtrated, washed using 
CH2Cl2 and dried. The loading was determined by measuring weight or Fmoc-
titration. 
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General procedure for amino acid coupling using Fmoc-NH-Resin. 
The Fmoc-protected amino acid loaded resin was treated with 20% piperidine and 
0.1 M HOBt in DMF (15 mL) for 5 min and subsequently the solvent was 
removed (by filtration). This procedure was repeated three times. The resin was 
washed using DMF (3 × 1 min). Having removed the Fmoc, the resin was treated 
with DIC (3.3 equiv, 1 M in DMF), HOBt (3.3 equiv, 1 M in DMF), the Fmoc-AA-
OH (3 equiv) and DMF and ‘stirred’ for approximately 40 min . The coupling was 
qualitatively monitored using the Kaiser test. When completed, the solvent was 
again removed by filtration and washed with DMF (3 × 1 min). 
 
General procedure for the cleavage from the chloritrityl-resin. 
The resin was washed twice using MeOH, twice with CH2Cl2 and twice with Et2O 
in order to remove all traces of DMF. Then 1% of ethanedithiol, 1% of TFA and 
1% of iPr3SiH in CH2Cl2 was added and the resin was mixed for 2 h. After 
filtration, the filtrate was concentrated, dissolved in MeOH and treated with 
Et2O, causing the peptide-chain to precipitate the solution. The solid peptide was 
dissolved in dioxane and freeze-dried under vacuum, yielding a white solid. The 
corresponding methyl esters were obtained either by treatment with CH2N2 in 
Et2O or with in MeOH and 1.5 equiv SOCl2 for 48 h.35 
 
(S)-2-(Fluoren-9-ylmethoxycarbonylamino)-hex-4-ynoic acid (63).  
(S)-2-Amino-hex-4-ynoic acid (30, 5.21 g, 40.9 mmol) was 
dissolved in water (35 mL) and Et3N (5.75 mL, 40.9 mmol) was 
added in one shot. Then FmocOSu (13.11 g, 38.9 mmol) was 
added in a solution of acetonitrile (35 mL, a clear solution was 
obtained by gentle heating). The pH was continuously kept below 9 by careful 
addition of Et3N. When the pH stabilized around 9, the reaction was stirred for 
10 min. The pH was lowered to 6 by addition of 2 M HCl and the volatiles was 
removed by reduced pressure. The mixture was acidified to pH = 2 and extracted 
using EtOAc (3 × 50). The organic layer was washed (brine), dried (Na2SO4) and 
evaporated. Further purification was performed by recrystallizing from hot 
EtOAc and heptane. Product 63 was obtained as white solid (13.66 g, 39.0 mmol, 
96%). [α]D = +62.0 (c = 1.15, CH2Cl2); 1H−NMR (300 MHz, CDCl3) δ 7.77 (d, J = 
7.3 Hz, 2H, ArH), 7.65−7.59 (m, 2H, ArH), 7.41 (t, J = 7.5 Hz, 2H, ArH), 7.32 (t, J 
= 7.2 Hz, 2H, ArH), 5.57 (bd, J = 7.6 Hz, 1H, NH), 4.57−4.48 (m, 1H, CαH), 
4.44−4.40 (m, 2H, CH2O), 4.29−4.22 (m, 1H, CαH-Fmoc), 2.81−2.73 (m, 2H, 
C≡CCH2), 1.80 (s, 3H, C≡CMe); 13C−NMR (75.5 MHz, CDCl3) δ 174.5, 155.5, 
Me
CO2HFmocHN
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143.4, 140.9, 127.4, 126.8, 124.9, 119.7, 79.7, 72.5, 67.3, 52.5, 47.1, 22.8, 3.7; IR ν 
2971, 1716, 1517, 1449, 1220, 1056 cm−1. 
 
Fmoc-Mpg-Ala-Pro-Ala-Gly-Mpg-
OMe (65). Using standard solid phase 
chemistry (700 mg resin, 0.496 mmol) 
and methyl esterfication, oligopeptide 
65 (230 mg, 0.29 mmol, 59%) was obtained as a white fluffy solid. 1H−NMR (400 
MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H, ArH), 7.65−7.56 (m, 3H, NH, 2 × ArH), 
7.42−7.37 (m, 3H, NH, 2 × ArH), 7.33−7.28 (m, 3H, NH, 2 × ArH), 7.09 (bd, J = 
7.0 Hz, 1H, NH), 5.83 (bd, J = 7.6 Hz, 1H, NHFmoc), 4.81−4.77 (m, 1H, CαH), 
4.67−4.60 (m, 1H, CαH), 4.55−4.31 (m, 5H, 3 × CαH, CH2O), 4.23 (t, J = 6.5 Hz, 
CαH-Fmoc), 4.05 (d, J = 15.9 Hz, 1H, CH2-Gly), 3.91 (d, J = 15.4 Hz, 1H, CH2-
Gly), 3.72 (s, 3H, OMe), 3.66−3.55 (m, 2H, CH2N), 2.69−2.49 (m, 4H, 2 × 
C≡CCH2), 2.28−1.91 (m, 4H, 2 × CH2), 1.75 (s, 3H, C≡CMe), 1.72 (s, 3H, 
C≡CMe),1.42−1.32 (m, 6H, 2 × Me-Ala); 13C−NMR (75 MHz, CDCl3) δ 170.8, 
170.7, 170.4, 170.3, 169.1, 168.2, 155.4, 143.2, 140.7, 127.2, 126.5, 124.5, 119.4, 
79.0, 76.9, 73.3, 72.5, 67.0, 60.2, 53.2, 52.4, 51.0, 49.0, 47.3, 47.2, 46.8, 42.7, 28.7, 
28.2, 25.1, 23.3, 22.3, 17.8, 17.6, 3.5, 3.4; HRMS (MALDITOF): calcd for 
C41H48N6O9 768.3483, found 790.8989 (Ma + Na)+. 
 
Fmoc-Mpg-Gly-Glu(OtBu)-Gly-Ala-Mpg-OH (64). Using standard solid phase 
chemistry (700 mg resin, 0.496 mmol) and methyl esterfication, oligopeptide 64 
(260 mg, 0.31 mmol, 62%) was obtained as a white fluffy solid. HRMS 
(MALDITOF): calcd for C43H52N6O11 828.3694, found 850.8803 (M + Na)+. 
 
Fmoc-Mpg-Gly-Ala-Pro-Ala-Gly-Ala-Mpg-OH (66). Using standard solid 
phase chemistry (750 mg resin, 0.51 mmol) and methyl esterfication, oligopeptide 
66 (340 mg, 0.39 mmol, 76%) was obtained as a white fluffy solid. 13C−NMR (75 
MHz, DMSO-D6) δ 172.3, 172.0, 171.1, 170.6, 170.4, 170.3, 170.1, 167.9, 155.7, 
143.6, 140.5, 131.6, 131.5, 128.5, 127.5, 127.0, 125.2, 120.0, 78.3, 77.6, 75.8, 74.7, 
74.5, 67.5, 66.5, 65.9, 60.8, 59.5, 54.3, 52.4, 52.2, 49.6, 48.6, 47.9, 46.8, 46.3, 34.4, 
30.0, 29.2, 28.6, 24.7, 23.5, 22.7, 22.4, 21.5, 18.6, 18.0, 17.3, 14.3, 14.2, 11.1, 3.6, 
3.5; HRMS (MALDITOF): calcd for C45H54N8O11 882.3912, found 906.7462 (M + 
Na)+. 
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Fmoc-Mpg-Ala-Gly-Ala-Pro-Ala-Gly-Ala-Gly-Mpg-OH (67). Following the 
general procedure for solid phase chemistry (750 mg resin, 0.510 mmol), 
oligopeptide 67 (358 mg, 0.35 mmol, 70%) was obtained as a white fluffy 
solid.13C−NMR (75 MHz, DMSO-D6) δ 172.4, 172.2, 172.0, 171.6, 170.7, 170.3, 
170.0, 168.6, 168.4, 167.9, 155.7, 143.6, 140.5 (2 ×), 128.2, 127.6, 127.0 (2 ×), 
125.2, 125.1, 120.0, 78.4, 77.7, 75.7, 74.5, 72.3, 65.9, 60.4, 59.5, 54.1, 52.3, 51.6, 
48.7, 46.9, 46.4, 43.8, 29.2, 24.7, 22.3, 21.7, 18.4, 18.2, 17.9, 3.5 (2 ×); HRMS 
(MALDITOF): calcd for C50H62N10O13 1010.4498, found 1032.9927 (M + Na)+. 
 
Fmoc-Mpg-Ala-Gly-Ala-Gly-Ala-Pro-Ala-Gly-Ala-Gly-Ala-Gly-Mpg-OMe 
(68). Using standard solid phase chemistry (825 mg resin, 0.561 mmol) and 
methyl esterfication, oligopeptide 68 (600 mg, 0.47 mmol, 84%) was obtained as a 
white fluffy solid.1 3C−NMR (75 MHz, DMSO-D6) δ 171.8 (3 ×), 170.9, 170.5, 
170.4, 170.0, 169.7 (2 ×), 168.3, 168.1, 167.9, 167.6, 155.4, 143.4, 140.3, 127.2, 
126.7, 124.9, 119.8, 78.1, 77.3, 75.5, 74.2, 65.6, 59.3, 59.2, 53.8, 52.0, 51.3, 48.3 (2 
×), 48.2, 48.1, 46.6, 46.5, 46.1, 41.9,  41.6, 41.5, 28.9, 24.4, 22.1, 21.4, 18.1 (2 ×), 
17.8, 17.2, 17.1, 3.3 (2 ×); HRMS (MALDITOF): calcd for C60H78N14O17 1266.5669, 
found 1288.988 (M + Na)+. 
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6  TOWARD A SYNTHESIS OF FE399 
 
6.1  Introduction 
  
In Chapters 4 and 5, our aims were directed to the replacement of sulfur-bridges 
by carbon analogues in order to reach stable, conformationally rigid peptide 
structures. It was shown that especially ring-closing alkyne metathesis in a 
number of cases appeared an effective tool to introduce conformational 
constraints. However, biological activity foremost depends on the properties of 
the ensemble, not just on the isolated units. Comparison of cystine and its carbon 
counterpart in terms of metabolical and chemical stability focuses solely on the 
properties of the diamino acid unit itself.  
Examples of biologically active cystine bridged peptides and comparison to the 
corresponding carbon analogues are rare and to a large extent summarized in 
Chapter 1. A relevant example is oxytocin (1),1 the properties of which have 
recently been compared to its carbon analogue 2 (Figure 1).2 In this example the 
biological activity of native oxytocin (1, EC50 = 2.7 ng/mL) is diminished to 38 and 
242 ng/mL for the Z- and E-analogues of 2, respectively. Hydrogenation of the 
mixture to give the saturated linkage further reduced the EC50 to 338 ng/mL. 
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Figure 1. Oxytocin (1) and its carbon analogue 2. 
 
In order to further evaluate the viability of replacement of cystine bridges by 
their carbon counterparts in terms of biological activity, we also devised a 
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synthetic strategy for a cystine-containing natural product and its carbon 
counterpart, namely FE399 (3, Figure 2). 3 
O O O
O
Me
H
N
NH
S S
3  
Figure 2. FE 399 (3). 
 
Relatively little is known of FE399 (3). It was isolated from cultured Ascopchyta 
sp. and indicates strong cytotoxicity and strong inhibition of tumor growth in 
vivo. Furthermore, FE399 has two conformations due to steric hindrance of the 
disulfide ring but the relative and absolute stereochemistry of the product is not 
known.  
Despite the shortage of information, we considered this molecule a useful target 
for total synthesis and that of its carbon counterpart, especially since a short and 
convergent synthesis may give rise to the formation of all possible stereoisomers, 
and hence the opportunity to determine the absolute configuration. In this 
chapter a synthetic approach to both of these molecules will be discussed. 
 
6.2  Retrosynthesis 
 
Target molecule FE399 (3) is a bicyclic molecule, containing two bridging cysteine 
residues and a functionalized 16-membered ring. Despite the fact that the 
stereochemical configuration at the three stereocenters is unknown, it is logic to 
assume that both cysteine residues possess the ‘natural’ (R)-configuration. The 
stereochemistry of the n-propyl side chain (C-11) is unknown and therefore 
requires a synthetic approach that allows facile inversion of this stereocenter. 
The retrosynthetic approach commences with cleavage of the bridging peptide 
bond (viz. 5-8). The resulting macrocyclic ring is then either formed through S-
bridge formation via two cysteine residues (5), or via ring-closing alkyne 
metathesis of two acetylene containing amino acids (8). The advantage of alkyne 
metathesis would be that a triple bond is formed which can be selectively 
transformed into the Z-olefin (viz. 7) via controlled Lindlar hydrogenation. Ring-
closing metathesis is expected to yield a mixture of geometrical isomers, and 
since the presence of a Z-olefin is deemed necessary for the final lactam 
formation, the alkyne metathesis pathway is preferred.  
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Scheme 1. Retrosynthetic approach to FE399.  
 
Finally, synthesis of the linear cyclization precursor 9 involves coupling of the 
two protected amino acids 12 to the suitably functionalized enantiopure aliphatic 
chain 10. In view of the unknown C-11 stereocenter, we aimed at constructing 
the latter fragment from aldehyde 11, since multiple methods exist to form the 
desired stereocenter in both enantiomeric forms via enantioselective 
functionalization  of the aldehyde group.  
 
6.3  Synthesis of the aliphatic chain 
 
Asymmetric allylation of aldehydes, based on reactive borane complexes such as 
13 (dIcr2BCH2CH=CH2),4 generally provides the corresponding homoallylic 
alcohols in excellent enantioselectivity. This readily accessible reagent reacts via 
a rigid chairlike transition state, in which the chiral ligand directs the outcome 
(Scheme 2). 
B O
H
R B
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R O
B-complex
R
Me
Me
Me
B)2
13  
Scheme 2. Mechanism of the asymmetric allylation. 
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Importantly, the chirality of this reaction can be inverted by going from 3-carene 
to 2-carene, which can be obtained by treatment of 3-carene with base.5 
Allylboron complex 13 was obtained by treatment of 3-carene with BH3·SMe2 
(Scheme 3).6,7 The resulting borane crystals (14) were collected,8 resuspended in 
diethyl ether and by the addition of anhydrous methanol slowly converted into 
complex 15 via methanolysis. 
 
Me
Me
Me
a b c
Me
Me
Me
B)2Me
Me
Me
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Me
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BOMe)2
1315143-carene
Scheme 3. Reagents and conditions: a) BH3·SMe2; b) MeOH, Et2O; c) AllylMgBr. 
  
In this exothermic reaction hydrogen gas was generated for approximately 2 
hours. After the evolution of hydrogen gas had ceased, the solvents were removed 
and the resulting complex 15 was treated with allylmagnesium bromide to give 
the final reagent 13. 
Initial studies to form 11 were carried out starting from nonane-1,9-diol, 
requiring laborious protection and deprotection steps. Despite acceptable yields, 
a far more efficient synthesis of 11 was devised via ozonolysis of relatively cheap 
methyl oleate (Scheme 4). Oleate is a naturally occurring unsaturated fatty acid 
and its methyl ester is commercially available for 25 € L−1. Ozonolysis, followed 
by reductive workup using triphenylphosphine provided 11 in 73% yield.9 
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Me
Me
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13  
Scheme 4. Reagents and conditions: a) O3, PPh3, CH2Cl2 (73%); b) 13, THF, –78 °C (52%, >99% 
ee.); c) i: Raney-nickel, H2, ii: NaOH, MeOH, 40 °C (94%, 2 steps).  
 
Exposure of aldehyde 11 to dIcr2BAllyl (13) and subsequent hydrolysis of the 
formed borinate using H2O2 gave rise to allylic alcohol 16. Hydrogenation 
catalyzed by Pd/C or PtO2 surprisingly failed, while Raney-nickel provided the 
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desired saturated compound. This was saponified in crude form using NaOH and 
subsequent acid/base extraction to afford hydroxy acid 10 in pure form and high 
yield. The ee of compound 10 was determined to be 99% with the aid of chiral 
HPLC. 
 
6.4  Towards an all carbon analogue of FE399 
 
Having established a synthesis for building block 10, two acetylene-containing 
amino acids were coupled to this aliphatic chain. Initial approaches involved 
formation of the C-11 ester bond, followed by saponification of the methyl ester. 
However, the newly formed ester was as easily cleaved as the targeted methyl 
ester. Therefore, a somewhat different approach was pursued, in which the amide 
bond was formed first, provided that the ester was not base-labile. This 
requirement was met by using the tert-butyl ester-protected amino acid 19 
(Scheme 5). 
Compound 12 was esterified using condensed isobutene and a catalytic amount of 
sulfuric acid in a pressure flask.10 The crude tert-butyl ester 19 was directly 
reacted with the aliphatic carboxylic acid 10 using Castro’s reagent to give 17 in 
good yield. After purification, the second condensation with Boc-protected 20 
using standard carbodiimide conditions delivered the RCAM-precursor 9 in 
reasonable yield. Obviously, the remaining protecting groups can be removed in a 
single operation using TFA. The (R)-configured amino acids were used since 
these were at that time available. 
Me
CO2H
OH
H2N CO2tBu
Me
OH
N
H
O
CO2tBu Me
O
N
H
O
CO2tBu
BocHN CO2H
10 17 9
O
BocHN
Me Me
Me
Me
Me
H2N CO2H
Me
c d
a b
(  )7 (  )7 (  )7
(R)-1219 20
 
Scheme 5. Reagents and conditions: a) H2SO4, isobutene (97%); b) Boc2O, NAHCO3, H2O/1,4-
dioxane (1 : 1), 100 °C, (99%); c) DiPEA, PyBOP, 19, CH2Cl2 (79%), d) DIC, 20, DMAP (82%).  
 
Application of RCAM using the conditions described in Section 5.3 to diacetylene 
9 resulted in a successful cyclization, albeit that the yield was rather low (28%). 
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Furthermore, the proton signals in 1H−NMR were much disturbed due to the 
occurrence of rotamers. It was anticipated that partial hydrogenation using a 
Lindlar reduction would provide an easier identifiable product. Disappointingly, 
use of lead-poisoned palladium on calcium carbonate in the presence of quinoline 
resulted in unexpected and complete decomposition of  starting material 8.  
 
Me
O
N
H
O
CO2tBu
9
O
BocHN
Me
Me
8
[Z]
7
(  )7(  )7 (  )7a bXMe
O
O
O HN CO2tBu
BocHN
Me
O
O
O HN CO2tBu
BocHN
 
Scheme 6. Reagents and conditions: a) (tBuO)3W≡CtBu, PhMe, 80 °C (28%); b) Lindlar reduction. 
 
This reaction eventually was not repeated due to the inherent complexity and 
sensitivity of the RCAM process. Alternatively, we decided to pursue an olefin 
metathesis approach, since metathesis of olefins is a more straightforward 
reaction. Using a similar sequence as outlined in Scheme 5, 2-(R)-amino-4-
pentenoic acid was esterified with trimethylsilylethanol, reacted with 10 using 
BOP-reagent and subsequently coupled to 2-(R)-(tert-butoxycarbonyl)-amino-4-
pentenoic acid to give dipeptide 22 (Scheme 7). 
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Scheme 7. Reagents and conditions: a) PyBOP, 2-(trimethylsilyl)ethanol 2-(S)-4-pentenoic acid 
ester, CH2Cl2 (48%); b) DIC, DMAP, (S)-2-(tert-butoxycarbonylamino)-4-pentenoic acid ((S)-28), 
CH2Cl2 (97%); c) i: TBAF, ii: EtOAc, HCl (74%, 2 steps); d) BOP, DiPEA, CH2Cl2 (11%). 
 
The TMSE-protection should enable intermediate ester cleavage using TBAF. 
This allowed a subsequent purification after which the amine was liberated using 
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HCl/EtOAc and a macrolactamization was performed on amino acid 23. 
Unfortunately, this latter reaction suffered from an 11% yield of 24 and even 
worse, RCM on 24, carried out under a variety of conditions, did not result in any 
of the desired bicyclic product. 
 
In an alternative sequence, it was decided to close the macrocyclic ring first via 
RCM and continue with an intramolecular peptide coupling. Using an identical 
procedure as for 22, the appropriate precursor 25 was synthesized in 22% overall 
yield starting from the corresponding olefinic amino acid derivatives 27 and 28 
(Scheme 8). Gratifyingly, ring-closing metathesis yielded the desired compound 7 
as an unidentifiable mixture of E/Z-isomers and rotamers. Hydrogenation of the 
crude ring-closed product eventually resulted in complete conversion into 
compound 6, where 1H–NMR-spectroscopy served to confirm the absence of the 
olefin. 
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Scheme 8. Reagents and conditions: a) 2nd gen Grubbs cat, PhMe, 80 °C (59%); b) H2, Pd/C, 
MeOH, c) i: TFA, ii: fluorocyanuric acid (13%, 3 steps); d) H2SO4, isobutene (97%); e) Boc2O, 
NaHCO3, H2O/1,4-dioxane (99%). 
 
Continuing the sequence by TFA-mediated deprotection of the amine and ester 
function and subsequent lactamization using in situ acyl fluoride formation with 
fluorocyanuric acid led to product 4, the formation of which was confirmed using 
determination of the exact mass.11 The amount of material, however, was 
insufficient for extensive characterization and comparison of its properties to 
those of FE399. 
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6.5  Towards FE399 
 
The synthetic strategy to FE399 posed additional difficulties related to the 
required orthogonal protecting groups for the sulfur atoms. Initial approaches 
relied on combining the commercially available dipeptide 29 with the previously 
described aliphatic chain 10. Markedly, as shown in Scheme 9, the amide bond 
formation-coupling using the typical DIC conditions was unsuccessful. The more 
successful amide installment which led to 32 might eventually lead to the 
required lactone. However, prior to this lactonization the cystine-formation was 
investigated since the weak ester bond might be incompatible with cystine-
formation. However, upon subjection of 32 to typical Birch conditions (lithium in 
ammonia) no recoverable products were found. It must also be noted that the 
hydrolysis and subsequent lactonization of 32 is known to give severe 
racemization at the cysteine moieties.  
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Scheme 9. Reagents and conditions: a) 30, DIC, DMAP, CH2Cl2; b) i: NaOH, MeOH; ii: PyBOP, 
DiPEA, 29, CH2Cl2 (38%); c) Li, NH3(l); d) i: Boc2O, Et3N; ii) 2 M LiOH (82%, 2 steps). 
 
As an alternative, the previously discussed TMSE-ester strategy was followed, 
which is illustrated in Scheme 10.12 
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Scheme 10. Reagents and conditions: a) i: PyBOP, DiPEA, Cys(Acm)-OTMSE, CH2Cl2; ii) pTSA, 
MeOH (30%, 2 steps); b) DIC, DMAP, Boc-Cys(Acm)-OH, CH2Cl2 (29%); c) TBAF. 
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The main advantage of the acetamidomethyl (Acm) group is its stability under 
the most common deprotection conditions. It can be easily removed by treatment 
with mercury(II)-salts, and it allows iodine-mediated oxidation without 
deprotection. Unfortunately, after TBAF-assisted deprotection the desired 
product was inseparable from byproducts that were formed in this reaction.  
Attempts to switch to different ester protective groups were not very successful. 
As already mentioned, the methyl ester cannot be hydrolyzed in the presence of 
the secondary ester. A more labile 2-Ts ethyl ester based cysteine could not be 
used because of its incompatibility with the lactam forming step. Furthermore, in 
the presence of the sulfur groups use of a benzyl ester is not possible. However, 
when free S-trityl-protected cysteine (Cys(Trt)) was reacted with DCC/tBuOH 
indeed a tert-butyl ester was isolated and subsequently attached to acid 10 in a 
reasonable yield of 58%.  
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Scheme 11. Reagents and conditions: a) CuCl, tBuOH, DCC; b) PyBOP, DiPEA, CH2Cl2 (58%, 2 
steps); c) Boc-Cys(Acm)-OH, DIC, Et3N, CH2Cl2. 
 
At this stage, the ester bond formation between Boc-Cys(Trt)-OH or Boc-
Cys(Acm)-OH and the secondary alcohol of 36 was ineffective for unknown 
reasons. Since in early stages we experienced much difficulties associated with 
this particular alcohol,13 the trityl group could be responsible for the diminished 
activity. The aliphatic chain could fold itself in such a fashion that the secondary 
alcohol of 36 is shielded by the rest of the molecule. 
 
6.6  Conclusions 
 
The synthesis of FE399 gave more difficulties than we initially anticipated. The 
originally planned retrosynthetic approach based on metathesis failed to give the 
desired carbon mimic in the case of alkyne substituents, but was eventually 
successful in the case of alkene metathesis. This led to a saturated carbon 
analogue of FE399, which due to the small amounts of isolated product was 
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insufficient for evaluation of its properties. Furthermore, in pursuing the natural 
product itself, unfortunately a suitable sequence was not found as a result of 
complications caused by the protecting group manipulations.  
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6.8  Experimental section 
 
For general experimental details, see: Section 2.8. 
 
 dIcr2BAllyl (13).14 3-Carene (42 g, 308 mmol) was added 
drop wise to a cooled (0 °C) solution of BH3·DMS (10 mL, 
106 mmol) in CH2Cl2 (50 mL). The clear solution was 
placed in the fridge for 48 h after which the suspension was 
filtered under an argon atmosphere and washed with cold Et2O. The isolated 
white solid (19.5 g, 68 mmol) was directly transferred to a flask, resuspended in 
Et2O (100 mL) and MeOH (10 mL) was added. The suspension was stirred until 
the solution became clear, after which the solvent was removed using vacuum 
evaporation. THF (150 mL) was added and a 2 M solution of allylmagnesium 
bromide (34.0 mL, 68.0 mmol) was added dropwise at –78 °C. The temperature 
was slowly raised to RT after which the resulting solution was used for follow-up 
chemistry.  
 
Methyl 9-oxononanoate (11).14 A solution of methyl oleate (20.1 
mL, 59 mmol) in CH2Cl2 (200 mL) was cooled to −78 °C. Ozone was 
bubbled through the solution until a faint blue color remained. After removal of 
the excess ozone using nitrogen, PPh3 (17.4, 66.4 mol) was added. The solvent 
was stripped and Et2O (50 mL) was added. After filtration the solution was 
distilled (92 °C, 90 mbar) resulting in 11 as a clear oil (8.3 g, 44.6 mmol, 83%). 
1H−NMR (400 MHz, CDCl3) δ 9.74 (s, 1H, CH=O), 3.67 (s, 3H, OMe), 2.47−2.43 
(m, 2H, CH2CH=O), 2.30 (t, J = 7.4 Hz, 2H, CH2CO2Me), 1.62−0.88 (m, 10H, 
CH2).  
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9-(S)-Hydroxydodecanoic acid (10). To a stirred solution of 
dIcr2BAllyl (3.90 g, 11.6 mmol) in THF (150 mL) at –78 °C was 
added aldehyde 11 (2.00 gram, 10.9 mmol) dropwise over a period of 20 min. The 
mixture was stirred at –78 °C after which it was slowly warmed to room 
temperature. The excess of borane-complex was oxidized by addition of H2O2 
(35%, 100 mL) and NaOH (10M, 2 mL) and subsequent refluxing for 2 h. Excess 
of H2O2 was destroyed by careful addition of aqueous saturated Na2S2O3 and the 
mixture was extracted using toluene (3 × 100 mL). The organic layer was washed 
(brine), dried (MgSO4) and evaporated. Further purification using flash 
chromatography (15% EtOAc in heptane) yielded desired compound 10 as a 
colorless oil (1.30 g, 5.5 mmol, 52%). Ee: >99%;15 1H−NMR (400 MHz, CDCl3) δ 
5.85−5.68 (m, 1H, =CH), 5.10−5.00 (m, 2H, =CH2), 3.62−3.51 (m, 1H, CHOH), 
3.59 (s, 3H, OMe), 2.30−2.16 (m, 3H, CH2COO, CH2), 2.13−2.00 (m, 1H, CH2), 
1.90−1.78 (m, 1H, CH2), 1.62−1.47 (m, 2H, CH2), 1.44−1.20 (m, 10H, 5 × CH2); 
13C−NMR (75 MHz, CDCl3) δ 174.2, 134.8, 117.7, 70.5, 51.3, 41.8, 36.6, 33.9, 29.3, 
29.1, 28.9, 25.4, 24.8. 
A solution of 16 (2.12 g, 9.30 mmol) in MeOH (1 M NH3, 30 mL) was treated with 
Raney-nickel (aqueous suspension, 1 mL) upon which hydrogen was bubbled 
through the solution. After 2 h the suspension was filtered over Celite and the 
filtrate was evaporated. The resulting oil was dissolved in MeOH (20 mL), 2 M 
NaOH (20 mL) was added and the mixture was heated at 40 °C for 2 h. After 
cooling down the reaction was extracted with EtOAc. The aqueous phase was 
acidified (pH < 2) and extracted using Et2O. The ether layer was concentrated, 
yielding 10 as a clean oil (1.89 g, 8.78 mmol, 94%). 1H−NMR (400 MHz, CDCl3) δ 
7.15 (bs, 1H, OH), 3.65−3.58 (m, 1H, CHOH), 2.32 (t, J = 7.8 Hz, 2H, CH2CO2H), 
1.65−1.58 (m, 2H, CH2), 1.47−1.25 (m, 14H, 7 × CH2), 0.93 (t, J = 6.8 Hz, 3H, Me); 
13C−NMR (75 MHz, CDCl3) δ 178.2, 71.4, 39.1, 36.9, 33.8, 29.2, 29.0, 28.8, 25.3, 
24.5, 18.6, 14.0; IR ν 3400, 2928, 2855, 1708, 1223, 612 cm−1; HMRS (FAB)+ calcd 
for C12H25O3 217.18037, found 217.1804. 
 
2-R-(9-S-Hydroxy-dodecanoylamino)-hex-4-ynoic acid tert-butyl ester 
(17). A suspension of (R)-2-amino-hex-4-ynoic acid 
((R)-12, 250 mg, 1.97 mmol) in 1,4-dioxane (10 mL) 
was cooled to −78 °C in a pressurizable bottle.16 Then 
H2SO4 (250 µL) was added and isobutene (~10 mL) 
was condensed in this flask. After sufficient isobutene was added, the bottle was 
sealed, allowed to warm to RT and stirred for 3 days. After cooling to −78 °C, the 
Me
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(  )7
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Me N
H
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Me
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bottle was opened and allowed to warm to ambient temperature. The mixture 
was added to aqueous NaOH (0.5 M, 20 mL) and subsequently extracted with 
Et2O (3 × 20 mL). After concentration, the crude product 19 (350 mg, 1.91 mmol, 
97%) was obtained. 
To a stirred solution of acid 10 (246 mg, 1.13 mmol) in CH2Cl2 (20 mL) were 
added BOP (400 mg 0.91 mmol) and (R)-2-aminohex-4-ynoic acid tert-butyl ester 
(19, 150 mg, 0.82 mmol) and the resulting mixture was stirred overnight. The 
solvent was evaporated and further purified using flash chromatography (35% 
EtOAc in heptane) delivered peptide 17 as a clear oil (279 mg, 0.71 mmol, 89%). 
[α]D = –7.6 (c = 0.41, CH2Cl2) 1H−NMR (400 MHz, CDCl3) δ 6.22 (bd, J = 8.0 Hz, 
1H, NH), 4.58−4.54 (m, 1H, CαH), 3.57 (m, 1H, CHOH), 2.70−2.55 (m, 2H, 
C≡CCH2), 2.22 (t, J = 7.2 Hz, 2H, CH2CO), 1.74 (t, J = 2.4 Hz, 3H, C≡CMe), 
1.64−1.58 (m, 3H, CH2), 1.46 (s, 9H, CMe3), 1.46−1.37 (m, 6H, CH2), 1.33−1.25 
(m, 7H, CH2), 0.93 (t, J = 6.8 Hz, 3H, Me); 13C−NMR (75 MHz, CDCl3) δ 172.2, 
169.6, 82.3, 82.3, 78.6, 73.6, 71.6, 51.3, 39.8, 37.5, 36.7, 29.6, 29.4, 29.2, 28.0, 
25.7, 23.2, 19.0, 14.3, 3.6; IR ν 3299, 2927, 2856, 1734, 1653, 1539, 1368, 1157 
cm−1.  
 
2-(R)-[9-S-(2-(R)-tert-Butoxycarbonylamino-hex-4-ynoyloxy)-
dodecanoylamino]-hex-4-ynoic acid tert-butyl 
ester (9). To a stirred solution of alcohol 17 (154 
mg, 0.40 mmol) in CH2Cl2 (10 mL) were added 
dropwise DIC (82 μl, 0.53 mmol), (R)-2-(tert-
butoxycarbonyl)aminohex-4-ynoic acid (119 mg, 0.53 mmol) and DMAP (15 mg, 
0.15 mmol) and the reaction was stirred overnight. After evaporation and further 
purification using flash chromatography (2% MeOH in CH2Cl2) compound 9 (196 
mg, 0.33 mmol) was obtained in 82% yield. 1H−NMR (400 MHz, CDCl3) δ 6.24 
(bd, J = 7.6 Hz, 1H, NH), 5.35−5.30 (m, 1H, NHBoc), 4.96−4.90 (m, 1H, CαH), 
4.60−4.54 (m, 1H, CαH), 4.42−4.37 (m, 1H, CαH), 2.76−2.45 (m, 4H, 2 × 
C≡CCH2), 2.23 (t, J = 7.2 Hz, 2H, CH2CO), 1.754 (t, J = 2.4 Hz, 3H, C≡CMe), 
1.751 (t, J = 2.4 Hz, 3H, C≡CMe), 1.65−1.22 (m, 16H, 8 × CH2), 1.48 (s, 9H, 
CMe3), 1.46 (s, 9H, Boc), 0.90 (t, J = 7.6 Hz, 3H, Me); 13C−NMR (75 MHz, CDCl3) 
δ 172.9, 170.5, 169.6, 154.8, 82.2, 79.8, 78.9, 78.6, 75.7, 73.3, 52.5, 51.3, 36.7, 36.3, 
34.2, 29.4, 29.3, 29.2, 28.4, 28.0, 25.7, 25.3, 23.4, 23.2, 18.5, 14.2, 3.7, 3.6.  
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tert-Butyl 3-(R)-[(tert-butoxycarbonyl)amino]-2,10-dioxo-20-(S) propyl-1-
oxa-9-aza-5-cycloicosyne-8-(R)-carboxylate (8).  
To peptide 9 (81.0 mg, 0.137 mmol) and (tBuO)3W≡CtBu 
(8.0 mg, 0.016 mmol) was added freshly distilled 
toluene (20 mL) and the mixture was heated at 80 °C 
for 3 h. After evaporation and further purification (2% MeOH in CH2Cl2) product 
8 was isolated as a white foam (21.2 mg, 0.039 mmol, 28%). 1H−NMR (400 MHz, 
CDCl3) δ 7.19−7.16 (m, 1H, NH), 6.26−6.22 (m, 1H, NHBoc), 5.43−4.93 (m, 1H, 
CαH), 4.91−4.78 (m, 1H, CαH), 4.65−4.50 (m, 1H, CHO), 2.73−2.43 (m, 4H, 2 × 
C≡CCH2), 2.06−2.05 (m, 2H, CH2CO), 1.79−1.22 (m, 16H, aliphatic chain), 1.50 
(s, 9H, Boc), 1.47 (s, 9H, CMe3), 0.90 (t, J = 7.3 Hz, 3H, Me). 
 
2-(S)-[9-S-Hydroxydodecanoylamino]-4-pentenoic acid 2-
(trimethylsilyl)ethyl ester (21). Using the 
coupling procedure as described for 17, (2-
(trimethylsilyl)ethyl) 2-(S)-4-pentenoic acid ester 
(73 mg, 0.34 mmol) and acid 10 (67 mg, 0.309 
mmol) were coupled, resulting in a clear oil ( 120 mg, 0.25, 80%). 1H−NMR (300 
MHz, CDCl3) δ 5.96 (d, J = 8.0 Hz, 1H, NH), 5.71−5.60 (m, 1H, CH=), 5.10−5.07 
(m, 2H, CH2=), 4.68−4.62 (m, 1H, CαH), 4.25−4.20 (m, 2H, CH2O), 3.60 (s, 1H, 
CHOH), 2.60−2.48 (m, 2H, CH2CH=), 2.22 (t, J = 7.6 Hz, 2H, CH2CON), 
1.60−0.93 (m, 19H, CH2), 1.05−1.00 (m, 2H, CH2Si), 0.07 (SiMe3); 13C−NMR (75 
MHz, CDCl3) δ 172.0, 171.3, 131.7, 118.6, 63.6, 51.2, 36.4, 32.3, 29.4, 29.0, 17.3, 
−1.6. 
 
2-(S)-[9-S-(2-(S)-tert-Butoxycarbonylamino-4-pentenoyloxy)dodecanoyl 
amino]-4-pentenoic acid  2-(trimethylsilyl)ethyl ester (22).  
Using the described protocol for 9, 2-(S)-(tert-
butylcarbonyl)-amino-4-pentenoic acid (244 mg, 
1.14 mmol) and 21 (470 mg, 1.14 mmol) were 
coupled. After isolation, 22 (670 mg, 1.09 mmol, 
97%) was obtained as a clear oil. [α]D = +7.0 (c = 1.17, CH2Cl2); 1H−NMR (300 
MHz, CDCl3) δ 5.96 (d, J = 7.3 Hz, 1H, NH), 5.71−5.62 (m, 2H, 2 × CH=C), 
5.13−5.07 (m, 4H, 2 × C=CH2), 5.10 (d, J = 7.4 Hz, 1H, NHBoc), 4.93−4.89 (m, 1H, 
CαH), 4.67−4.61 (m, 1H, CαH), 4.37−4.32 (m, 1H, CHO), 4.25−4.21 (m, 2H, 
CH2O), 2.60−2.44 (m, 2H, CH2C=), 2.52−2.45 (m, 2H, CH2C=), 2.20 (t, J = 7.8 Hz, 
2H, CH2CON), 1.70−1.22 (m, 16H, aliphatic chain), 1.47 (s, 9H, Boc), 1.04−1.00 
Me
O
N
H
O
CO2TMSE
O
BocHN
(  )7
Me
OH
N
H
O
CO2TMSE(  )7
(  )7Me
O
O
O HN CO2tBu
BocHN
Chapter 6 
 144
(m, 2H, CH2TMS), 0.90 (t, J = 7.3 Hz, 3H, Me), 0.07 (s, 9H, SiMe3); 13C−NMR (75 
MHz, CDCl3) δ 171.9, 171.3, 131.7 (2×), 118.6 (2×), 75.2, 63.6, 52.7, 51.2, 36.4, 
36.3, 35.9, 33.7, 29.0, 28.9 28.1, 25.3, 18.3, 17.3, 13.8, −1.6; MS (m/z): 
C32H58N2O7Si (M + H)+ 611, 511, 483, 368, 296, 188, 136, 116, 70. 
 
2-(R)-[9-S-(2-(R)-tert-Butoxycarbonylamino-4-pentenoyloxy)dodecanoyl 
amino]pent-4-enoic acid tert-butyl ester (25). 
Using the method described for 17, (R)-2-amino-4-
pentenoic acid (400 mg, 3.48 mmol) was protected as 
its corresponding tert-butyl ester. The unpurified 
crude product 27 was used for further reactions. 
1H−NMR (400 MHz, CDCl3) δ 5.81−5.69 (m, 1H, CH=C), 5.19−5.14 (m, 2H, 
=CH2), 3.47−3.41 (m, 1H, CαH), 2.52−2.42 (m, 1H, CH2), 2.41−2.37 (m, 1H, CH2), 
1.45 (s, 9H, CMe3). Upon condensation with 10 (243 mg, 1.13 mmol) and flash 
chromatography (33% EtOAc in heptane) the intermediate product was isolated 
as an oil (237 mg, 0.89 mmol, 78%). 1H−NMR (400 MHz, CDCl3) δ 6.00 (bs, 1H, 
NH), 5.75−5.62 (m, 1H, C=CH), 5.14−5.11 (m, 1H, C=CH2), 5.09−5.06 (m, 1H, 
C=CH2), 4.60−4.54 (m, 1H, CαH), 3.63−3.56 (m, 1H, CHOH), 2.63−2.53 (m, 1H, 
CH2C=), 2.51−2.43 (m, 1H, CH2C=), 2.19 (dt, J = 1.9 Hz, 7.8 Hz, 2H, CH2CO), 
1.74−1.24 (m, 16H, aliphatic chain), 1.46 (s, 9H, CMe3), 0.92 (t, J = 6.8 Hz, 3H, 
Me); 13C−NMR (50 MHz, CDCl3) δ 172.6, 171.0, 132.3, 118.6, 82.0, 71.3, 51.9, 
51.7, 39.4, 17.2, 36.6, 36.3, 29.3, 29.1, 28.9, 27.8, 25.4, 18.6, 14.0; IR ν 3316, 2928, 
2855, 1724, 1656, 1532, 1368, 1154 cm−1. Using the protocol as described for 9, 
the previously obtained alcohol (185 mg, 0.50 mmol) was condensed with 2-(R)-
(tert-butoxycarbonyl)amino-4-pentenoic acid ((R)-28, 125 mg, 0.58 mmol). Product 
25 (80 mg, 0.14 mmol, 28%) was isolated after flash chromatography (2% MeOH 
in CH2Cl2). 1H−NMR (400 MHz, CDCl3) δ 6.00 (d, J = 7.3 Hz, 1H, NH), 5.75−5.63 
(m, 2H, 2 × CH=C), 5.17−5.06 (m, 4H, 2 × C=CH2), 5.10 (d, J = 7.4 Hz, 1H, 
NHBoc), 4.93−4.88 (m, 1H, CαH), 4.60−4.55 (m, 1H, CαH), 4.37−4.32 (m, 1H, 
CHO), 2.62−2.54 (m, 2H, CH2C=), 2.52−2.45 (m, 2H, CH2C=), 2.19 (t, J = 7.8 Hz, 
2H, CH2CON), 1.70−1.22 (m, 16H, aliphatic chain), 1.47 (s, 9H, Boc), 1.44 (s, 9H, 
CMe3), 0.90 (t, J = 7.3 Hz, 3H, Me); 13C−NMR (75 MHz, CDCl3) δ 172.2, 171.5, 
170.6, 154.9, 132.2 (2 ×), 118.8, 118.6, 82.1, 79.6, 75.4, 53.1, 51.8, 36.9, 36.7, 36.2, 
34.2, 29.3, 29.2, 28.4 (3 ×), 28.2 (3 ×), 25.7, 25.3, 18.7, 14.1; HRMS (FAB)+ calcd 
for C31H55O7N2 567.40093, found 567.4011 (M + H)+. 
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3-(R),6-(R)-Diallyl-18-propyl-1-oxa-4,7-diazacyclooctadecane-2,5,8-trione 
(24). Product 25 (155 mg, 0.303 mmol) was treated with 
2M HCl in EtOAc (10 mL) for 2h upon which the volatiles 
were removed. The crude unprotected product was 
dissolved in CH2Cl2 and BOP ( 323 mg, 0.731 mmol) and 
DiPEA (198 mg, 1.52 mmol) were added. After stirring 
overnight the solvent was stripped and further 
purification using flash chromatography (2% MeOH in CH2Cl2) yielded product 
24 as a sticky oil (13 mg, 0.033 mmol, 11%, 2 steps). 1H−NMR (300 MHz, CDCl3) 
δ 6.28 (d, J = 7.0 Hz, 1H, NH), 6.15 (d, J = 6.8Hz, 1H, NH), 5.81−5.61 (m, 2H, 2 × 
=CH), 5.13−5.07 (m, 4H, 2 × =CH2), 4.91−4.63 (m, 3H, 2 × CαH, CHO), 2.61−0.82 
(m, 21 H); 13C−NMR (50 MHz, CDCl3) δ 172.4, 169.9, 165.2, 132.3, 131.7, 119.0, 
118.4, 75.6, 52.2, 51.7, 37.0, 36.5, 32.8, 26.7, 25.8, 24.8, 22.5, 18.6, 18.5, 13.8, 
13.7. 
 
tert-Butyl 3-(R)-[(tert-butoxycarbonyl)amino]-2,10-dioxo-20-(S) propyl-1-
oxa-9-aza-5-cycloicosene-8-(R)-carboxylate (7). 
To a stirred solution of 25 (80 mg, 0.17 mmol) in 
anhydrous toluene (10 mL) was added Grubbs 
catalyst (2nd gen, 8 mg, 9 µmol). The mixture was 
heated at 60 °C for 8 h. After evaporation and 
further purification using flash chromatography (33% EtOAc in heptane) product 
7 was isolated as an off-white solid (45 mg, 0.10 mmol, 59%); 1H−NMR (300 MHz, 
CD3OD) δ 5.57−5.40 (m, 2H, 2 × =CH), 4.89−4.84 (m, 1H, CαH), 4.46−4.38 (m, 
1H, CαH), 4.14−4.08 (m, 1H, CHOH), 2.55−2.39 (m, 4H, CH2C=), 2.19−2.15 (m, 
2H, CH2CO), 1.69−1.23 (m, 16H), 1.46 (s, 9H, Boc), 1.44 (s, 9H, CMe3), 0.91 (t, J = 
7.2 Hz, 3H, Me); 13C−NMR (75 MHz, CDCl3) δ 174.4, 172.9, 170.3, 158.6, 128.3, 
127.7, 81.0, 74.8, 53.7, 51.3, 35.7, 34.5, 34.2, 32.5, 28.8, 27.5, 27.2, 26.7 (3 ×), 26.4 
(3 ×), 24.4, 23.8, 17.8, 12.4; IR ν 2934, 1721, 1670, 1482, 1180, 1071, 1054, 1032 
cm−1. 
 
(R,R,R)-11-Propyl-12-oxa-2,20-diaza-bicyclo[12.4.2]icosane-3,13,19-trione 
(4). Through a suspension of 7 (27 mg, 61 µmol) and Pd/C 
(10%, 20 mg) in MeOH (10 mL) was bubbled hydrogen 
gas for 2 h. After filtration over Celite product 6 was 
obtained as a white solid.17 The product was dissolved in 
TFA (50% in CH2Cl2, 4 mL) and stirred for 4 h. After 
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evaporation, CH2Cl2 (3 mL), fluorocyanuric acid (16 mg, 0.122 mmol) and DiPEA 
(110 µL, 0.06 mmol) were added and stirring was continued for 16 h. Upon 
evaporation silica gel chromatography was performed (60% EtOAc in heptane) 
resulting in 4 as a white solid (2.9 mg, 7.9 µmol, 13%). HRMS (FAB+): calcd for 
C20H34N2O4  367.25968, found 367.2597 (M + H)+. 
 
Ethyl 3-(benzylsulfanyl)-2-(R)-(3-(benzylsulfanyl)-2-(R)-[(9-(R)-
hydroxydodecanoyl)amino]propanoylamino)propanoate (32).  
To a stirred solution of acid 10 (221 mg, 1.02 
mmol) in CH2Cl2 (10 mL) were added DiPEA 
(440 µL, 2.44 mmol), PyBOP (650 mg, 1.20 
mmol) and H2N-Cys(Bzl)-Cys(Bzl)-OEt (530 
mg, 1.22 mmol) respectively. After stirring for 16 h the solvent was removed and 
further purification using flash chromatography (2% MeOH in CH2Cl2) was 
performed. Product 32 was isolated as an amorphous solid (250 mg, 0.39 mmol, 
38%). 1H−NMR (400 MHz, CDCl3) δ 7.37−7.21 (m, 10H, 2 × Ar), 7.09 (d, J = 7.7 
Hz, 1H, NH), 6.35 (d, J = 7.4 Hz, 1H, NH), 4.74−4.68 (m, 1H, CαH), 4.57−4.51 (m, 
1H, CαH), 4.19 (q, J = 7.1 Hz, 2H, OCH2), 3.79 (s, 2H, ArCH2S), 3.70 (s, 2H, 
CH2S), 3.61−3.57 (m, 1H, CHOH), 2.91−2.69 (m, 4H, 2 × CH2S), 2.18 (t, J = 7.6 
Hz, 2H, CON), 1.65−1.25 (m, 16H, 8 × CH2), 0.92 (t, J = 6.7 Hz, 3H, Me); 
13C−NMR (75 MHz, CD3OD) δ 174.5, 170.9, 170.0, 137.7, 137.5, 133.9, 129.7, 
128.3, 127.6, 126.3, 125.1, 125.0, 116.8, 109.7, 71.9, 70.1, 60.9, 51.7, 38.7, 36.7, 
35.3, 35.2, 32.3, 31.6, 28.9, 28.7, 28.4, 25.1, 25.0, 18.0, 12.7, 12.6; IR ν 3305, 2924, 
2882, 1744, 1631, 1544, 1213, 1032 cm−1; HRMS (EI) calcd for C34H50N2O5S5 
630.31611, found 653.30588 (M + Na)+. 
 
2-(1,1,1-Trimethylsilyl)ethyl 3-[(acetylamino)methyl]sulfanyl-2-(R)-[9-(S)-
hydroxydodecanoyl]aminopropanoate (34). Using the conditions as 
described for 17, THP-protected alcohol 10 (200 mg, 
0.671 mmol) and Cys(Acm)-TMSE (235 mg, 0.805 
mmol) were coupled. After flash chromatography 
(50% EtOAc in heptane) the intermediate product (305 mg, 0.625 mmol, 79%) 
was obtained. 1H−NMR (400 MHz, CDCl3) δ 6.95 (s, 1H, NHAc), 6.56 (d, J = 7.2 
Hz, 1H, NH), 5.88−5.74 (m, 1H, C=CH), 5.10−5.04 (m, 2H, C=CH2), 4.77−4.65 (m, 
2H, CαH / CH-THP), 4.48−4.29 (m, 2H, SCH2N), 4.29−4.21 (m, 2H, OCH2), 
3.92−3.49 (m, 9H, THP, CHO-THP), 3.11−2.80 (m, 2H, CH2S), 2.28 (t, J = 7.8 Hz, 
2H, CH2CON), 2.05 (s, 3H, Ac), 1.73−1.29 (m, 14H, 7 × CH2), 1.04−1.00 (m, 2H, 
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CH2TMS), 0.06 (9H, SiMe3); 13C−NMR (75 MHz, CDCl3) δ 173.3, 170.5, 170.1, 
134.8, 116.6, 97.6, 96.6, 75.1, 64.2. 62.3, 52.7, 42.1, 39.5, 34.9, 25.4, 19.7, −1.63.  
The intermediate product was dissolved in MeOH (5 mL) and treated with pTSA 
(10 mg) for 18h at ambient temperature. After further purification using flash 
chromatography (75% EtOAc in heptane) product 34 (50 mg, 0.10 mmol, 30%, 2 
steps) was obtained. [α]D = –2.12 (c = 1.09, CH2Cl2); 1H−NMR (300 MHz, CDCl3) δ 
7.17 (d, J = 7.4 Hz, 1H, NHAc), 6.77 (d, J = 7.6 Hz, 1H, NH), 5.85−5.76 (m, 1H, 
CH=), 5.13−5.07 (m, 2H, =CH2), 4.4-4.69 (m, 1H, CαH), 4.44−4.28 (m, 2H, 
SCH2N), 2.28 (t, J = 7.4 Hz, 2H, CH2CON), 2.02 (s, 3H, NHAc), 1.65−1.29 (m, 
14H, CH2), 1.02−0.99 (m, 2H, CH2Si), 0.04 (s, 9H, SiMe3); 13C−NMR (75 MHz, 
CDCl3) δ 173.3, 170.5, 134.3, 117.4, 70.4, 64.2, 52.7, 41.7, 36.5, 36.2, 33.9, 28.9, 
25.3, 22.9, 17.3, 1.6; IR ν 3265, 3066, 2928, 2854, 1727, 1658, 1536, 1247, 1169, 
840 cm−1; MS (m/z): C23H44N2O5SSi (M + H)+ 489, 461, 390, 372, 300, 194, 95, 73. 
 
2-(1,1,1-Trimethylsilyl)ethyl 3-[(acetylamino)methyl]sulfanyl-2-(R)-[9-(R)-
(3-[(acetylamino)methyl]sulfanyl-2-(R)-[(tert-butoxycarbonyl)amino] 
propanoyloxy)dodecanoyl]aminopropanoate (35). Using the conditions as 
described for 25, 3-acetylamino-methylsulfanyl)-2-
(R)-tert-butoxycarbonylaminopropionic acid and 34 
were coupled. After flash chromatography (75% 
EtOAc in hexane) desired product 35 (17 mg, 22 
µmol, 29%) was obtained. 1H−NMR (300 MHz, CDCl3) δ 6.93−6.78 (d, J = 8.0 Hz, 
2H, 2×NHAc), 6.69 (d, J = 8.0 Hz, 1H, NH), 5.81−5.70 (m, 1H, CH=C), 5.47 (d, J = 
7.6 Hz, 1H, NHBoc), 5.12−5.07 (m, 2H, CH2=), 4.95 (m, 1H, CαH), 4.77−4.73 (m, 
1H, CαH), 4.46−4.36 (m, 4H, 2 × SCH2N), 4.26−4.21 (m, 2H, CH2O), 2.04 (s, 3H, 
Me), 2.03 (s, 3H, Me), 1.66−1.31 (m, 16H, CH2), 1.47 (s, 9H, Boc), 1.06−1.01 (m, 
2H, CH2Si), 0.06 (s, 9H, SiMe3); MS (m/z): C34H62N4O9S2Si (M + H)+ 763, 663, 
593, 307, 289, 279, 154, 136, 120, 107, 89, 73, 57. 
 
tert-Butyl 2-(R)-[(9-(R)-hydroxydodecanoyl)amino]-3-(tritylsulfanyl) 
propanoate (36). DCC (2.84 g, 13.0 mmol), tBuOH 
(1.30 g, 17.6 mmol) and CuCl were stirred for 3 days. 
After dilution using CH2Cl2 (30 mL), H2N-Cys(Trt)-OH 
(1.00 g, 2.8 mmol) was added and the resulting suspension was stirred for 1 h. 
Concentration to ~5 mL and filtration yielded the crude tert-butyl ester of 
cysteine which was directly used in the next step. To a stirred solution of acid 10 
(66 mg, 0.31 mmol) in CH2Cl2 (5 mL) were added DiPEA (125 µL, 0.73 mmol), 
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crude H2N-Cys(Trt)-OtBu (200 mg, 0.48 mmol) and BOP (134 mg, 0.31 mmol) and 
the resulting mixture was stirred overnight. After evaporation and further 
purification using flash chromatography (3% MeOH in CH2Cl2) 36 was obtained 
as an amorphous solid (110 mg, 0.18 mmol, 58%); 1H−NMR (400 MHz, CDCl3) δ 
7.46−7.43 (m, 6H, Ar), 7.31−7.25 (m, 6H, Ar), 7.24−7.18 (m, 3H, Ar), 5.98 (bd, J = 
7.3 Hz, 1H, NH), 5.58−4.52 (m, 1H, CαH), 3.64−3.55 (m, 1H, CHOH), 2.56 (ddd, J 
= 5.6 Hz, 12.6 Hz, 16.9Hz, 2H, CH2S), 2.16 (t, J = 7.4 Hz, 2H, CH2CON), 
1.71−1.37 (m, 16H, 8 × CH2), 1.43 (s, 9H, CMe3), 0.92 (t, J = 6.7 Hz, 3H, Me); 
13C−NMR (75 MHz, CDCl3) δ 172.0, 169.2, 144.0, 129.2, 127.6, 126.5, 82.4, 71.5, 
51.3, 39.7, 37.5, 36.5, 34.4, 34.0, 29.5, 29.3, 28.0, 25.7, 25.0, 19.0, 14.2. 
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1  Oxitocin is a mammalian nonapeptidehormone that controls mammary and uterine 
smooth muscle contraction, has neurotransmitting properties in the central 
nervous system, and displays autocrine and/or paracrine functions in the ovaries 
and testes. 
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11  Fluorocyanuric acid was used to avoid steric hindrance. 
12  The hydrogenation step was scheduled in a later stage of the synthesis. 
13  Initial esterfication studies failed when acid chlorides, mixed anhydrides and 
Mitsunobu-coupling conditions were applied.  
14  All spectroscopic data were in accordance with previously reported literature 
values. 
15  The racemic product was prepared as a reference compound via addition of 
allylMgBr to the aldehyde. Chiral HPLC revealed no trace of the other enantiomer. 
16  Grolsch beer bottles (‘beugelflessen’) proved to be excellent pressure flasks. 
17  Due to the formation of rotamers, the only useful information that could be derived 
from the 1H–NMR spectrum was the absence of the olefinic protons. 
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SUMMARY 
 
Proteins are Nature’s catalysts which continuously drive the metabolism of all 
living creatures. DNA decoding gives rise to specific linear amino acid chains, 
which fold themselves or influence by other proteins into more complex 
ensembles, namely proteins. The folding process leads to frequently encountered 
patterns among which coiled α-helices and flat β-sheets stand out as the most 
important ones. 
The α-helices and β-sheets are relevant because of the relationship between their 
structure and biological activity. These secondary structures are often found in 
areas of the proteins where recognition and binding take place.  
This thesis aims at developing methods for introducing conformational restriction 
in β-turns, the turn elements present in β-sheets, as exemplified in Scheme 1. A 
conformationally restricted peptide might either be formed via incorporation of a 
bridging diamino acids in a growing peptide chain (path a), or via covalent bond 
forming processes after folding into a turn structure (path b). 
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Scheme 1. Two conceptually different pathways to introduce conformational restriction in β-
turns.  
 
In Chapter 1 an overview is given of the application of ring-closing olefin 
metathesis in order to prepare constrained peptides. Advantages and drawbacks 
of ring-closing metathesis reactions in oligopeptides are highlighted. The chapter 
ends with several examples of stabilized peptides which possess retained or even 
increased biological activity. 
Chapter 2 describes the chemoenzymatic synthesis of enantiopure acetylene-
containing amino acids. Practical synthetic pathways are detailed to pepare 
amino acid amides, which form an extension of research that has been previously 
carried out in our group. Enzymatic resolution on these substrates, involving an 
aminopeptidase that selectively hydrolyzes the naturally configured (S)-amino 
Summary 
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acid amides, then leads to the enantiomerically pure amino acids which are used 
throughout this thesis. 
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Scheme 2. Chemoenzymatic approach to prepare enantiopure amino acids. 
 
In Chapter 3, methodology involving the coupling of organozinc/copper 
compounds with halogenated acetylenes is investigated. This has led to the 
synthesis of a series of new acetylene-containing amino acid derivatives. 
Furthermore, the strategy has been applied to the synthesis of conformationally 
restricted diamino acids that may serve as isosteres of cystine in peptide 
structures.  
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Scheme 3. Construction of conformationally rigid isosteres of cystine via organozinc/copper–
bromoacetylene couplings. 
 
Chapter 4 involves the application of inter- and intramolecular copper-catalyzed 
1,3-dipolar cycloaddition reactions (click-reactions) to introduce conformational 
restriction in peptide strands. Reaction of acetylenic amino acids with a variety of 
azides resulted in several potentially biologically relevant compounds such as 
mimics of the amino acid citrulline. However, in our hands, formation of triazoles 
via intramolecular cycloaddition in peptides remained unsuccessful. 
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Scheme 4. Concept of intramolecular 1,3-dipolar cycloaddition in peptides. 
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In Chapter 5, ring-closing alkyne metathesis (RCAM) on suitable acetylene-
equipped peptides is the subject of research. The preparation of the required 
catalyst and several precursor oligopeptides are discussed. Depending on the 
particular amino acids and the length of the peptide, various constrained 
oligopeptides were successfully prepared under RCAM conditions. Furthermore, 
the conformational properties of these constrained peptides were analyzed by 
NMR and compared to those of comparable cystine-stabilized peptides.  
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Scheme 5. Several examples of restricted β-turn mimics. 
 
In Chapter 6, studies towards a synthesic route of the natural product FE399, 
containing a cystine bridge, are described, as well as towards carbon analogues. 
While ring-closing alkyne metathesis failed to give one of the desired carbon 
mimics, ring-closing olefin metathesis eventually led to a carbon isostere of the 
natural product. Unfortunately, we were unable to prepare the natural product 
itself within the timeframe of this thesis.  
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Scheme 6. Retrosynthetic approach to FE399 and a carbon analogue. 
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SAMENVATTING 
 
Eiwitten zijn de natuurlijke katalysatoren die het metabolisme van alle levende 
wezens aansturen. DNA-codering genereert specifieke aminozuurketens, die 
zichzelf of onder invloed van andere eiwitten in complexe eiwitstructuren 
vouwen. Dit vouwproces leidt tot frequent terugkerende secundaire 
structuurelementen waarvan de α-helix en het β-sheet de meest belangrijke zijn. 
De α-helix en het β-sheet zijn belangrijk vanwege de relatie tussen hun structuur 
en de daarmee samenhangende biologische activiteit. Dit soort secundaire 
structuren wordt voornamelijk aangetroffen in eiwitregionen waar herkenning en 
binding plaatsvinden.  
In dit proefschrift wordt aandacht besteed aan de ontwikkeling van nieuwe 
methoden voor het conformationeel vastleggen van de β-turn binnen de β-sheets, 
zoals getoond in Schema 1. Een conformationeel vastgelegde eiwitketen kan 
worden verkregen via het inbouwen van een bruggend diaminozuur in een 
groeiende peptideketen (route a) of via covalente bindingsvorming met behulp 
van een geschikte katalytische reactie na het invoeren van de afzonderlijke 
aminozuren in de peptideketen (route b). 
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Schema 1. Twee verschillende routes om een β-turn vast te leggen. 
 
In Hoofdstuk 1 wordt een overzicht gegeven van de actuele ontwikkelingen om 
via ringsluitingsalkeenmetathese (RCM) conformationeel vastgelegde eiwitten te 
synthetiseren. De voor- en nadelen van deze metathesereacties in korte 
aminozuurketens worden weergegeven. Het hoofdstuk eindigt met enkele 
voorbeelden van conformationeel vastgelegde peptideketens waarvan de 
biologische activiteit gelijk is gebleven of zelfs verbeterd. 
Hoofdstuk 2 beschrijft de chemoenzymatische synthese van enantiomeerzuivere 
acetyleenhoudende aminozuren. Praktische syntheseroutes zijn beschreven, die 
een uitbreiding vormen van eerder binnen de Rutjes groep op dit gebied 
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ontwikkelde kennis. Enzymatische hydrolyse van racemische aminozuuramiden 
met behulp van een aminopeptidase, geeft selectief de natuurlijke 
geconfigureerde aminozuren, terwijl de niet-natuurlijk geconfigureerde 
aminozuuramiden intact blijven. Deze aldus verkregen aminozuren worden 
vervolgens gebruikt in de rest van dit proefschrift. 
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(  )n (  )n
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Schema 2. Chemoenzymatische benadering voor de synthese van enantiomeerzuivere aminozuren. 
 
In Hoofdstuk 3 wordt een methode onderzocht om geactiveerde organo-
zink/koper verbindingen te koppelen met verschillende gehalogeneerde 
acetylenen. Deze methode leidt tot de synthese van enkele nieuwe 
acetyleenhoudende aminozuren. Ook wordt deze methode onderzocht voor de 
synthese van starre diaminozozuren die mogelijk als brug kunnen worden 
ingebouwd in korte aminozuurketens.  
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Schema 3. De opbouw van starre diaminozuren via geactiveerde organo-zink/koper verbindingen. 
 
Hoofdstuk 4 behandelt de toepasbaarheid van inter,- en intramoleculaire 
kopergekatalyseerde 1,3-dipolaire cycloaddities (zogenaamde ‘klik-reacties’) 
tussen acetylenen en organische aziden om aminozuurketens conformationeel 
vast te leggen. De reactie tussen een acetyleenhoudend aminozuur met 
verschillende aziden levert enkele mogelijk biologisch relevante verbindingen op, 
zoals mimics van het aminozuur citrulline. Ondanks deze intermoleculaire 
voorbeelden is de vorming van de triazool via intramoleculaire cycloaddities voor 
ons weinig succesvol gebleken. 
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Schema 4. Het concept van intramoleculaire 1,3-dipolaire cycloadditie in peptiden. 
 
In Hoofdstuk 5 is ringsluitingsalkynmetathese (RCAM) op acetyleen-houdende 
oligopeptiden het onderwerp van onderzoek. De synthese van de benodigde 
wolfraamkatalysator en een reeks precursormoleculen wordt besproken. 
Afhankelijk van de ingebouwde acetyleenhoudende aminozuren en de lengte van 
de aminozuurketen zijn verschillende vastgelegde eiwitstructuren gemaakt via 
RCAM. Deze conformationeel vastgelegde structuren zijn vervolgens met behulp 
van NMR-technieken vergeleken met vergelijkbare natuurlijke structuren. 
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Schema 5. Enkele voorbeelden van conformationeel vastgelegde β-turn mimics. 
 
Hoofdstuk 6 behandelt onderzoek naar een syntheseroute van de natuurstof 
FE399 en koolstofbevattende analoga daarvan. Waar RCAM niet succesvol bleek 
bij het verkrijgen van de gewenste analoga, leidde RCM tot een gewenst 
koolstofanalogon. De synthese van de natuurstof zelf kon niet worden volbracht 
binnen het tijdsbestek van dit promotieonderzoek. 
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Schema 6. Retrosynthetische benadering van FE399 en een koolstofanalogon.  
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